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Abstract
Transplantation-associated Kaposi’s sarcoma (KS), causativeiy associated with 
human herpes virus 8 (HHV-8), is particularly prevalent in Saudi Arabia, although the 
prevalence rate of HHV-8 infection in the general population there is comparable to 
that in other geographical regions. The serologic and genomic prevalences of HHV-8 
in samples representing the general population (n=238), patients with end-stage renal 
disease (n=78), and renal allograft recipients (n=66) were investigated. To evaluate if 
oral shedding of HHV-8 might play a role in transplantation KS, the extent of HHV-8 
shedding in the mouth compared to other anatomical compartments, and the 
presence of multiple HHV-8 infection were also studied. PCR protocols were applied 
to amplify 3 fragments of the viral genome (from open reading frames 26 and K1 ) 
from whole-mouth saliva, parotid saliva, buccal and palatal exfoliates, plasma, sub­
sets of peripheral blood cells, and KS lesional tissue, and to quantify the salivary viral 
load. Demographic and clinical data were analysed to identify risk factors for HHV-8 
infection. A higher HHV-8 seroprevalence was observed in patients with renal 
disease compared to the general population, but no significant difference in HHV-8 
DNA detection rates in CD45+ cells was found. The oral cavity was identified as a 
major site of HHV-8 shedding in renal disease patients regardless of a previous 
history of KS. In patients with end-stage renal disease, HHV-8 DNA was more 
frequently detectable in oral samples than in blood. They and renal allograft 
recipients showed evidence of being multiply infected by HHV-8. These findings 
suggest that iatrogenic, salivary HHV-8 transmission between patients with renal 
disease prior to transplantation accounts for the relatively high prevalence of HHV-8 
infection. Implementation of measures to minimise contamination of oral fluid 
between renal disease patients may play a role in controlling HHV-8 transmission and 
reduce the incidence of transplantation-associated KS.
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1.1 Overview of herpesviruses
1.1.1 General features
Herpesviruses are a family of DNA viruses found commonly in humans and animals.
They are widely disseminated in nature and most animal species carry at least one
herpesvirus and frequently several, diverse herpesviruses. The number of
herpesviruses in nature is likely to exceed the 130 herpesviruses identified to date.
Herpesviruses share the following four biological properties:
(i) Synthesis of viral DNA and assembly of their capsid occur in the nucleus of 
infected cells.
(ii) They encode their own enzymes involved in nucleic acid metabolism and 
synthesis and protein processing - although the array of enzymes may vary 
from one herpesvirus to another.
(iii) Production of infectious viral particles is invariably accompanied by 
destruction of the infected cell.
(iv) Latent infection that persists for the life of their natural hosts. The latent viral 
genomes usually take the form of circular episomes, with only a small subset 
of viral genes being expressed. Latent genomes retain the capacity to 
replicate and cause disease upon reactivation. The site of latency differs 
from one herpesvirus to another.
1.1.2 Structure of Herpesviruses
1.1.2.1 The virion
Herpesviruses have a common virion architecture (Figure 1.1) consisting of:
• Core, containing linear double-stranded DNA.
• Capsid, surrounding the core and containing 162 capsomeres. It is 
icosahedral in shape and approximately 100 to llOnm in diameter.
• Tegument, an amorphous-appearing material between the capsid and the 
envelope.
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• Envelope, forming the outer layer of the virion and containing viral 
glycoprotein spikes on its surface.
Herpesvirions vary in size from 120 to nearly 300 nm. The variation is in part due to 
variability in the thickness of tegument. Another major source of variability is the state 
of the envelope. Intact envelopes are impermeable and generally retain the quasi- 
spherical shape of the virion during preparation for electron microscopy. Damaged 
envelopes have a diameter much larger than that of intact virions (reviewed by 
Roizman & Pallett 2001 ).
Figure 1.1 Schematic structure of a herpesvirus
Tegument 
 Envelope 
  Capsid
[Source: (Solomon, 2007)]
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1.1.2.2 Genomic organisation
Herpesvirus genomes vary in length from 120 to 250 kilobase pairs (kbps) and 
contain 60 to 120 genes. Herpesvirions contain, in addition to viral DNA, 25-35 virus- 
encoded proteins and host-specific phospholipids derived from the nuclear 
membrane.
The length of the genome is characteristic for each genus. Herpesviruses can be 
distinguished from each other not only by the size and base composition of their 
DNA, but also by the structural arrangement of their unique and repeated sequences. 
Variations in the number of internal and terminal repeat regions result in minor 
variations in the size of individual isolates.
Herpesvirus genes may be characterized as either essential or dispensable for 
growth in cell culture. Essential genes regulate transcription and are required to 
construct the virion. Dispensable genes for the most part function to enhance the 
cellular environment for virus production, to defend the virus from attack by host 
immune system and to promote cell-to-cell spread. All herpesvirus genomes contain 
lengthy terminal repeats, both direct and inverted (reviewed by Roizman & Pallett 
2001).
Herpesviruses can be divided into six structurally distinct groups on the basis of the 
presence and location of repeated sequences longer than 100 base pairs (bps) 
(Figure 1.2):
(i) Group A viruses possess a large sequence in one terminus which is directly 
repeated at the other terminus. They include human herpesviruses 6 and 7 
(HHV-6 and HHV-7).
(ii) Group B viruses possess a terminal sequence that is directly repeated 
numerous times at both termini. Typically an area of low GC content (L-DNA)
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is flanked by repetitive regions of high GC content (H-DNA). Examples include 
human herpesvirus 8 (HHV-8), also known as Kaposi’s sarcoma-associated 
herpesvirus (KSHV), and the primate herpesvirus saimiri (HVS), also known 
as simian herpesvirus 2 (SHV-2).
(iii) Group C viruses, for which both terminal and internal repeat sequences are 
present throughout the viral genome, and which further subdivide it into well- 
defined unique sequences. These include Epstein-Barr virus (EBV) and 
chimpanzee herpesvirus (pongine herpesvirus 1 ).
(iv) Group D viruses have a terminal region which is repeated in an inverted 
orientation internally. Examples include varicella-zoster virus (VZV) and a 
large number of viruses isolated from mammals and birds.
(v) Group E viruses have a more complex genomic structure, in which sequences 
at both termini are repeated in inverse orientation and juxtaposed internally. 
They include herpes simplex viruses types I (HSV-I) and 2 (HSV-2) and 
human cytomegalovirus (CMV).
(vi) Group F viruses have no repeat regions in the genome, and are exemplified 
by murine herpesvirus 1.
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Figure 1.2 Architecture of herpesvirus genomes 
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The herpesviruses also vary significantly in terms of their base composition, with the 
guanine-cytosine (GC) content ranging from 46% in VZV to 69% in HSV (Roizman, 
1996). An under-representation of the CpG dinucleotide pair and a relative excess of 
CpA and TpG dinucleotides, relative to frequencies predicted from their 
mononucleotide compositions, have been observed in the lymphotropic 
herpesviruses, possibly due to methylation-dependent CpG suppression in rapidly 
dividing cells (Honess et al., 1989). However, despite these major differences, 
comparison of herpesvirus DMA sequences shows large regions of distant co-linear 
homology at the predicted protein level. Relatively well conserved genes code for 
frans-activating factors and enzymes involved in viral replication, such as DMA 
polymerase, ribonucleotide reductase and thymidine kinase, and some structural 
glycoproteins, including the major spike components (Stewart at a/., 1996). The 
similarities are largely restricted to the early and late genes expressed during the 
productive cycle, while genes expressed in latently infected cells are usually unique, 
suggesting a possible origin from cellular DMA.
1.1.3 Herpesviruses nomenclature and classification
The International Committee on the Taxonomy of Viruses (ICTV)-endorsed 
nomenclature consists of designation of herpesviruses by serial Arabic numbers and 
the family or subfamily of the natural host of the virus (e.g. Human herpesvirus 7, 
Cercopithecine herpesvirus 1) (Roizman and Pellett, 2001). All names are in italics 
and have the first letter of the first word capitalized. Other words are not capitalized 
unless they are proper nouns, or parts of proper nouns (Van Regenmortel, 1999).
The members of the family Herpesviridae have been classified by the ICTV’s 
Herpesvirus Study Group into three subfamilies (i.e., the Alphaherpesvirinae, the 
Betahepesvirinae, and the Gammaherpesvirinae) based largely on host range and 
tropism, as well as in vitro growth rate and characteristics of viral latency (Roizman at
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a/., 1981; Chee and Barrell, 1990; Murphy et a i, 1995) (Table 1.1 & Fig 1.3). Further 
subdivision into genera is based on DNA sequence homology, similarities in genomic 
sequence arrangement and viral proteins demonstratable by immunological methods 
(Roizman et a i, 1981; Roizman, 1982).
1.1.3.1 Alphaherpesviruses
The subfamily Alphaherpesvirinae includes the genera Simplexvirus (HSV-1 & HSV- 
2), Varicellovirus (VZV), Equine herpesvirus 1 (EHV-1) and Pseudorabies virus 
(PRV). They have a relatively short reproductive cycle, rapid spread in culture, 
efficient destmction of infected cells, and are able to establish latent infection 
primarily, but not exclusively, in sensory ganglia.
1.1.3.2 Betaherpesviruses
The subfamily Betaherpesvirinae includes the genera Cytomegalovirus (CMV), 
Muromegalovirus (MHV-1), and Roseolovirus (HHV-6 & HHV-7). Betaherpesviruses 
replicate in a variety of cell types in vivo, including epithelial cells, while the host cell 
range is more restricted in vitro. Infection progresses slowly and is accompanied by 
cell enlargement (cytomegaly) and by the appearance of characteristic nuclear 
eosinophilic inclusion bodies, formed by the accumulation of defective particles 
containing enveloped viral proteins without DNA (also referred to as assembled 
capsids). Latent infection has been confirmed in many tissues, although 
lymphoreticular cells, secretory glands and renal tissue are the more common sites.
1.1.3.3 Gammaherpesviruses
The subfamily Gammaherpesvirinae includes the genera Lymphocryptovirus and 
Rhadinovirus, with little nucleotide sequence homology or antigenic cross-reactivity 
existing between these two groups. Gammaherpesviruses are characterized by their
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tropism for lymphoid cells and their capacity to induce cell proliferation in vivo, 
resulting in transient or chronic lymphoproliferative disorders, and in vitro, where 
many can immortalise the infected cells. They have a narrow natural host range 
which is restricted to the family or order to which the natural host belongs. Most 
Gammaherpesviruses replicate inefficiently in haematopoietic cells, but some have 
efficient productive cycles in epithelial cells and fibroblasts. Latent virus is usually 
detected in lymphoid organs (Campbell eta!., 2005).
The lymphocryptoviruses (or gamma-1 herpesviruses) include EBV and related 
viruses of Old World primates such as chimpanzees {Herpesvirus pan), orangutans 
{Herpesvirus orangutan) and gorillas {Herpesvirus gorilla). These viruses share a 
tropism for B lymphocytes (Chee and Barrell, 1990), and a genomic architecture 
characteristic of group B or C, and a similar gene organisation. Furthermore, several 
of their structural and nonstructural proteins are antigenically related resulting in the 
elicitation of cross-reactive antibodies (Gerber and Birch, 1967; Chu etal., 1971).
The rhadinoviruses (or gamma-2 herpesviruses) are classically the herpesviruses of 
primates. The extreme intragenomic GC heterogeneity, resulting in fragmentation by 
density centrifugation, led to the coining of the term rhadinivirus (meaning fragile, in 
Greek) (Roizman et al., 1981). They can be divided into two distinct lineages, RV1 
and RV2. Examples include the ateles virus of spider monkeys (HVA), the Saimiri 
virus o f squirrel monkeys (HVS), Rhesus rhadinovirus (RRV), some viruses of horses 
e.g. Equine herpesvirus 2 (EHV2) (Telford et al., 1993) and mice, e.g. murine 
herpesvirus strain 68 (MHV-68) (Sunil-Chandra et al., 1994). The only human 
herpesvirus in this group is human herpesvirus 8 (HHV-8) (Chang et al., 1994). It has 
been classified in this genus due to its close similarity to HVS. HHV-8 is an RV-1 
gamma-2 herpesvirus. There may be as yet undiscovered viruses of the RV-2 lineage 
capable of infecting humans (Lacoste et al., 2001).
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Table 1.1 Taxonomy of herpesviruses
Alphaherpesvirinae:
Simplexvirus
Varicellovirus
Human herpesvirus 1, 2 (HSV-1, HSV-2) 
Human herpesvirus 3 (VZV)
Betaherpesvirinae:
Cytomegalovirus
Muromegalovirus
Roseolovirus
Human herpesvirus 5 (CMV)
Mouse cytomegalovirus 1 (MHV-1) 
Human herpesvirus 6, 7 (HHV-6, HHV-7)
Gammaherpesvirinae:
Lymphocryptovirus Human herpesvirus 4 (EBV) 
Rhadinovirus Human herpesvirus 8 (HHV-8)
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Figure 1.3 Classical neighbour-joining phylogenetic tree of near full length genome 
isolates demonstrating the relationship between different herpesvirsuses
[Source: Stebbing etal., 2006]
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Within these three subfamilies of herpesviruses, eight are known to infect humans. 
These are summarised in Table 1.2
Table 1.2 Human Herpesviruses
[Source: Roizman and Pellett, 2001]
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1.2 Physical and genomic structure of human herpesvirus 8
1.2.1 The discovery of HHV-8
A viral aetiology for Kaposi’s sarcoma (KS) was suspected long before the onset of 
the acquired immunodeficiency syndrome (AIDS) epidemic (Oettle, 1962). During the 
1970s herpesvirus-like particles, thought to be CMV, were found by electron 
microscopy in tumour cells (Giraldo et al., 1972). Subsequent studies identified, in 
lesional tissues, the DNA of CMV, HHV-6, human papilloma viruses (HPVs) and 
other viral or bacterial pathogens, all of which were put forward as candidate 
aetblogical agents. However, only a minority of KS lesions was found to carry DNA of 
the implicated viruses (Huang et a/., 1992; Kempf et a!., 1995; Monini et a/., 1996c).
Although no aetiologic agent was identifiable, epidemiologic studies in the late 1980s 
suggested that a sexually transmitted agent was the cause of KS, this being 
transmitted independently of human immunodeficiency virus (HIV). The suspected 
agent was presumed to be more efficiently transmitted through homosexual than 
heterosexual contact, resulting in a much higher incidence rate among gay male 
AIDS patients than other AIDS risk groups. The agent was also likely to be poorly 
transmissible through blood products since KS prevalence rates among HIV-infected 
transfusion recipients and haemophiliacs were relatively low (Beral etal., 1990; Beral, 
1991; Beral etal., 1992).
Given that there may be a separate KS agent, it was reasoned that the genomic 
difference between proposed infected (KS) and uninfected (skin) tissues from an 
individual patient with AIDS-KS should be that of the infectious agent. A subtractive 
hybridization technique, representational difference analysis (RDA), based on 
polymerase chain reaction (PCR) (Lisitsyn et al., 1993) enrichment of unique DNA 
fragments was employed by Chang and colleagues (Chang et al., 1994). With the 
use of genomic DNA from an AIDS-KS lesion that was compared to unaffected DNA
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from the patient, two unique DNA fragments were isolated. These two DNA 
fragments (KS330Bam and KS631Bam), which showed high homology to known 
herpesvirus sequences, were used as Southern hybridization probes and for the 
generation of PCR primers. Both segments were homologous to two members of the 
gammaherpesvirus sub-family. KS330Bam was 51% homologous to opening reading 
frame (ORF) 26 of HVS and 39% homologous to ORF BDLF1 of EBV. KS631Bam 
was homologous to a tegument protein coded by ORF 75 of HVS and ORF BNRF1 of 
EBV. The unique sequences were found in 90% of KS lesions from AIDS patients. 
Subsequent studies showed that the vast majority of KS lesions from patients with 
AIDS and from other groups at risk of KS carried DNA of this novel virus (Ambroziak 
et a/., 1995; Schalling at a/., 1995; Boshoff at a/., 1995b; Chang and Moore, 1996). 
HHV-8 is therefore the most recently discovered human tumour virus and has been 
detected in virtually all cases of KS.
1.2.2 Morphology
The morphological characteristics of HHV-8 are typical of herpesviruses (Figure 1.1). 
These features were confirmed in electron micrographs of HHV-8-infected primary 
effusion lymphoma (PEL) cell lines (Arvanitakis at a/., 1996; Renne at a/., 1996b; 
Said at a/., 1996b), and biopsy samples of KS (Walter at a i, 1984; Orenstein at a i, 
1997). HHV-8 appears as 100-150 nm particles, has a target-like ultrastructural 
appearance with an electrondense central core surrounded by a lipid envelope 
(Renne at a i, 1996b). Capsid substructures, such as ring-shaped capsomers of 
approximately 9 nm in diameter arranged in linear arrays, have also been observed 
(Arvanitakis at a i, 1996; Said at a i, 1996b).
The capsid composition of Gammaharpasvirinaa, including HHV-8, has since been 
characterised by means of biochemical and imaging analyses. It has been confirmed 
that only a portion of the synthesised capsids undergoes viral DNA packaging during
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the lytic replication phase. As with the alpha- and betaherpesviruses, this leads to the 
formation of at least three capsid species, A, B and C, with masses of approximately 
200, 230, and 300 MDa, respectively. A capsids consist of an empty icosahedral 
shell; B capsids contain only scaffolding protein (ORF 17.5); and C capsids contain 
packaged DNA and no scaffolding protein. It has been hypothesised that the B 
capsids may mature to C capsids, which in turn may function as the precursors of 
infectious virus particles. The A capsids are probably the dead end products of B and 
C capsids (Nealon et al., 2001).
Nealon and co-workers also confirmed that the hexameric and pentameric 
capsomers are composed of the major capsid protein (MCP) encoded by ORF 25. 
The heterotrimeric complexes, forming the capsid floor between the hexons and 
pentons, are each composed of one molecule encoded by ORF 62 and of two 
molecules encoded by ORF 26. These three proteins (encoded by ORF 25, 62 and 
26) have a significant amino acid sequence homology to capsid proteins of both 
alpha- and betaherpesviruses. A fourth small, basic, and highly antigenic protein, 
encoded by ORF 65, was also identified, and in contrast does not show any 
significant sequence homology to its structural counterparts from the other 
subfamilies. A fifth protein, encoded by ORF 17.5, is only found in B capsids (Nealon 
et a/., 2001).
1.2.3 Genomic characteristics
Complete genome sequences of two HHV-8 isolates have now been determined, one 
from a PEL cell line (Russo et a/., 1996) and the other from a KS specimen (Neipel et 
a/., 1997), both revealing the characteristic co-linear genomic organization of 
rhadinoviruses. HHV-8 genome is 140.5 kb in length and is of low GC content 
(53.5%) (Figure 1.4). The linear double-stranded HHV-8 DNA comprises a segment 
called L-DNA or long unique region (LUR) that is surrounded by terminal repeat
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regions (TRs) consisting of 801 bp direct repeat units with a high GC content (84.5%) 
called H-DNA. The L-DNA region of HHV-8 genome has at least 90 ORFs and five 
internal repeat regions (Russo etal., 1996; Neipel etal., 1997; Cohen etal., 2005).
As with other gammaherpesviruses, essential ORFs that code for viral replication and 
assembly proteins are arranged in blocks and are referred to as the conserved 
genes. There are approximately 67 such genes conserved among members of 
herpesvirus subfamilies. In HHV-8, these include: ORF 25, coding for the major 
structural protein; ORF 9, for DNA polymerase; and ORF 17, for a proteinase and 
assembly protein (Moore et al., 1996b). Non-conserved gene blocks in the HHV-8 
genome lie between the conserved blocks and contain some ORFs that are found in 
other rhadinoviruses including homologues to mammalian proteins. Like other 
rhadinoviruses, HHV-8 has numerous open reading frames with striking homology to 
known cellular genes. All known rhadinoviruses have unspliced genes that seem to 
have been captured from the host cell during viral evolution. Typically, they code for 
proteins that interfere with the immune system, for enzymes involved in nucleotide 
metabolism, and for putative regulators of cell growth (Russo et al., 1996; Neipel et 
al., 1997; Neipel et al., 1998). The HHV-8 genome has cellular homologues not found 
in other rhadinoviruses including a homologue to human interleukin 6 (IL-6), 
members of the CC chemokine family and interferon regulatory factors (IRFs). These 
gene products may contribute to the pathogenesis of HHV-8 and will be discussed in 
more detail in Section 1.3. Genes specific to HHV-8 lineage (McGeoch and Davison,
1999) are listed in Table 1.3.
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Figure 1.4 The Human herpesvirus 8 (HHV-8) genome
Note: The genome consists of a long unique region (140.5 kb) encoding for over 80 open 
reading frames (ORFs), surrounded by terminal repeat regions (TRs) consisting of 801 base 
pair direct repeat units with a high G+C content. Three large regions (I, II and III) contain 
genes conserved among the Rhadinoviruses, whereas the regions between them contain 
unique genes. Many of these unique genes encode homologues for host cellular proteins 
(shown in red with dotted outlines; genes without known homologues are shown in yellow with 
dotted outlines). Genes that are potentially important in the pathogenesis of KS are labelled.
Abbreviations: CCP, complement control protein; v-cyc, viral D-type cyclin; vFLIP, viral FLICE 
inhibitory protein; vGPCR, viral G-protein-coupled receptor; vlL-6, viral interleukin 6; vIRF, 
viral interferon regulatory factor; kb, kilobase; LANA, latency-associated nuclear antigen; vMIP 
(vCCL), viral macrophage inflammatory protein
[Source: Expert Reviews in Molecular Medicine, 2001 Cambridge University Press]
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Table 1.3 Genes specific to the HHV-8 lineage
[Source: McGeoch and Davison, 1999]
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1.3 HHV-8 gene expression and encoded proteins of relevance
As with the other herpesviruses, HHV-8 exhibits two modes of replication: lytic, in 
which viral DNA is replicated by the virus-encoded polymerase and encapsidated into 
infectious virions; and latent, in which viral episomes replicate in tandem with host 
cell DNA using host cell replication machinery. Both modes of replication are 
characterized by virtually distinct gene expression programs. HHV-8 establishes 
latency in the host and is under stringent latent replication control in PEL cell lines 
(Russo et a/., 1996; Gao et al., 1996a; Sa rid et al., 1998). While a minority of cells in 
culture may express lytic cycle proteins at any given time, chemical induction with 
tetradecanyl phortxDl acetate (TRA) is needed for the full expression of lytic gene 
products in PEL cells in vitro. Three broad categories (classes) of gene expression 
have been described (Sarid et al., 1998), based on their expression outcomes after 
TPA induction (although this may not reflect the true in vivo state): class I (which are 
unaffected by TPA induction and presumably represent latent viral transcripts); class 
II (which are expressed without TPA but are induced to higher transcription levels by 
TPA treatment and typically represent the virus encoded cytokines, signal 
transduction genes and small polyadenylated RNAs [TO.7 & T1.1]); and class III 
(which are primarily structural and replication genes that are transcribed only 
following TPA treatment and are presumably responsible for lytic virion production).
1.3.1 Latent infection
HHV-8 becomes latent in the majority of cells it infects. During this stage of the virus 
life cycle, the viral genome resides in the nucleus as closed circular episomal DNA 
expressing a small subset of viral genes. Potentially, this minimises the number of 
viral epitopes that are presented by infected cells to cytotoxic T lymphocytes (CTLs) 
(Renne et al., 1996a). It seems likely that the genes expressed during latency play a 
major role in the pathogenesis of HHV-8. The major latent loci are as summarized 
below.
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1.3.1.1 ORF 71 (K13)
ORF 71 produces vFLIP, a homologue to cellular FLICE (FADD [Fas-associated 
death domain]-like interleukin-1 beta-converting enzyme) inhibitory proteins (FLIPs). 
vFLIPs found in other herpesviruses are known to inhibit fas-mediated apoptosis by 
preventing the recruitment of caspase-8 (FLICE) to the death-induced signalling 
complex (Thome et al., 1997). vFLIP in HHV-8 has a similar function and can prevent 
apoptosis in infected cells (Djerbi et al., 1999; Sturzl et a!., 1999). ORF 71 utilises 
internal ribosome entry site (IRES>-mediated initiation to produce a functional protein 
and that ensures the protection of infected cells from CTL-induced cell killing 
throughout the cell cycle (Bieleski and Talbot, 2001). vFLIP also has the ability to 
transform Rat-1 and Balb/3T3 fibroblast cells by activation of the nuclear factor kappa 
B (NF-kappaB) pathway. NF-kappaB is a transcriptional regulatory factor that in turn 
up-regulates the expression of a wide variety of inflammatory cytokines and adhesion 
molecules, playing a pivotal role in promoting inflammation and cell proliferation (Pati 
et a/., 2001; Caselli et a/., 2006; Sadagopan et a/., 2007). This suggests that vFLIP 
has activity beyond its role as an inhibitor of death receptor signalling, and may play a 
causative role in the pathogenesis of HHV-8-associated malignancies (Sun et a!., 
2003; Matta and Chaudhary, 2004; Chugh et ai., 2005; Matta et al., 2006; Wang et 
a/., 2006; Sun et a/., 2006).
1.3.1.2 ORF 72
ORF 72 encodes viral cyclin (v-cyclin), which is the viral homolog to cellular cyclin 
and is most closely related to cyclin D. The HHV-8 v-cyclin has been shown to 
associate primarily with cdk6 and to a lesser extent with cdk4, both important cell 
cycle regulators (Li et al., 1997; Radkov et al., 2000). v-cyclin is able to interfere with 
the phase G1 of the cell cycle via the inactivation of retinoblastoma tumour 
suppressor protein (pRb) and the Cdk inhibitors p16 (Ink4a), p21Cip1 and p27Kip1 
(Verschuren et al., 2004), thereby enhancing the survival of HHV-8-infected cells
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(Meyerson and Harlow, 1994; Swanton etal., 1997; Ellis etal., 1999).
HHV-8 v-cyclin is expressed in latently infected spindle cells and PEL cell lines, and 
in KS tissues (Cesarman et al., 1996; Godden-Kent et al., 1997; Davis et al., 1997b; 
Reed et al., 1998), suggesting that it may have a role in either the proliferation or the 
arrest of differentiation of these cells.
1.3.1.3 ORF 73
ORF 73 encodes the latency associated nuclear antigen-1 (LANA-1). LANA-1 is 
detected in the majority of KS lesions as well as in cell lines derived from PELs. 
LANA-1 plays a role in HHV-8 maintenance by tethering the viral episome through 
the terminal repeat to host chromosome, ensuring persistence in the daughter cells 
after successful rounds of cell division (Ballestas et al., 1999; Cotter and Robertson, 
1999; Radkov et al., 2000; Stuber et al., 2007). The terminal repeat DNA binding 
domain is localized to LANA-1 residues 996-1139 (Srinivasan et al., 2004; Komatsu 
et al., 2004), and interacts with SUV39H1 histone methyltransferase, a key 
component of heterochromatin formation (Sakakibara et al., 2004; Stuber et al., 
2007). This interaction creates the characteristic pattern of intra-nuclear dots 
observed in immunofluoresence assays.
In normal uninfected cells, G1/S progression is negatively regulated by binding of 
pRb to E2F transcription factor. In infected cells, LANA-1 competes with E2F for 
binding of pRb, thus freeing E2F to activate the transcription of genes involved in cell 
cycle progression. LANA-1 also binds p53, a tumour suppressor gene involved in 
many types of human cancers (Vogelstein et al., 2000), and blocks p53-mediated 
apoptosis, allowing HHV-8-infected cells to persist (Friborg, Jr. et al., 1999; Barbera 
et al., 2004). The amino terminus of LANA can interact with its carboxy-terminal 
domain. This interaction is potentially important for facilitating associations with other
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cell cycle regulatory proteins (Kaul et al., 2007). These novel associations render 
LANA a key factor in relation to the maintenance of latency and subsequent 
transformation of HHV-8 infected cells.
1.3.1.4 ORFs K10.5,K11.1 and K12
K10.5, K11.1 and K12 are considered as latent genes but can be induced by TPA 
during lytic replication of the virus, and may therefore be classified as class II 
transcripts (Sarid et a/., 1998; Jenner et a!., 2001). K10.5 expresses LANA-2 protein 
(also called vlRF-3). HHV-8 vlRF-3 interacts with cellular interferon regulatory factor 
7 (IRF-7) and this interaction specifically suppresses IRF-7 DNA binding activity, 
thereby inhibiting the IFN alpha gene expression upon virus infection, suppressing 
both IFN-mediated and tumour suppressor-mediated host surveillance, which 
ensures a comprehensive avoidance of host anti-viral activity (Joo et a/., 2007). 
Interferons (IFNs) are a group of cytokines with wide ranging effects including 
defence against viral infection and inhibition of cell growth. Interferon regulatory 
factors (IRFs) regulate the transcription of IFNs thereby modifying the effects brought 
about by IFN activity (Reis et a/., 1992; Taniguchi et a/., 1995). HHV-8 vlRF-3 is 
expressed latently only in cells and cell lines (i.e. PEL, PEL cell lines and Multicentric 
Castleman’s disease [MCD]) of haematopoietic origin, but not in KS tumours, 
possibly contributing to HHV-8 tumorigenesis in hematopoietic tissues. HHV-8 vlRF-3 
is abundantly expressed in the nuclei of cultured HHV-8 infected B cells. Reporter 
assays showed that HHV-8 vlRF-3 inhibits p53 expression, like LANA-1, potentially 
contributing to the proliferation of infected B cells in MCD (Rivas et a/., 2001 ).
The ORF K11.1 gene encoding viral interferon regulatory factor 2 (vlRF-2) is latently 
expressed in PEL cell lines (Burysek et a/., 1999). While IRFs have the ability to bind 
nucleotides, vlRF-2 can bind oligonucleotides corresponding to NF-kappaB (Burysek 
et a/., 1999; Burysek and Pitha, 2001). vlRF-2 inhibits the effects of cellular IFN
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through its interaction with a ds RNA activated protein kinase (PKR) (Burysek and 
Pitha, 2001). PKR is normally induced by IFN and mediates the anti-viral and anti­
proliferative effects of IFN (Sen and Ransohoff, 1993). Down-regulating the antiviral 
response caused by PKR, vlRF-2 may be important for maintenance of viral latency 
(Burysek and Pitha, 2001).
The ORF K12 gene encodes Kaposin A, which has been shown to induce 
tumorigenic transformation and is expressed in the PEL cell lines, BCBL-1 and KS-1 
(Sadler ef a/., 1999; Muralidharef a/., 2000; Kliche etal., 2001).
1.3.2 Lytic infection
The majority of the HHV-8 genome remains silent during latent infection. The 
programme of gene expression during lytic replication was revealed by DNA array 
expression profiling of PEL cell lines without and with stimulation by TPA (Jenner et 
a/., 2001; Paulose-Murphy et a/., 2001). The lytic genes mainly express class II and 
class III transcripts (Sarid et a/., 1998). The first group of genes expressed after the 
induction of lytic replication are typically regulators of gene expression, including the 
immediate early transactivators. Viral homobgs of cellular genes involved in 
regulation or signal transduction are expressed after the viral regulatory genes but 
before those involved in DNA replication. The structural genes and those involved in 
virus expression and maturation are expressed later, generally after 24 h post­
induction (Jenner ef a/., 2001 ).
Class II transcripts major lytic genes that are transactivators and homologues of 
cellular genes are as follows:
1.3.2.1 ORFs 50, K8 and 57
The first groups of genes expressed after the induction of lytic replication are typically
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regulators of gene expression including the immediate early transactivators ORF 50 
(Rta or Lyta), ORF K8 (Zta or Kb-ZIP) and ORF 57 (post-transcriptional regulator of 
gene expression) (Jenner et al., 2001). The ORF 50/Rta promoter region is heavily 
methylated in latently infected cells. Déméthylation of the promoter by TPA induces 
lytic cycle replication (Chen at al., 2001). It has been demonstrated that the ORF 50 
protein is capable of stimulating HHV-8 lytic genes through transcription cascades 
resulting in replication of the virus in vitro similar to the Zta and Rta proteins of EBV 
(Renne etal., 1996b).
1.3.2.2 ORFs K4, K4.1 and K6
ORFs K4, K4.1 and K6 (located at the left end of LUR) of HHV-8 encode three 
secreted chemokines (chemoattractant cytokines). Viral macrophage inflammatory 
proteins (vMIP-l, vMIP-ll and vMIP-lll) are encoded by ORFs K4, K4.1 and K6, 
respectively (Moore et al., 1996a; Neipel et al., 1997; Nicholas et al., 1997). vMIP-l 
and vMIP-ll share 50% similarity at the amino acid level (Moore et al., 1996a) while 
vMIP-lll is less closely related. The three chemokines have been shown to induce 
angiogenesis, suggesting their roles in the pathogenesis of KS (Luttichau et al., 
2007). vMIP-l binds selectively to the CCR8 chemokine receptor, expressed 
predominately on Th2 type T cells, and acts as a CCR8 agonist (Endres et al., 1999; 
Dairaghi et al., 1999), while vMIP-ll acts as a specific agonist of CCR3 (Boshoff et al.,
1997) and vMIP-lll of CCR4 (Stine et al., 2000). All the three major chemokine 
receptors, CCR3, CCR4 and CCR8, are chemoattractant receptors for Th-2 
lymphocytes and their recruitment, and inhibit the Th-1 immune response thus 
potentially protecting HHV-8-infected cells (Stine et al., 2000).
1.3.2.3 ORF 16
ORF 16 of HHV-8 encodes a homologue of the cellular anti-apoptotic protein Bcl-2, 
with which it shares 16% sequence homology (Russo et al., 1996; Sa rid et al., 1997;
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Neipel et al., 1997; Cheng at a!., 1997). These HHV-8 v-bcl-2 transcripts can be 
detected at low levels in KS lesions and PEL cell lines, and can be induced in PEL 
cell lines by TPA (Sarid at a!., 1997).
The Bcl-2 family of proteins act as either inhibitors or promoters of apoptosis, playing 
an important role in tissue homeostasis and the immune response (Chao and 
Korsmeyer, 1998). The prosurvival function of cellular Bcl-2 is a result of 
heterodimerization with proapoptotic family members such as Bak, Bax, and Bad. 
However, the mechanism by which v-bcl-2 protects against apoptosis was initially 
unclear. Early cellular assays indicated that v-bcl-2 does not homodimerize nor 
heterodimerize with proapoptotic Bcl-2 family members such as Bak and Bax (Cheng 
at a/., 1997). However, more recently, it has been confirmed that v-bcl-2 has its own 
distinct selectivity for binding BH3 peptides from the proapoptotic proteins Bak, Bax, 
and Bad (Cheng at a/., 1997; Huang at a/., 2002).
1.3.2.4 ORF 74
ORF 74 of the HHV-8 genome encodes viral G-protein-coupled receptor (vGPCR) 
and is most related to the human interleukin 8 (IL-8) receptors. HHV-8 GPCR is a 
constitutively expressed chemokine-like receptor exhibiting affinity for a wide range of 
chemokines and does not require activation through an agonist (Arvanitakis at a/.,
1997). vGPCR expressed in NIH3T3 cells has been shown to induce tumour 
formation when injected into nude mice and conditional transgenic expression of 
vGPCR by cells of endothelial origin trigger an angiogenic programme in vivo, leading 
to development of an angioproliferative disease that resembles KS, and is essential 
for its progression (Jensen at a/., 2005; Thirunarayanan at a/., 2007). Before the 
discovery of HHV-8, AIDS-associated KS was already known to express elevated 
levels of vascular endothelial growth factor (VEGF) that lead to angiogenesis, and it 
was found that vGPCR-transfected cells secrete elevated levels of VEGF (Bais at a/..
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1998).
HHV-8-GPCR is capable of interacting with a much broader array of chemokines of 
both the CXC and CC families than most mammalian receptors, and can be modified 
in its signalling activity by them (Couty and Gershengom, 2004). Studies 
demonstrated that factors such as growth-related oncogene-alpha and -gamma can 
activate HHV-8-GPCR above its constitutive signalling level, and are, therefore, 
considered full agonists of the receptor (Arvanitakis et al., 1997; Rosenkilde and 
Schwartz, 2000). In contrast, factors such as the HHV-8-encoded CC chemokine 
vMIP-ll and human stromal cell-derived factor-1 alpha (SDF-1 alpha) are inverse 
agonists of HHV-8-GPCR since they inhibit HHV-8-GPCR constitutive signalling, 
converting the receptor from an active to an inactive state (Geras-Raaka etal., 1998).
HHV-8-GPCR utilizes a variety of signalling pathways to modulate the biology of its 
host. It activates the transcription factor NF-kappaB in primary endothelial cells and in 
a KS-derived endothelial cell line (Pati et al., 2001) and nuclear factor of activated T 
cells (NFAT) (Pati et al., 2003). Both NF-kappaB and NFAT activation induce 
secretion of several growth factors and proinflammatory and proangiogenic cytokines 
(IL-6 and IL-8), and increase the expression of adhesion molecules (e.g. VCAM-1, 
ICAM-1) (Bais et al., 1998; Pati et al., 2001; Schwarz and Murphy, 2001; Pati et al., 
2003). It has been suggested that strategies to block vGPCR may represent a novel 
approach for the treatment of KS (Jensen et al., 2005; Mutlu et al., 2007).
1.3.2.5 ORFK9
In addition to the latently expressed vIRFs discussed above, HHV-8 encodes other 
homologues of cellular IRFs lytically. The ORF K9-encoded vlRF-1 is homologous to 
cellular IRFs. It inhibits cellular responses to IFNs (Gao et al., 1997; Zimring et al.,
1998), and can down-regulate the transcriptional activation induced by IFNs alpha,
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beta , and gamma (Li et al., 1998). This activity suppresses the host’s IFN-mediated 
innate immune response to viruses. vlRF-1 also acts as an oncogenic protein by 
transforming rodent fibroblasts in vitro and causing tumour formation in nude mice 
(Gao at a/., 1997). It has been demonstrated that vlRF-1 can bind to p53 (Nakamura 
ef a!., 2001). By suppressing phosphorylation and acétylation of p53, vlRF-1 inhibits 
its activity and prevents apoptosis in the infected cell (Vogelstein at a/., 2000; 
Nakamura at a/., 2001). More recently, vlRF-1 has been shown to inhibit the 
transforming growth factor-beta (TGF-beta) signaling (Seo at a/., 2005). TGF-beta is 
known to control proliferation, differentiation and other functions in most cell types.
1.3.2.6 0RFK2
ORF K2 of HHV-8 encodes vlL-6, that is approximately 24% homologous to human 
IL-6 (hlL-6) (Moore at al., 1996c). vlL-6 is readily secreted by HHV-8-infected cells in 
PELs during latency, MCD and, to a lesser extent, in KS lesions (Moore at al., 1996c; 
Parravicini atal., 2000). Similar to hlL-6, vlL-6 activates signal transduction pathways 
through its interaction with the gp130 receptor, but unlike hlL-6, does not need to 
interact with the IL-6 co-receptor (IL-6R) to activate signalling. However, interaction 
with both gp130 and IL-6R may increase signalling efficiency (Wan at al., 1999) and 
more recently, it has been confirmed that vlL-6 is capable of utilizing human alpha 
receptor (IL-6Ralpha) as part of a hexameric complex with enhanced signaling 
potency (Boulanger at al., 2004). Both hlL-6 and vlL-6 are able to inhibit apoptosis 
and induce B-cell proliferation (Moore at al., 1996a). Mice inoculated with vlL-6- 
transfected NIH3T3 cells develop more highly vascularised tumours than control mice 
and the tumours also express higher levels of VEGF (Aoki at al., 1999). HHV-8 vlL-6 
and vGPCR have recently been found to upregulate expression of angiopoietin-2 
(Ang2), a secreted proangiogenic and lymhangiogenic molecule, in lymphatic 
endothelial cells. This expression is thought to contribute to the high level of Ang2 in 
individuals with KS; hence molecular mechanisms regulating its expression might
44
Chapter 1______________________________________________________________ Introductory Considerations
present a target for future anti-KS therapeutics (Vart et al., 2007).
A number of genes involved in nucleic acid synthesis are coded for in the HHV-8 
genome, in common with all herpesviruses (Roizman and Pellett, 2001). 
Rhadinoviruses, including HHV-8, encode a larger number of these proteins 
compared to other herpesviruses (Virgin et a!., 1997). Some of these proteins include 
DNA polymerase (0RF9), thymidine kinase (TK) (ORF 21), dihydrofolate reductase 
(DHFR) (ORF 2) and ribonucleotide reductase (ORF 60 and 61) (Russo et a!., 1996; 
Neipel et a/., 1997; Nicholas et a/., 1998; Goudsmit et a/., 2000). This group of genes 
is expressed as class III products during the late lytic phase. Their function may be to 
replace or enhance cellular DNA biosynthesis to aid in virion production.
1.3.3 Other HHV-8-encoded proteins
1.3.3.1 ORF 26
ORF 26 is a late gene which encodes the structural protein TRI-2 (Nealon et a/.,
2001). It displays lytic expression between 24 h to 48 h post-induction, with peak 
expression at 36 h (Jenner et a/., 2001; Paulose-Murphy et a/., 2001). TRI-2 joins 
with TRI-1 (ORF62) to form the heterotrimeric capsid triplexes (Nealon et a/., 2001). 
The triplexes reside between the hexomeric and pentomeric MCP (ORF 25) 
capsomers and make up the floor of the capsid. Two molecules of TRI-2 and one 
molecule of TRI-1 join to form each of the capsid's 320 triplexes (Nealon et ai., 2001 ). 
TRI-2 is present in 640 copies per capsid and is the second most abundant and third 
largest structural component of the capsid. TRI-2 is 21% identical and 41% similar to 
the HSV-1 triplex component VP23 (Nealon et ai., 2001 ).
1.3.3.2 ORF K l
ORF K1 is the first gene at the left end of the HHV-8 genome. It codes for a 46-kDa 
highly glycosolated transmembrane protein with similarities to the immunoglobulin
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receptor family (Neipel et al., 1997; Lagunoff and Ganem, 1997; Lee at a!., 1998a; 
Stebbing at a!., 2006). It is expressed in the early lytic phase after induction by TPA in 
PEL cell lines and is thought to have a transforming potential (Lee at a!., 1998b). 
Expression of K1 induces focus formation and morphological changes in Rat-1 
fibroblasts, and can immortalize common marmoset lymphocytes to IL-2-independent 
proliferation to induce lymphomas in vivo. While it has no homologues in other 
herpesviruses, there is an equivalent position in the HVS genome from which 
transforming proteins are encoded (Lee at a!., 1998b).
The K1 protein has been shown to initiate signalling pathways in B cells which result 
in the tyrosine phosphorylation of cellular proteins, mobilisation of intracellular 
calcium, and the activation of transcription factors such as NFAT (Lee at a!., 1998a; 
Lagunoff at a!., 1999; Damania at a/., 2000). It has also been shown to down regulate 
B-cell antigen receptor complex expression in the plasma membrane (Lee at a/.,
2000). The amino terminus of the protein interacts with p chains of B-cell receptor 
complexes to retain them in the endoplasmic reticulum, suggesting a role in the 
survival of HHV-8-infected cells. An additional role for the protein in mediating 
paracrine activation of cells in which it is expressed has been proposed (Samaniego 
at a/., 2001). They demonstrated that cells expressing the protein showed increased 
NF-B-dependent promoter activity. NF-B is responsible for activating a number of 
inflammatory responses. The K1 protein may therefore activate uninfected endothelial 
cells in a paracrine manner through the activation of NF-B-dependent promoters and 
secretion of inflammatory cytokines.
The K1 is a 289-amino acid hypervariable protein. K1 of most strains is conserved in 
the N-terminal region (amino acids 1-19, predicted to be the signal peptide sequence) 
and the C-terminal region (amino acids 227-276, predicted to be a hydrophobic 
transmembrane domain and a small intracellular domain), but is highly variable in the
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central region (amino acids 20-226, a predicted extracellular domain). Of the central 
region, the domain between amino acids 51-92 (variable region 1 or VR1) and 
between amino acids 191-231 (variable region 2 or VR2) are the most heterogenous 
(Figure 1.5). Certain segments within and connecting these two blocks are 
conserved, presumably to maintain the tertiary structure of the protein (Meng et al., 
1999).
Figure 1.5 Schematic illustration of the primary structure of the HHV-8 K1 protein
The signal peptide (SP) and transmembrane (TM) regions are indicated by stippling, and the 
two hypervariable domains VR1 and VR2 are indicated by crosshatching. Within the 
cytoplasmic (Cyt.) domain, the immunoreceptor tyrosine-based activation motif (ITAM) is 
indicated by solid black. [Source: Hughes and Hughes, 2007]
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1.4 Genomic variation among HHV-8 strains
Studies comparing HHV-8 sequences from both KS biopsies and PEL cell lines 
confirm that the genome is highly conserved, with only 0.1% nucleotide variation 
between sequences (Russo et al., 1996; Moore et al., 1996b; Neipel et al., 1997; 
Nicholas et al., 1997). Initial studies conducted on the genetic variability and 
polymorphism of HHV-8 focused on two small gene fragments of ORF 26 and ORF 
75 from KS specimens. However, ORF 26 was soon found to be one of the more 
highly conserved genes with only 2% divergence over a 500-bp region and very few 
substitutions that result in a change at the amino acid level (Moore and Chang, 1995; 
Huang et al., 1995; Boshoff et al., 1995b; Marchioli et al., 1996; Moore et al., 1996b; 
Zong et al., 1997). Limited sequence variation has also been found within two regions 
of ORF 75 (Zong et al., 1997). In a combined analysis of several genomic regions, 
including ORFs 26 and 75, Zong et al. (1997) found up to 1.5% only overall 
nucleotide variation between isolates, and grouped these into three different main 
variants, provisionally termed A, B and C (Zong et al., 1997). More recently, very low 
rates of sporadic variation were found within an extended ORF 26 region (965-bp) 
sequence at nucleotide positions other than the 26 characteristic polymorphorisms 
used to define the different genotypes (A/C, J, K/M, D/E, B, Q, R and N) (Zong et al., 
2007b).
ORF K1, by contrast, displays up to 16% nucleotide and 32% amino acid variability, 
with sequences clustering into four main genotypes, I to IV, based on phylogenetic 
analysis and distinctive deletions (Meng et al., 1999). Zong et al. (1999) also 
identified four main genotypes/subtypes, but assigned them A, B, C and D, and 
further divided these into subgroups based on amino acid differences of at least 5%. 
A more recent comprehensive study of 139 samples, from which at least VR1 
sequence data were available, has yielded 24 defined ORF K1 subtypes and 
confirmed that the subtypes correlate with ethnicity and geography (Zong et al..
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2002). This extreme polymorphism of ORF K1 has been exploited to investigate the 
genomic diversity of HHV-8 (Stebbing et al., 2006; Hayward and Zong, 2007). 
Subtypes A and C are the most related, while subtype B is the most divergent 
(Hayward, 1999; Hughes and Hughes, 2007) (Figure 1.6). The B subtype is found 
predominantly in sub-Saharan Africa or in persons of African heritage, and has only 3 
subgroups (B1, B2 and B3). Less frequently, African (Zong et a!., 2002; Treumicht et 
a!., 2002; Hayward and Zong, 2007) and Brazilian samples (Nascimento et a/., 2005) 
carry A5 subtype ORF K1 sequences. The A and C subtypes have a wide distribution 
throughout Europe, USA, Asia and the Middle East. The C2 variants predominate in 
both Saudi Arabian renal transplant-associated KS (Hayward, 1999; Zong et a/., 
1999) and classic KS from the USA and Scandinavia (Zong et a/., 2002). The C5 
variant, which is thought to be a hybrid between A and 0  genotypes (Hayward, 1999; 
Zong et a/., 1999), has been identified in Saudi Arabian renal transplant-associated 
KS (Hayward, 1999; Zong et a/., 1999) and in Morrocan classical, post-transplant and 
AIDS-associated KS (Duprez et a/., 2006). The D subtype appears to be rare and 
isolated to the Pacific Island region (Poole et a/., 1999). Sequences recovered from a 
Brazilian Amerindian population showed a 25-30% variation in nucleotide sequence 
from types A to D. These have been assigned to a new variant termed ‘E’ (Biggar et 
a/., 2000). Subtype E is also hyperendemic in Ecuador (Whitby et a/., 2004) and 
Amerindians in French Guiana (Kazanji et a/., 2005). Two further subtypes, 
designated F and G, have recently been identified (Kajumbula et a/., 2006; Hayward 
and Zong, 2007). AIDS KS patients in the US are normally infected with subtypes A1, 
A4 and C3. The predominance of these few subtypes suggests a combination of 
multiple, but limited reactivation from endogenously infected descendants of 
immigrants from endemic parts of the world together with localized horizontal spread 
(Zong et al., 1999; Zong et al., 2002). An association of HHV-8 subtype A with 
homo/bisexual males has been reported in Brazil (Nascimento et ai, 2005).
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Figure 1.6 Predicted domain structure and key features of 0RF-K1
Hatched bars denote signal peptide and transmembrane (TM) domains. Predicted N- 
glycosylation sites (NXS/NXT) (solid triangles), the 12 conserved Cys residues (solid circles), 
locations of highly variable VR1 and VR2 domains and summary listing of major subtype 
amino acid difference values both within and outside of the VR blocks are indicated. [Source: 
Zong et al., 1999].
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In addition, a novel subtype has been identified only in South Africa, based on the 
analysis of the ORF 75 gene, and classified as subtype N (Alagiozoglou et al., 2000). 
At least two major variants of HHV-8 can be distinguished using the K15 gene 
between the ORF75 and the terminal repeat, situated at the right-end of the genome. 
The two variants, named P (predominant or prototype) and M (minor) alleles, show 
only 33% amino acid sequence identity (Poole et a/., 1999; Hayward and Zong, 
2007). The P allele is the more frequent among HHV-8 genomes characterized, and 
has been found in association with five K1 subtypes (A - E) (Poole et a/., 1999). The 
rarer M allele has thus far been found in association with the A, B and C subtypes 
(Poole et a/., 1999). The K15-M and K15-P alleles appear to share similar functions in 
spite of their extensive sequence difference, both inducing the activation of the Erk2 
and JNK1 kinases, the NF-kappaB transcription factor and the expression of similar 
range of cellular inflammatory genes (Wang et a/., 2007).
Loci across the genome have been investigated to determine whether the clustering 
patterns as suggested by ORF K1 sequencing can be confirmed. Data from three 
major loci, ORF 26, T0.7/K12 and ORF 75, confirm that a linkage exists across the 
genome with ORF K1 subtype patterns. In most instances, the four major ORF K1 
subtypes (A, B, C and D) can also be discriminated at these loci (Poole et a/., 1999). 
However, although there is a general trend for linkages at different loci across the 
HHV-8 genome, this is not always the case (Zong et a/., 2007a).
The wide geographical and ethnic distribution of ORF K1 subtypes suggests that the 
major subgroups originated in paleolithic times through isolation and founder effects, 
associated with the expansionary migrations of modem humans out of east Africa 
first into sub-Saharan Africa starting 100,000 years ago (B subgroup), then into South 
Asia, Australia and the Pacific Rim beginning 60,000 years ago (D/E subgroup), with 
very little subsequent remixing, and, finally, as two major branches into Europe and
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North Asia (both via the Middle East) between 10,000 and 35,000 years ago (A and C 
subgroups) (Zong et al., 1999; Stebbing et al., 2006; Hayward and Zong, 2007). 
Within the A and C branches, individual variant clades (A1 to A10 and Cl to 07) 
probably arose between 10,000 and 12,000 years ago as human populations 
expanded out from a limited number of Eurasian Ice Age refuges (Hayward and 
Zong, 2007).
1.5 Tropism of HHV-8
1.5.1 Detection of HHV-8 in KS, PEL and MOD affected tissue 
HHV-8 DMA has been found in biopsy samples of all forms of KS irrespective of 
geographic origin, age, or gender of the patient (Chang et al., 1996; Kasolo et al., 
1997; Penn, 1997; Metaxa-Mariatou et al., 2004; Mwakigonja et al., 2007; Pak et al., 
2007). The HHV-8 infection load appears to be higher in oral than in AIDS-related 
cutaneous KS tissue (Pak et al., 2007).
In the KS tissue, HHV-8 DMA is present in a latent form in the vascular endothelial 
and spindle cells (Boshoff et al., 1995a; Decker et al., 1996; Sturzl et al., 1997; 
Staskus et al., 1997; Schulz, 1998; Dupin et al., 1999), in addition to lytic virus 
present in a low number of infiltrating inflammatory monocytes (Blasig et al., 1997). 
Experiments using PCR in-situ hybridization reveal that HHV-8 can infect the atypical 
endothelial cells lining the vascular spaces in KS lesions and endothelial tumour 
(spindle) cells of fully developed, nodular KS lesions, but is not generally present in 
normal endothelial cells (Boshoff et al., 1995a; Li et al., 1996). This has been 
confirmed by microdissection studies (Boshoff et al., 1995a). In-situ hybridization 
(Staskus et al., 1997) and immunohistochemical studies localising with LANA 
(Rainbow et al., 1997) have confirmed HHV-8 gene expression in KS spindle cells 
within tumours.
52
Chapter 1______________________________________________________________ Introductory Considerations
HHV-8 DNA has also been detected in PELs (Cesarman et al., 1995b; Dupin et a!.,
1999). PEL cell lines such as BCBL-1 and BC-3 carry HHV-8 in a latent form, and lytic 
replication can be induced by TPA (Renne et al., 1996a; Schulz, 1998; Dupin et al.,
1999). It appears that the cellular tropism of HHV-8 varies with the lesion involved. 
Staskus et al. (1999) used IL-6 expression as a marker of HHV-8 involvement in KS, 
PEL and MCD. They demonstrated that although PEL parallels KS in the pattern of 
latent and lytic cycle viral gene expression, the predominant infected cell type in PEL 
is the B cell, compared to spindle and endothelial cells in KS. MCD differed from KS 
not only in the infected cell type (B-cell and T-cell lineage) but also in the pattern of 
viral gene expression, with only a few cells in the lesion infected and all of these cells 
expressing lytic-cycle genes (Staskus et al., 1999).
1.5.2 Detection of HHV-8 in non KS, PEL and MCD affected tissue
1.5.2.1 Skin other than KS
HHV-8 DNA has been detected in normal skin of patients with HIV-associated KS 
(Gaidano et al., 1996; Cort)ellino et al., 1996c; Smith et al., 1997b), with classic and 
endemic KS (Dupin et al., 1995; Lebbe et al., 1997) and in HIV-negative organ 
transplant patients without KS (Rady et al., 1995). The HHV-8 infection load appears 
to be lighter in the normal skin than in KS lesions (Dupin et al., 1995).
1.5.2.2 Gastrointestinal tract
Early reports suggested that HHV-8 DNA is rarely detected in throat swabs and 
sputum of HIV-infected patients with KS (Whitby et al., 1995). Initial studies also 
suggested that HHV-8 DNA was not present in saliva of patients with HIV-related KS 
(Ambroziak et al., 1995), but subsequent workers have found HHV-8 DNA not only in 
oral KS lesions (Jin et al., 1996; Flaitz et al., 1997; Mwakigonja et al., 2007; Pak et 
al., 2007) but also in the normal oral mucosa of healthy immunocompetent (Duus et 
al., 2004) and HIV-seropositive individuals (Triantes et al., 2004) and in tonsils and
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adenoids of children (Chagas et al., 2006b). HHV-8 has also been detected in 
gingival biopsies and crevicular fluid samples (Mardirossian at a!., 2000) and in oral 
ulcers (Di Alberti at a!., 1997c; Syrjanen at a!., 1999) from HIV-seropositive patients, 
and in saliva of people who were or were not co-infected with HIV and those with or 
without active KS and can be present in both cellular and cell-free salivary fluid 
(Blackboum at a!., 1998).
HHV-8 DNA was detected: in mouth rinses from Zimbabwean women with KS 
(Lampinen at a/., 2000); whole unstimulated saliva and oral buccal and lingual 
scrapes from immunocompromised patients with HIV infection or persons with 
haematologic malignancies (Triantes at a!., 2004); saliva and mouth swabs from 
HHV-8 seropositive female prostitutes in Kenya (Taylor at a!., 2004); and saliva from 
children with sickle cell disease in Uganda (Mbulaiteye at a!., 2004). HHV-8 DNA was 
also found in saliva and oral swabs of HHV-8 seropositive homosexual American 
men with and without KS (Koelle at a/., 1997; Blackboum at a!., 1998; Pauk at a/., 
2000; Widmer at a/., 2006; Casper at a/., 2007). In addition, studies among HIV- 
infected patients with KS showed that the prevalence of salivary HHV-8 DNA were 
similar between patients with and without oral KS lesions and HHV-8 was also 
detected in saliva from patients with resolved KS (Koelle at a/., 1997).
Previous findings suggest that major salivary glands may not be important 
contributors to HHV-8 shedding (Pauk at a/., 2000; Corey at a/., 2002). However, 
HHV-8 lytic activation was found to occur as HHV-8-infected kératinocytes 
differentiate into mature epithelium, which in turn may be responsible for the presence 
of infectious HHV-8 in saliva (Johnson at a/., 2005). Furtherermore, the various oral 
compartments (e.g. saliva, mucosa) can harbour distinct HHV-8 strains suggesting 
that different strains may preferentially persist and replicate in different cell types 
(Beyari at a/., 2003).
54
Chapter 1______________________________________________________________ Introductory Considerations
HHV-8 DNA in oral fluid may be detected at levels independent of peripheral blood 
mononuclear cell (PBMC) viraemia (Lampinen et al., 2000) and may be intermittent 
(Koelle at a!., 1997; Pauk at a!., 2000; Laney at a/., 2004; Casper at a!., 2007), but 
individuals who shed virus at one time point are more likely to shed at other times 
(Laney at a!., 2004).
The detection of salivary IgA antibodies with specificities to a latent (ORF 73) and a 
lytic antigen (ORF K8.1) of HHV-8 in patients with regressed KS indicates anti-HHV-8 
antibody activity in saliva and their possible influence on mucosal replication of HHV-8 
(Mbopi-Keou at a!., 2004).
HHV-8 DNA has also been amplified from duodenal aspirates and intestinal biopsy 
tissue of HIV-infected individuals (Thomas at a!., 1996). However, stool samples 
could not be found HHV-8 DNA positive in one study (LaDuca at a/., 1998).
1.5.2.3 Paripharal biood
HHV-8 exhibits a broad in vivo and in vitro tropism for blood cells. HHV-8 DNA and 
transcripts have been identified in peripheral B cells, T cells, monocytes, circulating 
spindle cells, haemopoietic stem cells, progenitor endothelial cells and fibrocytes 
(Table 1.4). It has been suggested that HHV-8 infection of lymphocytes and 
monocytes is responsible for the dissemination of HHV-8, accounting for the 
multicentric nature of KS (Hengge at ai., 2002b).
HHV-8 DNA and transcripts have been identified in PBMCs of patients with KS 
(Humphrey at ai., 1996; Koelle at ai., 1997; Viviane at ai., 1997; Purvis at ai., 1997; 
LaDuca at ai., 1998; Metaxa-Mariatou at ai., 2004) and MCD (Kikuta at ai., 1997b). 
The detection rate of HHV-8 in PBMCs of individuals with KS is generally reported to
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be more than 50% and appears to be correlated with the stage and extent of KS 
(Campbell et al., 2000; Camera et al., 2000).
A polyclonal antibody specific for v-IL-6 has been used to demonstrate expression of 
viral cytokine in HHV-8-infected haematopoetic cells in lymph nodes and in un­
induced PEL cell lines (Moore et al., 1996a). The presence of circular and linear 
HHV-8 genomes in PBMCs was reported in one study, reflecting the presence of both 
latently and productively infected cells (Decker et al., 1996).
HHV-8 plasma viraemia has been suggested to be an important event in KS 
pathogenesis and detectable HHV-8 DNA in serum or plasma is usually associated 
with active disease (Harrington et al., 1996; Tedeschi et al., 2001; Campbell et al.,
2003).
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Table 1.4 HHV-8 in peripheral blood sub-populations
Ceil type CDMarker Details Reference
CD19 3 HIV-infected patients with KS (Ambroziak ef a/., 1995)
CD19 1 patient with post-transplant KS 
and 1 patient with AIDS-KS
(Harrington eta!., 1996)
CD19 B cells infected with HHV-8 from 
BC-1 cell line
(Mesri et al., 1996)
B cells
CD19 2 HIV negative patients with MCD 
and 1 patient with localized 
Castleman's disease (LCD)
(Kikuta eta!., 1997b)
CD19 9 patients with and 1 without KS (Henry et a!., 1999)
CD19 3 HIV-infected men with and 
without KS
(Monini eta!., 1999)
CD19 1 patient with stable and 2 patients 
with progressive KS
(Pellet et a!., 2006)
CDS 1 patient with post-transplant KS 
and 1 patient with AIDS-KS
(Harrington eta!., 1996)
CD2 2 HIV negative patients with MCD 
and 1 patient with LCD
(Kikuta et a!., 1997b)
T cells CD2 4 patients with AIDS-KS (Henry eta!., 1999)
CDS 1 patient with AIDS-KS (Sirianni et a!., 1997b)
N/S 1 late stage AIDS-KS patient (Monini eta!., 1999)
CD2 1 patient with progressive KS (Pellet ef a/., 2006)
CD14 1 patient with classic KS and 2 
patients with AIDS-KS
(Henry et a!., 1999)
Monocytes N/S 5 HIV infected men with and without KS
(Monini eta!., 1999)
CD14 1 patient with stable and 1 patient 
with progressive KS
(Pellet et a!., 2006)
Circulating 
spindle cells
N/S
CD31
3 patients with AIDS-KS, 2 patients 
with post-transplant KS and 11 
with classic KS
1 HIV-1-infected gay man without 
KS
(Sirianni et a!., 1997a) 
(Kumar eta!., 2007)
Haemopoietic 
stem cells / 
progenitor 
endothelial 
cells, fibrocytes
CD34
CD34
1 patient with classic KS and 8 
patients with AIDS-KS
1 patients with stable and 3 
patients with progressive KS
(Henry eta!., 1999) 
(Pellet et al., 2006)
All
haemopoietic
cells
CD45 38 HIV-1-infected patients without 
KS and 9 blood donors
(Kumar et al., 2007)
N/S: not specified
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1.5.2.4 Genital tissue and fluids
Several studies suggest the presence of HHV-8 in prostatic tissues of some HIV- 
infected men with or without KS (Coitellino et al., 1996c; Staskus et al., 1997; 
Diamond et al., 1998; Montgomery et al., 2006). In situ hybridization (Staskus et al.,
1997) and immunohistochemistry (Montgomery et al., 2006) studies showed that 
HHV-8 gene expression in prostatic glandular epithelium is common in people without 
KS, lending support to the supposition that the virus is widely disseminated in the 
healthy male population. However, studies by PCR have not yet identified prostatic 
tissue from men without KS to be infected with HHV-8 (Tasaka et al., 1996; 
Corbellino et al., 1996a; Rubin et al., 1998).
HHV-8 was found to be preferentially detected in semen rather than spermatocytes, 
suggesting secretion into seminal fluids (Monini et al., 1996b; Howard et al., 1997), 
but it cannot be excluded that HHV-8-infected mononuclear cells occasionally 
represent the source of HHV-8 in semen. It has been detected in some semen 
samples from HIV-infected patients with or without KS, but the reported detection 
rates in the United Kingdom and the United States vary from 0% (of only four 
samples tested) to 33% (Ambroziak et al., 1995; Marchioli et al., 1996; Gupta et al., 
1996; Howard et al., 1997). The results obtained in semen samples from healthy, 
HIV-seronegative donors are even more controversial. A high HHV-8 detection rate 
was reported from Italy, where it was initially reported to be 91% positive (Monini et 
al., 1996b), but later to be 23% positive (Monini et al., 1996a) similar to that detected 
in semen donors from the United States (Lin et al., 1995). On the other hand, no 
positive samples were found among 115 semen donors in the United Kingdom 
(Howard et al., 1997) or in 20 in Milan, Italy (Corbellino et al., 1996a). Some of these 
discrepant results probably reflect regional differences in HHV-8 prevalence, or 
selection of semen donors, or both.
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The genital tissues of women also harbour HHV-8, with the virus found in cervical 
and vaginal swabs from HIV positive African women (Lampinen et al., 2000; Taylor et 
al., 2004). However, HHV-8 has so far not been found in vulval mucosa or cervical 
malignancies of females without a history of HIV disease (Tasaka et al., 1997).
1.5.2.5 Respiratory tract
HHV-8 DNA has been detected in nasal secretions (Blackboum et al., 1998) and in 
bronchoalveolar lavage (BAL) fluid from severely immunocompromised HIV-infected 
patients with pulmonary symptoms. HHV-8 DNA in BAL fluid may indicate the 
presence of subclinical KS (Tarp et al., 2001 ).
1.5.2.6 Neuronal tissue
There are limited data available, as yet, about the possible neurotropism of HHV-8. It 
has been suggested in one report that dorsal root ganglia in patients with AIDS and 
KS harbour viral DNA (Corbellino et al., 1996b). HHV-8 has also been detected in the 
cerebrospinal fluid from HIV-infected patients (Brink et al., 1998). Furthermore, HHV- 
8 DNA has been demonstrated in cerebral tissue from patients with multiple sclerosis 
and also in healthy brain tissue (Merelli et al., 1997; Chan et al., 2000).
1.5.2.7 Urine
Urine has recently been identified as another body fluid into which HHV-8 can shed. 
HHV-8 was detected in urine samples from 6.4% of Malawian KS patients (Beyari et 
al., 2004),11% of Brazilian KS patients and 28% of HIV-1-infected patients without 
KS (Santos-Fortuna and Caterino-de-Araujo, 2005).
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1.5.2.8 In vitro studies
In vitro, HHV-8 has been shown to infect a variety of human and animal cells, such as 
human B cells, human epithelial cells, human endothelial cells, human foreskin 
fibroblast cells, human carcinoma cells (bladder, prostate, lung, and squamous), owl 
monkey kidney cells, and baby hamster kidney (BHK-21) cells (Flore et al., 1998; 
Renne et al., 1998; Moses et al., 1999; Vieira et al., 2001). Indeed, Bechtel et al. 
(2003) confirmed that most adherent cell lines, irrespective of species of origin or 
tissue lineage, are permissive for HHV-8 viral entry and the establishment of latency 
(Bechtel et al., 2003). This indicates a wide distribution of receptors, possibly 
integrins, capable of binding to the virus (Akula et al., 2002).
1.6 Routes of HHV-8 transmission
The primary mode of HHV-8 transmission remains unresolved. Extensive evidence 
exists for both sexual transmission (Lin et al., 1995; Howard et al., 1997; Casper et 
al., 2002) and non-sexual transmission (Koelle et al., 1997; Vieira et al., 1997; 
Blackboum et al., 1998; Lampinen et al., 2000; Pauk et al., 2000; Duus et al., 2004; 
Triantes et al., 2004; Widmer et al., 2006; Casper et al., 2007).
1.6.1 Sexual transmission
Transmission of HHV-8 is primarily sexual among homosexual men (Vieira et al., 
1997; Melbye et al., 1998; Martin et al., 1998; Dukers et al., 2000; Casper et al., 
2002; Martre et al., 2007). HHV-8 infection is more common among people practising 
high-risk sexual behaviours (Casper et al., 2006) and those attending sexually 
transmitted disease clinics than blood donors (Kedes et al., 1996; Simpson et al., 
1996; Lennette et al., 1996). An association of HHV-8 and HSV-2 infections was 
found in HIV-infected US military men (Crum et al., 2003) and Italian prison inmates 
(Sarmati ef a/., 2007), further suggesting sexual HHV-8 transmission. Further 
evidence comes from the finding of nearly identical HHV-8 strains in Cuban HIV
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couples discordant for KS (Kouri et al., 2007).
However, the specific mechanisms of transmission remain controversial (Martro et 
a!., 2007). Some of the early studies on the relationship between KS and sexual 
practices report an association between oral-anal sex and AIDS KS (Grulich and 
Kaldor, 1996; Vieira eta!., 1997). One study associated specific sexual techniques to 
serococonversion (Dukers et a/., 2000), implicating recent oral-genital sex as a strong 
risk factor. Cross-sectional studies have demonstrated an association between the 
presence of HHV-8 antibodies and anal-genital sex, oral-anal sex, and deep kissing 
with an HIV-1-positive partner (Melbye et a/., 1998; Grulich et a/., 1999; Pauk et a/., 
2000).
On the assumption that HHV-8 can be sexually transmitted, the virus would need to 
be shed at high titres in semen. Indeed, HHV-8 DNA has been detected in prostate 
tissue biopsies of HIV-seropositive men with and without KS (Corbellino et a/., 1996c; 
Staskus et a/., 1997; Diamond et a/., 1998; Montgomery et a!., 2006), indicating that 
HHV-8 can be shed from the prostate into semen.
Furthermore, longitudinal studies of viral shedding have shown that HHV-8 is not 
substantially shed in semen or rectal tissue, but instead is persistently found in the 
oral cavities of many individuals (Pauk et a/., 2000; Corey et a/., 2002). Infectious 
HHV-8 has now been detected in high titres in saliva of HHV-8-seropositive 
individuals (Koelle et a/., 1997; Vieira et a/., 1997; Blackboum et a/., 1998; Pauk et 
a/., 2000). Since oral-genital sex is a common practice among homosexual men, as is 
deep kissing (Myers et a/., 1992; Pauk et a/., 2000; Dukers et a/., 2000; Crum et a/., 
2003), saliva rather than semen is now considered as a significant vehicle of HHV-8 
transmission.
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Among heterosexuals, correlations with sexual transmission have not been 
consistently maintained (Smith et al., 1999; Wawer et al., 2001). Heterosexual 
transmission is not likely to be a major route and seems to require frequent sexual 
exposure to occur. HHV-8 prevalence is elevated in heterosexuals who report 
consorting with multiple sexual partners (Bestetti et al., 1998; Tedeschi et al., 2000; 
de Sanjose et al., 2002).
1.6.2 Non sexual transmission
1.6.2.1 Horizontal /Household
There is gathering evidence that sexual transmission is not the primary route of 
infection with HHV-8 in countries of high prevalence. In Africa, HHV-8 seroprevalence 
is relatively high in children, with seroprevalence reaching adult levels before 
adolescence (Mayama et al., 1998; Gessain et al., 1999; Plancoulaine et al., 2000). 
These data suggest transmission via close, non-sexual routes. Intrafamilial 
transmission has been suggested by the presence of HHV-8 DNA in households with 
high density or crowding (Mbulaiteye et al., 2004; Brown et al., 2005) and by the 
finding that children are more likely to be HHV-8 seropositive if they have mothers or 
siblings who are seropositive (Plancoulaine et al., 2000; Mbulaiteye et al., 2005; 
Simonart, 2006). Clustering of HHV-8 seroprevalence between spouses, children, 
and siblings was demonstrated in a Sardinian study population (Angeloni et al.,
1998).
In Middle Eastern countries, evidence of HHV-8 infection in children also supports 
non-sexual transmission. In Egyptian children, HHV-8 seroprevalence exceeded 50% 
in children older than 6 yr and increased steadily up to 10 yr, thereafter stabilising 
(Andreoni et al., 1999). In these children, HHV-8 primary infection has been positively 
associated with close contact with at least two other children in the community, 
pointing to saliva as an important route of paediatric infection (Andreoni et al., 2002).
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Moreover, for Israeli children, HHV-8 seroprevalence also rises with age. Davidovici 
et al. (2001) reported that HHV-8 infection in children of a seropositive mother was 
influenced by the antibody titre of the mother, but was unassociated with the HHV-8- 
infected father.
Gessain at al. (1999) found HHV-8 infection to be common among children in 
Cameroon. Seroprevalence steadily increased from 27% at age of 4 yr to 39% in the 
12-14 yr group, to above 48% in children over 15 yr, approaching the level of HHV-8 
infection in adults. Plancoulaine at al. (2000) studied a population of villagers of 
African origin in French Guiana and showed that the HHV-8 seroprevalence was 15% 
by age of 15 yr and rising sharply to about 30% after 40 yr; they provided evidence to 
implicate horizontal familial transmission between children and their mother but not 
their fathers, and between children and their siblings. A similar study conducted in 
rural Tanzania found associations between the HHV-8 serostatus of spouses and 
between the serostatus of a father and that of his children (Mbulaiteye at al., 2003b).
In a study of KS patients and their first-degree relatives in Malawi (Cook at al., 2002a; 
Cook at al., 2002b), and between Ugandan mother-child pairs (Mbulaiteye at al.,
2006), both identical and non-identical HHV-8 sub-genomic sequences were 
observed between family members, suggesting transmission of HHV-8 along both 
intra- and extra-familial transmission routes.
A recent study in sub-Saharan Africa demonstrated the absence of HHV-8 DNA in 
the breast milk of seropositive mothers, suggesting that contact with breast milk is not 
a likely source of horizontal transmission of virus to infants (Brayfield at al., 2004). 
However, a study conducted by Dedicoat and co-workers in South Africa showed 
presence of HHV-8 DNA in 12 out of 43 breast milk samples (Dedicoat at al., 2004). 
A positive correlation with hepatitis B infection suggests that HHV-8 is transmitted
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horizontally in conditions of close contact and crowding (Mayama et al., 1998). 
Although the precise mode of non-sexual horizontal transmission has not been clearly 
established, the relatively frequent carriage of HHV-8 in oral fluids suggests that 
transmission may occur via shedding from the oral cavity.
1.6.2.2 Oral
There have been an increasing number of studies whose results support the 
hypothesis that the mouth and oropharynx are dominant sites of HHV-8 shedding, 
and saliva as an important vehicle of HHV-8 transmission (Koelle et al., 1997; 
Gessain et al., 1997; Di Alberti et al., 1997a; Blackboum et al., 1998; Plancoulaine et 
al., 2000; Lampinen et al., 2000; Cook et al., 2002a; Beyari et al., 2003; Taylor et al., 
2004; Duus et al., 2004; Triantos et al., 2004; Mbulaiteye et al., 2004; Mbopi-Keou et 
al., 2004; Martro et al., 2004; Widmer et al., 2006; Chagas et al., 2006a; Casper et 
al., 2007; Pak et al., 2007; de Souza et al., 2007b). In addition, the high prevalence of 
infection before adolescence in endemic areas and the higher frequency of the 
detection of HHV-8 in saliva compared with semen (Pauk et al., 2000) provide 
indirect evidence of non-sexual transmission.
In U S HIV-infected homosexual men, increased HHV-8 oropharyngeal shedding has 
been observed to correlate with increased CD4 count, inflammation in the oral cavity 
and absence of antiretroviral therapy (Casper et al., 2004). However, Widmer et al. 
(2006) reported the detection of oral HHV-8 in the Swiss HIV-infected Cohort Study 
patients with or without KS not to be influenced by patients HIV immune status, but 
did observe a trend toward higher detection in patients with KS. They also reported 
that oral HHV-8 shedding had no predictive value either for the development of KS 
lesions or for survival.
Although the virus has been detected in saliva, the identities of the cell types
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harbouring HHV-8 in vivo in the oral cavity and producing virus particles is unclear. 
Corey et ai. (2002) compared HHV-8 DNA content in whole saliva versus parotid duct 
secretions and found HHV-8 to be absent or markedly lower in parotid fluid than 
whole saliva; minor salivary gland biopsies performed in 4 HHV-8-seropositive 
persons who shed HHV-8 in their saliva showed no evidence of HHV-8 in the biopsy 
tissues using in situ hybridization. However, HHV-8 DNA has been previously found 
in buccal cells of healthy immunocompetent individuals (Duus at a/., 2004) and 
buccal and palatal exfoliates of Malawian KS patients and their relatives (Cook at a/., 
2002a; Cook at al., 2002b; Beyari at a/., 2003). In addition, the ability of the virus to 
infect primary human kératinocytes has also been shown (Cerimele at a/., 2001; Duus 
at a/., 2004).
A model of reactivation and shedding similar to EBV has been suggested in which 
HHV-8 shed into the mouth originates from activation in latently infected B cells 
infecting the epithelial cells that line the lymph nodes (Sixbey at a/., 1984; Bigoni at 
a/., 1996; Ivarsson at a/., 1999). In palatine tonsils of two HIV-infected HHV-8- 
seropositive persons, the lytic gene products of HHV-8 in B cells within the germinal 
centre and the epithelial lining of tonsil could be detected, suggesting that lytic 
replication of HHV-8 in B cells within the germinal centre may transfer HHV-8 to the 
epithelial surface either by its migration to the surface epithelium or by contiguous 
infection (Corey at a/., 2002). An alternative model suggests that HHV-8 persists and 
replicates in oral epithelial cells of KS patients or even of healthy individuals, and that 
these are the principal source of virus in saliva (Vieira at a/., 1997; Duus at a/., 2004).
A study in South Africa reported that HHV-8 DNA was detectable in 145 of 978 
maternal saliva samples (mean virus load: 488,450 copies/ml), suggesting saliva as a 
significant vehicle of mother-to-child transmission (Dedicoat at a/., 2004). HHV-8 may 
therefore be transferred from mother to child via premastication of food and use of
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shared saliva-contaminated items. Other than close contact and the use of shared 
items (spoons, plates, etc.) in an endemic area like Africa, behavioural practices 
associated with saliva exchange in sub-Saharan Africa may play a role in 
transmission of HHV-8. The use of saliva in healing medical practices, religious 
initiation or ritual practices, and feeding practices have been implicated (Wojcicki, 
2003; Wojcicki et al., 2007). However, close contact and sharing amongst patients in 
renal care units has not yet been fully investigated.
1.6.2.3 Vertical
Whether HHV-8 infection may be transmitted from mother to child is still unclear, with 
studies showing conflicting results. A study in South Africa suggests a rate of vertical 
transmission as high as 30% (Bourboulia et al., 1998). Other studies showed that 
transmission appears to increase with increasing maternal antibody titres (Sitas et al., 
1999b; Lisco et al., 2006). However, It has been demonstrated that seropositive 
infants bom to seropositive mothers, later become seronegative by 24 months 
(Calabro et al., 2000), suggesting that positive results are due to the transfer of 
maternal antibodies (Gessain et al., 1999; Calabro et al., 2000). On the other hand, 
Mantina et al. (2001) showed detection of viral DNA in PBMCs at the time of delivery 
for 2 of 89 infants bom to HHV-8-seropositive mothers, which suggests that in utero 
infection occurs but rarely (Mantina et al., 2001). A study in Zambia showed no 
association between the HHV-8 infection rates among infants and their respective 
mothers (Brayfield et al., 2003). A more recent study in Italy also suggests that 
vertical transmission of HHV-8 is either unlikely or very rare (Sarmati et al., 2004).
1.6.2.4 Blood
HHV-8 also appears to be transmissible, although less frequently, via exposure to 
blood. Some studies suggest that blood transfusion is associated with a very small 
risk of HHV-8 transmission (Operskalski et al., 1997; Engels et al., 1999; Challine et
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al., 2001; Pellett et a!., 2003; Mbulaiteye et a!., 2003a; Garcla-Astudiilo and Leyva- 
Cobian, 2006), with the paucity of B lymphocytes, accompanying most types of 
transfusion, thought to contribute to this low transmission risk (Engels et ai., 1999). 
Furthermore, previous studies have shown HHV-8 infection to be relatively rare in 
frequently transfused groups, such as haemophiliacs (Operskalski et a!., 1997) and 
thalassemia or sickle cell anemia patients (Lefrere et a!., 1997). In addition, low- 
prevalence areas generally show a similar prevalence of HHV-8 between injecting 
drug users (IDUs) and the general population (Renwick et a!., 2002).
On the other hand, a number of studies (Velez-Garcia et a!., 1985; Bendsoe et a!., 
1990; Padilla et ai., 1990; Aboulafia et al., 1991 ; Belec et al., 1998; Baillargeon et al., 
2001; Enbom et al., 2002) implicating that transfusion and parenteral exposure are 
risk factors for KS have long existed. Some studies, which were performed in 
intermediate or high endemic populations, have shown that the HHV-8 prevalence is 
somewhat higher among IDUs compared with the general population (Cannon et al., 
2001; Sosa et al., 2001; Parisi et al., 2002). Furthermore, the recovery of infectious 
HHV-8 from a seropositive healthy North American blood donor (Blackboum et al.,
1997) and HHV-8 transmission by blood transfusion in the US (Dollard et al., 2005) 
and Uganda (Hladik et al., 2006) have been reported. Selective screening for HHV-8 
during cellular therapy (Lefrere et al., 2007) and blood transfusion in 
immunocompromised populations (Baillargeon et a i, 2001; Hladik et a i, 2006; Moore 
et a i, 2007) have been suggested.
1.6.3 Haemodialysis
HHV-8 transmission in the haemodialysis setting has been a controversial issue. 
Some studies have found a higher prevalence of HHV-8 antibodies in hemodialysis 
patients than in the normal blood donors (Qunibi ef ai, 1998; Regamey ef ai, 1998; 
Hsu ef ai, 2002), or a higher risk of occupational HHV-8 infection among medical staff
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caring for HHV-8 risk group patients including patients on haemodialysis (Gartner et 
al., 2003), suggesting that this transmission route may be possible. Other studies 
comparing HHV-8 antibodies in haemodialysis patients with that in the general 
population (Luppi et a!., 1999; Cattani et ai., 2001; Di Stefano et a!., 2006) and 
analysing patterns of change in HHV-8 serostatus (Zavitsanou ef a!., 2006) suggest 
HHV-8 transmission in the haemodialysis setting to be uncommon .
1.6.4 Organ transplantation
Studies from various groups, which generate findings based on serology and 
molecular tracking of infection, have shown that organ-related transmission of HHV-8, 
especially in regions where the virus is not endemic, is more common than previously 
thought (Parravicini ef a/., 1997; Regamey ef a/., 1998; Luppi ef al., 2000a; Luppi ef 
al., 2000b; Sarid ef al., 2001; Cattani ef al., 2001; Kapelushnik ef al., 2001; Munoz ef 
al., 2002; Barozzi ef al., 2003; Collart ef al., 2004; Marcelin ef al., 2004; Becuwe ef al.,
2005) and that the risk of KS could be exceedingly high when the organ donor and 
recipient are both HHV-8 seropositive (Bergallo ef al., 2007). The development of the 
neoplasm may reflect a decreased capacity of the host to destroy cells haitouring 
latent HHV-8 because of continuous immunosuppression (Bottalico ef al., 1997). 
Accordingly, systematic screening for HHV-8 antibodies in recipients and organ 
donors (Milliancourt ef al., 2001), screening of grafts for HHV-8, use of post­
transplantation HHV-8 diagnostics (Marcelin ef al., 2007), pre-emptive interventions in 
HHV-8 infected individuals with antivirals (Luppi ef al., 2003; Garcia-Astudillo and 
Leyva-Cobian, 2006), and the use of donor-derived HHV-8-specific T cells for the 
control of post-transplant KS (Barozzi ef al., 2003) have been advocated.
However, in regions where the virus is endemic, such as Italy, most recipients of renal 
allografts are seropositive for HHV-8 before transplantation, but none show clinical 
manifestations of KS until immunosuppressive therapy begins, which suggests that
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post-transplant KS is caused by virus reactivation (Parravicini et al., 1997; Cattani et 
a!., 2001; Weigert et a!., 2004; Bergallo et a!., 2007). Post-transplant primary virus 
transmission from an outside source rather than donor-to-recipient transmission has 
also been suggested (Jenkins et a!., 2002; Bergallo et a!., 2007). Primary infection 
after transplantation has been suggested to pose a greater risk of complications than 
does reactivation of pre-existing virus (Sarid ef al., 2001; Marcelin ef al., 2004) and 
early post transplant KS seems to be associated with a poorer outcome (Cozar ef al., 
1990). Therefore the distinction between HHV-8 reactivation and primary infection 
may be important for predicting outcome in regard to KS development.
1.7 Primary HHV-8 infection
Clinical manifestations of primary infection with HHV-8 have been described but are 
not thought to be associated with significant concurrent morbidity in 
immunocompetent populations (Kasolo et a i, 1997; Kikuta ef a/., 1997a; Plancoulaine 
ef ai, 2000; Luppi ef ai, 2000b; Andreoni ef ai, 2002). In immunocompetent children, 
primary HHV-8 infection may be asymptomatic or associated with a febrile 
maculopapular rash (Plancoulaine ef ai, 2000; Andreoni ef ai, 2002; Gilden ef a i, 
2007).
The outcome of primary HHV-8 infection in immunosuppressed hosts can be 
variable, and it is also more difficult to directly attribute symptoms to HHV-8 rather 
than the immunosuppression. However, bone marrow failure, splenomegaly and 
fever have been reported in adult patients upon organ transplantation (Luppi ef ai, 
2000b) and transient angiolymphoid hyperplasia was found to occur as part of an 
HHV-8-seroconversion syndrome in an HIV-infected adult (Plancoulaine ef ai, 2000). 
Furthermore, a case report of an HIV-1-seropositive male noted HHV-8 
seroconversion five weeks prior to the sudden onset of symptoms, which included 
fever, arthralgia, cervical lymphadenopathy, and splenomegaly. PCR of the cervical
69
Chapter 1______________________________________________________________Introductory Considerations
mass specimen revealed HHV-8 DNA, vascular hyperplasia, and "intense" activation 
and proliferation of B cells which was negative for EBV gene expression. The febrile 
episode was prolonged but resolved spontaneously within 2 months (Oksenhendler et 
al., 1998a). It has also been reported that HIV-positive patients with evidence of 
subsequent HHV-8 seroconversion showed a greater relative risk for progression to 
KS than did those who had seroconverted for HHV-8 prior to HIV-1 infection 
(Goudsmit et a/., 2000). Hence it appears that primary HHV-8 infection has a higher 
morbidity in those who are HIV-1-infected than in those who reactivate a previous 
latent HHV-8 infection, as did primary infection after transplantation.
1.8 HHV-8 associated diseases
1.8.1 KS
KS is a vascular tumour that was brought to the attention of the medical community 
over a century ago in 1872 by the report of purple-coloured nodular skin lesions in 
five elderly men by Moritz Kaposi. Four epidemiological forms of KS based on clinical 
and epidemiological differences are now recognised: classic KS, endemic-HIV- 
negative KS, iatrogenic KS, and HIV-associated or epidemic KS. In 1994, Chang and 
co-workers reported the identification of fragments of herpesvirus-like DNA in AIDS- 
KS biopsy samples (Chang et a/., 1994). HHV-8 is now accepted as the etiological 
agent for all the various forms of KS.
1.8.1.1 Clinical features and epidemiology
The four distinct epidemiological forms of KS are characterized by different 
demographic parameters, risk factors, clinical presentation, and outcomes (Cohen et 
al., 2005). For many years, KS was thought to be a lesion that affected predominantly 
elderly patients of Mediterranean, East European, Arabic or Jewish ancestry 
(Franceschi and Geddes, 1995; Antman and Chang, 2000; Cohen et al., 2005); this 
form is known as classic KS. The incidence peaks after the decade of life
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(DiGiovanna and Safai, 1981). It affects the extremities, is generally indolent and is 
more common in men than women (sex ratio estimated to be from 3:1 to 15:1) 
(Franceschi and Geddes, 1995; Hengge et al., 2002a). Classic KS runs a chronic 
course and rarely metastasises. Patients survive an average of 10-15 yr before dying 
of unrelated causes (Cohen at a/., 2005). Complications include lymphoedema, 
hyperkeratosis and other neoplasms such as non-Hodgkin’s lymphoma and cutanous 
malignant melanoma (Fried man-Bimbaum eta!., 1990; Iscovich eta!., 1999).
KS was already present in equatorial Africa for many decades preceding the HIV 
epidemic (Oettle, 1962). A 1971 report showed that KS accounted for 9% of all 
reported cancers in Ugandan males (Taylor at a/., 1971). A study published in 1993 
showed that KS in HIV-negative and HIV-positive patients accounted for 
approximately 50% of all tumours diagnosed in men in some central African countries 
(Wabinga at a/., 1993). African or endemic KS is usually more aggressive than the 
classic form of KS (D'Oliveira and Torres, 1972). 'Endemic' KS affects two main age 
groups: young men with an average age of 35 yr and children with an average age of 
3 yr (Wabinga at a/., 1993). In adults, it presents as a benign nodular cutaneous 
disease or as a florid mucocutaneous oral visceral disease. In young children, it can 
be aggressive, with localised cutaneous disease progressing to invade adjacent soft 
tissues and bones or rapidly disseminating to lymph nodes and visceral organs.
The third form of KS has been described in iatrogenically immunosuppressed organ 
transplant recipients and in a wide spectrum of patients receiving chronic 
immunosuppressive therapy (Penn, 1983; Qunibi at a!., 1988; Farge, 1993; Szende 
at a!., 1997; Sachsenberg-Studer at a!., 1999; Garcia-Astudillo and Leyva-Cobian,
2006). Iatrogenic KS may be aggressive, involving lymph nodes, the mucosa and the 
viscera but remission can occur spontaneously after discontinuation of 
immunosuppressive therapy. However, there is a high risk of graft loss (Brooks,
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1986; Veroux et al., 2004; Moray et ai., 2004; Huang et al., 2004).
The fourth variant of KS, the 'epidemic' type, was identified in the early 1980s. It 
heralded the AIDS epidemic (Hymes et al., 1981), and was later recognised as an 
AIDS-defining condition in HIV-infected individuals, the most common neoplasm 
occurring in patients with AIDS (Beral et al., 1990; Rabkin et al., 1995) and the first 
clinical manifestation in about one quarter of AIDS patients (Goedert, 2000). The 
overall risk of KS in AIDS patients is estimated to be more than 20,000 times greater 
than that of the general population and 300 times that of other immunosuppressed 
patients (Beral et al., 1990). Striking differences in risks of acquiring AIDS-KS were 
observed between different HIV transmission groups, with the risk in homosexual 
men being more than men with haemophilia and the risk in women acquiring HIV 
from bisexual men being higher than heterosexual intravenous drug users (Haverkos 
and Drotman, 1985; Beral et al., 1990; Serraino et al., 1995; Goedert, 2000). Anti­
retroviral therapy (ART) has been shown to greatly reduce the incidence of KS in HIV 
disease (Gill et al., 2002; Cattelan et al., 2005; Grabar et al., 2006; Martro et al., 
2007). On the other hand, proliferation of KS as part of ART-associated immune 
reconstitution inflammatory syndrome has occasionally been observed (Weir and 
Wansbrough-Jones, 1997; Connick et a i, 2004; Nathan, 2007).
Epidemic KS is typically lymphoadenopathic and tends to involve the viscera and 
mucosa as well as the skin. It is commonly multifocal, symmetrical and frequently on 
the upper body, head and neck (Hengge et a i, 2002a; Wamburu et ai, 2006) and 
may involve the lower limbs (Onunu et a i, 2007). It may evolve quickly, both in local 
progression of lesions to tumours and in visceral dissemination, leading to organ 
dysfunction and high mortality (Hengge et ai, 2002a; Wamburu et a i, 2006). Before 
ART became available, oral KS was among the first clinical manifestations of AIDS 
(Silverman et ai, 1986; Schwartz, 2004), the oral KS lesion appearing as a red-
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purple macule, an ulcer, or as a nodule or mass. Intraoral KS occurs on the heavily 
keratinized mucosa, the palate being the site of predilection in more than 90% of 
reported cases; other affected sites include the gingiva, tongue and the buccal 
mucosa (Silverman ef a/., 1986; Epstein and Scully, 1991; Glick, 1992; Nichols et a i, 
1993). Intraosseous involvement of the jaws with KS has been reported (Langford et 
al., 1991; Nichols et al., 1995; Noel et al., 2007). The oral lesions may result in pain, 
dysphagia, difficulty with mastication, bleeding, and may be cosmetically displeasing 
(Epstein and Scully, 1991; Nichols et al., 1993; Flaitz et al., 1997). A female 
predisposition to oral KS has been observed recently in Tanzania, this being 
associated with HIV/AIDS and advanced nodular histopathology (Mwakigonja et al., 
2007).
1.8.1.2 Histogenesis of KS
The histopathology of the 4 clinico-epidemiological forms of KS is essentially the 
same, with characteristic changes related to stage in the development of the KS 
tumour. KS is a complex, multifocal, highly and abnormally vascularized tumour-like 
lesion which develops from early inflammatory stages of patch/plaque to late, nodular 
tumours composed predominantly of spindle cells (Pyakurel et al., 2007). In the 
“patch” stage the histological picture is that of endothelial-lined spaces surrounding 
normal blood vessels; there is often a variable degree of inflammatory infiltrate. The 
“plaque” stage is characterised by an increased growth of spindle-shaped vascular 
processes in the dermis, along with the formation of slit-like vascular spaces filled 
with erythrocytes. In the late, “nodular” stage, the lesion is comprised primarily of 
spindle shaped cells arranged in large sheets, some of which are undergoing mitosis, 
with slit-like vascular spaces and haemosiderin pigmentation (Cockerell, 1991).
KS represents a unique variant of tumour growth with continuous recruitment of 
tumour precursor cells as well as proliferation and decreased apoptosis of spindle
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cells (Pyakurel et al., 2006). KS may be a reactive proliferation rather than a true 
malignancy with metastatic dissemination (Duprez et a!., 2007). The spindle cells are 
thought to be the tumour cells that form the bulk of established KS but their 
histogenesis is unknown. The majority of spindle cells express lymphatic endothelial 
cell markers, including CD31 and CD34 markers. However, some express markers of 
smooth muscle cells, macrophages and dendritic cells (Nickoloff and Griffiths, 1989; 
Sturzl et a/., 1992), suggesting that spindle cells represent a heterogeneous 
population of cells, or cells that arise from a pluripotent mesenchymal precursor cell. 
All KS spindle cells express vascular endothelial growth factor receptor 3 (VEGFR-3), 
which is usually expressed only by lymphatic endothelium and by neoangiogenic 
vessels, but not by mature vascular endothelial cells, indicating that KS spindle cells 
may be of the endothelial lineage that can differentiate into lymphatic cells (Dupin et 
a!., 1999; Carroll eta!., 2004; Pyakurel et a/., 2006).
KS, like most tumours, produces and responds to cytokines. Spindle cells or 
infiltrating CD8+ lymphocytes and macrophages express high levels of IL-6, basic 
fibroblast growth factor (bFGF), gamma interferon, and a variety of other cytokines 
(Ensoli et a!., 1989; Miles et a!., 1990; Sirianni et a!., 1998; Fiorelli et a/., 1998; Dupin 
et a/., 1999). Biologically active IL-6 and bFGF can promote spindle cell proliferation. 
Gamma-IFN can induce KS-like tumour formation in nude mice and these tumours in 
turn produce bFGF (Ensoli eta!., 1989; Fiorelli eta!., 1998).
HIV-1-associated KS exhibits a more aggressive clinical course than the other types 
of KS. Therefore, it has been proposed that HIV-1 gene products may positively 
influence KS development (Ensoli et a/., 1994). The tat gene in HIV-1 codes for an 
early trans-activator protein (Tat) essential for HIV-1 viral replication (Fisher et a/., 
1986). It is released into the extracellular fluid during acute HIV infection, can 
promote spindle cell growth in vitro (Ensoli et ai., 1993) and induces an angiogenic
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phenotype in nude mice (Vogel et al., 1988). Normal endothelial cells display a 
spindle cell-like morphology when exposed to Tat in the presence of other cytokines 
(e.g. IL-1, tumor necrosis factor, and gamma interferon) in culture. Indeed, it has 
been proposed that these cytokines, whose production is up-regulated in persons 
with HIV-1 infection, work synergistically with Tat in KS development (Barillari et a/., 
1992). Studies have indicated that Tat may influence the specific tissue distribution of 
KS (nose, oral and genital mucosa) observed in HIV-infected individuals (Prakash et 
a!., 2000).
1.8.1.3 Establishing the causal role of HHV-8 in KS
Four observations link HHV-8 causally to the aetiopathogenesis of KS:
i) HHV-8 DMA is present, by PCR in all epidemiological forms of KS, in all fresh 
biopsies tested and in the vast majority of paraffin-embedded material (Moore and 
Chang, 1995; Ambroziak et al., 1995; Schalling et al., 1995; Boshoff et al., 1995b; 
Chang and Moore, 1996; Kasolo et al., 1997; Penn, 1997). The virus is found in HIV- 
positive and HIV-negative patients with KS (Ambroziak et al., 1995). To strengthen 
the molecular epidemiological association between HHV-8 and KS further, it was 
demonstrated by PCR in situ hybridization, RNA in situ hybridization and 
immunohistochemistry that HHV-8 is present in spindle cells in nearly all KS lesions 
(Boshoff et al., 1995b; Li et al., 1996; Sturzl et al., 1997; Rainbow et al., 1997; 
Staskus et al., 1997; Dupin et al., 1999; Kellam et al., 1999; Sturzl et al., 1999).
ii) The detection of HHV-8 DNA in PBMCs significantly correlates with the risk of 
developing classic KS (Brown et al., 2006). In addition, HHV-8 sequence may be 
detected by PCR in the peripheral blood of HIV-positive individuals before the onset 
of KS lesions (Whitby ef a/., 1995; Lefrere ef a/., 1996; Moore ef a/., 1996c). In 
individuals without KS or HIV infection, the HHV-8 detection rate in PBMCs is more 
variable.
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iii) Seroprevalence studies indicate that in populations at risk of developing KS, there 
was a higher prevalence of HHV-8 infection (to be discussed in more detail later). 
Epidemiological prospective cohort studies have shown that among HIV infected gay 
men seroconversion to HHV-8 is strongly predictive of the future development of KS 
(Melbye et al., 1998; Renwick et al., 1998; O'Brien et al., 1999; Jacobson et al., 
2000).
iv) HHV-8 encodes several genes that can stimulate cellular proliferation and 
migration, prevent apoptosis, and counter the host immune response (as described in 
Section 1.3), transforming cells in susceptible hosts to a malignant phenotype, 
thereby contributing to the establishment and progression of KS (Moore and Chang, 
2003; McAllister and Moses, 2007).
1.8.2 Primary effusion lymphoma
Primary effusion lymphomas (PEL), also known as body cavity-based lymphomas, 
are a type of high grade non-Hodgkin’s lymphoma that develop nearly exclusively in 
the pericardial, peritoneal and pleural cavities as lymphomatous effusion, usually in 
the absence of any identifiable tumour mass. Most cases occur in HIV-infected 
individuals (Cesarman and Knowles, 1997), but a small number of patients with PEL 
who are HIV-seronegative have been identified (Klepfish et al., 2001). Cesarman and 
co-workers (1995a) reported that HHV-8 was specifically associated with PEL, and 
they noted that PEL contains high viral copies when grown in vivo, rendering them 
useful for the characterisation of individual strains of the virus. Phenotyping may be 
difficult because the cells characteristically lack the lineage-restricted markers of both 
T and B lymphocytes. Clonal immunoglobulin gene rearrangement found in all cases 
studied has established PEL as a B-cell neoplasm (Cesarman and Knowles, 1999; 
Carbone and Gloghini, 2005). Co-infection of PEL cells by both EBV and HHV-8 has 
been observed (Hamoudi et al., 2004), but association with HHV-8 alone has also
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been reported (Said et al., 1996a; Co bo et a!., 1999). Notably, most PELs in HIV- 
seropositive patients are EBV-positive. However, EBV alone may not be sufficient for 
tumour development. Thus it is possible that HHV-8 acts in conjunction with EBV to 
induce full transformation (Miller, 1990; Cesarman et a/., 1995a). Thus far, no 
effective therapy has been established for HIV-associated PEL. Consequently, the 
prognosis is poor, and the reported median survival is about 18 weeks. Of interest 
are reports of clinical improvement after ART (Oksenhendler ef a/., 1998b).
1.8.3 Multicentric Castleman’s disease
Castleman’s disease (CD) (angiofollicular lymphoid hyperplasia or giant lymph node 
hyperplasia) is a rare, non-malignant, usually polyclonal form of lymphadenopathy 
(Frizzera, 1992). It is classified histologically into the hyaline-vascular type and the 
plasma cell type. Clinically, it may t>e classified into two forms: (i) localized CD, which 
is usually of hyaline-vascular histologic type, is located in the mediastinum in 70% of 
affected patients, and can usually be cured by surgical excision; or (ii) a systemic 
variant, multicentric Castleman’s disease (MCD), usually of plasma-cell type 
(Frizzera, 1992; Kardziev ef a/., 2006). MCD adopts an aggressive, often fatal clinical 
course and usually presents with multifocal lymphadenopathy and a variety of 
systemic symptoms, such as fever, rash, cytopenia, and hypergammaglobulinemia. 
This disease is common among AIDS patients; HHV-8 DNA sequences could be 
found in all HIV-related cases of MCD, in contrast to less than half in HIV- 
seronegative cases (Soulier ef a/., 1995). Moreover, HHV-8 viral load in the 
peripheral blood of MCD patients tends to correlate with the increased severity of 
symptoms, worse prognosis (Grandadam ef a/., 1997) and exacerbations 
(Oksenhendler ef a/., 2000). The clinical course of HHV-8-positive MCD tends to be 
poorer, particularly among HIV-seropositive individuals, and is not always improved 
by therapy with ART (Zietz ef a/., 1999; Dupin ef a/., 2000). HHV-8 DNA has been 
localised in plasmablasts of B cell lineage in the mantle zone of the B-cell follicles
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(Kellam et al., 1999; Katano et ai., 2000). The role of HHV-8 pathogenesis in MCD is 
not clear. However, vlL-6 is highly expressed in a subset of plasmablasts and may 
drive HHV-8-infected naïve B cells to become plasmablasts and to develop various 
lymphoproliferative lesions (Du et a!., 2001). In addition, patients with MCD may 
develop other HHV-8-associated diseases: PEL (Ascoli et a!., 2001), KS (Soulier et 
a!., 1995; Zietz et al., 1999), or both (Codish et al., 2000). Recently, a case of 
concomitant HHV-8-positive MCD and KS has been reported in the same lymph node 
of an HIV-negative liver transplant patient (Gaitonde et al., 2007).
1.8.4 Other diseases
HHV-8 infection has been proposed as an aetiological agent in a number of other 
diseases including multiple myeloma (Said et al., 1997; Hsu et al., 2001; Csire et al., 
2007), some reactive lymphadenopathies (Luppi et al., 1996), pemphigus vulgaris 
(Memar et al., 1997; Jang et al., 2000), a variety of skin carcinomas and lymphomas 
(Lazzi et al., 2006), sarcoidosis (Di Alberti et al., 1997b), primary pulmonary 
hypertension (Cool et al., 2003), hemophagocytic syndrome (Re et al., 2007), 
inflammatory myofibroblastic tumours (Gonzalez-Vela et al., 2007) and Kikuchi 
disease (Cho et al., 2007). Despite these associations, no conclusive evidence has 
been found to strongly link any of these diseases to infection with HHV-8.
1.9 HHV-8 epidemiology
1.9.1 Methods used to determine HHV-8 prevalence
HHV-8 DNA is readily detected by Southem blotting or PCR in KS, PEL and some 
lymphoid tissue from patients with MCD. Smaller amounts of viral DNA are present in 
non-neoplastic tissue from HHV-8-infected individuals, in particular in PBMCs, 
semen, urine, saliva and breast milk (Decker et al., 1996; Blackboum and Levy, 
1997; LaDuca et al., 1998; Dedicoat et al., 2004; Beyari et al., 2004). The detection 
rate of HHV-8 in PBMCs of individuals with KS is generally reported to be more than
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50% and appears to be correlated with the stage and extent of KS (Campbell et al., 
2000; Camera et al., 2000; Laney et al., 2007). Likewise HHV-8 DNA detection and 
viral load in patients with active KS is more frequent than in patients with disease 
remission (Aluigi et al., 1996; Albrecht et al., 2004; Laney et al., 2007). Furthermore, 
studies have suggested that the HHV-8 DNA detection rate in peripheral blood of KS 
patients and in patients subsequently progressing to KS is higher than in patients 
who do not develop KS or are at low risk of KS (Whitby et al., 1995; Lefrere et al., 
1996; Moore et al., 1996c; Smith et al., 1997b; Min and Katzenstein, 1999; Engels et 
al., 2003; Laney et al., 2007). The reported HHV-8 genoprevalence in individuals 
without KS is variable, particularly in healthy individuals without HIV infection (ranging 
from 0% to 80%) (Dupon et al., 1997; Kikuta et al., 1997a; Cattani et al., 1998; Belec 
et al., 1998; Hud nail et al., 2003; Zavos et al., 2005).
Viraemia, measured as viral DNA in serum or plasma, has also been estimated 
(Bourboulia et al., 2004). However, it has been reported that HHV-8 DNA in plasma in 
patients with KS may only be measured when the viral load in PBMCs is particularly 
high (Harrington etal., 1996; Boivin et al., 2002).
Many serological assay formats have been developed to test for the presence of 
HHV-8 antibodies and to complement testing by PCR. First generation assays were 
developed using HHV-8 infected PEL cell lines as the source of antigen. PEL cell 
lines express latent antigens, predominantly LANA which was the first serologic 
antigen identified by indirect immunofluorescence assay (IFA); while it is specific, it is 
generally less sensitive (about 80% sensitivity) (Gao et al., 1996b). Treatment of PEL 
cells with TPA induces expression of lytic antigens. IFA using lytic antigens can yield 
higher sensitivity rates than LANA assays. However, they suffer from problems 
associated with cross reactivity to other herpesvirus antibodies (Lennette et al., 
1996). In an early IFA report, the cell line used (BC-1 ) was dually infected with HHV-8
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and EBV, requiring absorption of EBV-specific antibodies to minimise cross-reactivity 
(Moore et al., 1996b). Lytic replication of HHV-8, but not EBV, could be induced in 
BC-1 cell lines with n-butyrate, allowing the detection of antibodies to a prominent, 
40-kDa, lytic structural antigen (Miller et a!., 1996). Although of limited use for 
determining the seroprevalence of HHV-8 in the general population, the results 
obtained with these early assays indicated that, not surprisingly, most individuals with 
AIDS-associated KS and a much smaller proportion of HIV-infected individuals 
without KS carried antibodies to HHV-8 (Miller et a/., 1996; Moore et a/., 1996c).
Other assays involve the detection of antibodies to unknown lytic antigens. These 
include an IFA using another PEL cell line, BCBL-1, treated with phorbol esters to 
induce the lytic replication cycle (Lennette et a/., 1996; Smith et a/., 1997b). With 
these assays, antibodies could be detected in nearly 100% of AIDS-associated KS 
patients and in 25% of United States blood donors (Lennette et a!., 1996).
Although assays using these lytic-phase PEL cell lines are the most sensitive and 
widely used, a dilemma is presented due to possible cross reactivity to other 
herpesvirus antibodies, particularly as no HHV-8 negative PEL cell lines exist to act 
as controls for non-specific reactions (Lennette et a/., 1996). This consideration has 
led to the development of second generation assays such as that described by Inoue 
et a! (2000). In this IFA assay, recombinant ORF K8.1 antigen expressed by Semliki 
forest virus is used (Inoue et a/., 2000). This antigen has no homologue to other 
herpesviruses, hence cross-reactivity does not occur. The availability of negative 
controls lends specificity to this assay. An enzyme-linked immunosorbent assay 
(ELISA) based on a four-branch, multiple antigenic peptide derived from K8.1 has 
been shown to yield high sensitivity and specificity values when well-characterized 
HHV-8-infected individuals with KS were used as the positive controls and non­
infected subjects as the negative controls (Lam ef a/., 2002). However, in a recent
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study, when non-KS individuals with high probability of HHV-8 infection were included 
in the positive control group, a significant reduction in the sensitivity was observed, 
implicating that inclusion of such a group may further improve a more accurate 
assessment of assay sensitivity (Perez et al., 2006).
A purified whole-virion ELISA has been developed to facilitate high throughput 
testing. This rapid ELISA assay may be used to screen large numbers of sera to find 
those at risk for developing KS (Chatlynne at a/., 1998). To further increase sensitivity 
and specificity, other ELISAs have been developed using, as antigens, various 
recombinant proteins and oligopeptides (Andre at a/., 1997; Davis at a/., 1997a; Pau 
at a/., 1998). Antigens commonly utilised in this type of serological assay include 
products from ORF 65 (Pau at a/., 1998), ORF 73 (Gao at a!., 1999) and ORF K8.1 
(Perez at a!., 2006). However, these peptide ELISAs can be used for trends in 
populations with high probability of being HHV-8 infected, and negative results should 
be confirmed by IFA (Perez at a/., 2006).
A number of studies comparing the variable performance of different serological 
HHV-8 tests exist (Rabkin at a/., 1998; Spira at a/., 2000; Schatz at a/., 2001; Pellett 
at a/., 2003; Sergerie at a/., 2004). Evidence suggests that patients show 
heterogeneous serologic responses to defined HHV-8 antigens; therefore, 
combinations of antigen assays may achieve the best detection rates (Lang at a/., 
1999; Spira at a/., 2000; Laney at a/., 2006; Bergallo at a/., 2007) and the use of a 
combination of both latent and lytic assays to evaluate seropositivity should avoid the 
possibility of false negative results and provide an exact evaluation of the rate of 
seroconversion (Marcelin at a/., 2007). Recently, a combined quantitation of both 
humoral and cellular immunity has been suggested to be a superior method in 
assigning HHV-8 infection status (Lonard at a/., 2007).
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Although some studies suggest wide differences in infection rates in populations at 
risk of KS based on the type of antigen and serological method used (Rabkin et al., 
1998; Enbom et al., 2000; Sergerie et al., 2004), properly performed assays in 
standardized formats have been found to be highly concordant (Schatz et al., 2001).
1.9.2 HHV-8 seroprevalence and geographical distribution 
Many studies have been undertaken to determine the seroprevalence of antibodies to 
HHV-8. The seroepidemiologic studies clearly show that HHV-8 is prevalent 
throughout the world, although there may be local variations in seroprevalences 
(Whitby et al., 1995; Gao et al., 1996b; Kasolo et al., 1997; Whitby et al., 1998; 
Rezza et al., 1998; OIsen et al., 1998; Pema et al., 2000; Iscovich et al., 2000; 
Chokunonga et al., 2000; Schulz, 2000a; He et al., 2007). A variety of techniques 
have been used in these studies, but to date there is no gold standard against which 
to measure the efficacy of these techniques, so some may overestimate and others 
underestimate the true prevalence (Laney et al., 2006; Perez et al., 2006).
Unlike most human herpesviruses, HHV-8 is not spread universally among all human 
populations. The highest seroprevalences in healthy populations are found in sub- 
Saharan Africa (Ablashi et al., 1999; de The et al., 1999; Schulz, 2000b), where the 
prevalence among adults ranges from 22% in central Africa to 71% in Zambia (Olsen 
et al., 1998; Belec et al., 1998; He et al., 1998). Very high rates, between 79% and 
87%, have been reported in the Congo and in Botswana (Engels et al., 2000). In 
black South African blood donors and patients with cancer other than KS, the 
seroprevalence is 32% (Sitas et al., 1999a). In Mediterranean countries, the 
seroprevalence averages 8% to 10%, although population pockets where the 
prevalence is as high as 20% can be found (Angeloni et al., 1998; Whitby et al., 
1998; Calabro et al., 1998; Chatlynne and Ablashi, 1999; Schulz, 2000b; Davidovici 
et al., 2001; Vitale et al., 2001; Zavitsanou et al., 2007). In three studies undertaken
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in Saudi Arabia, serum antibodies to HHV-8 were detected in 7%, 3.9% and 1.7% of 
healthy participants (Qunibi et al., 1998; Almuneef et al., 2001; Alzahrani et al., 
2005). In the United States, seroprevalences ranging from 0% to 26% have been 
reported (Lennette et al., 1996; Gao et al., 1996b; Baillargeon et al., 2002; Pellett et 
al., 2003; Martro et al., 2004; Casper et al., 2006). In northern Europe, Germany, 
Cuba, Southeast Asia, and the Caribbean, seroprevalence falls into the 1% to 4% 
range (Ablashi et al., 1999; Kouri et al., 2004; Zavitsanou et al., 2007; Lonard et al., 
2007) with the seroprevalence of HHV-8 antibodies in blood donors from Japan 
estimated as 0.2% to 3.2% (Fujii ef a/., 1999; Satoh ef a/., 2001). However, some 
surveys found the antibody prevalence to HHV-8 to be 19% in Taiwan (Huang ef a/.,
2000), 47% in northwest China (Dilnur ef a/., 2001) and 20% in Sweden (Enbom ef 
a/., 2000); the later report also showing a wide variety of results depending on the 
assay used.
HHV-8 seroprevalences in South America have also been documented. The 
seroprevalence in blood donors was found to be 4% from Argentina and 3% from 
Chile (Perez ef a/., 2004). In Brazil, varying seroprevalences - upto 79% among 
Amerindians (Biggar ef a/., 2000; Ishak ef a/., 2007; de Souza ef a/., 2007b), 16% in 
urban communities (Freitas ef a/., 2002), 6% in non-Amerindian populations living on 
the banks of the Trombetas river (de Souza ef a/., 2007b) and 2.8% in Campinas and 
surrounding cities (Perez ef a/., 2004) - have been reported. In Peruvian blood 
donors, HHV-8 seroprevalence was recently found to b>e as high as 56% (Mohanna ef 
a/., 2007).
In many populations, especially those in northern Europe, Brazil and North America, 
the HHV-8 seroprevalence is 2 to 10 times higher in men than women (Whitby ef a/., 
1995; Cesarman ef a/., 1995b; Lennette ef a/., 1996; Kedes ef a/., 1997; Chatlynne 
and Ablashi, 1999; Greenblatt ef a/., 2001; Perez ef a/., 2004). Some of these
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differences may be due to higher seroprevalence in homosexual than heterosexual 
men and women. However, a recent study has reported a significantly higher 
seroprevalence amongst Brazilian Amerindian females than males (Ishak et al.,
2007). In other populations such as Israel (Iscovich et a!., 2000), Greece (Zavitsanou 
et a/., 2007), Argenitina and Chile (Perez et a/., 2004) the seroprevalence was found 
to be similar in men and women. While a complete picture of the seroepidemiology of 
HHV-8 in the African continent is not yet available, all surveys to date indicate that 
HHV-8 antibodies are seen in about equal frequency in men and women (Olsen et 
a/., 1998; Gessain et a!., 1999).
The seroprevalence in children tends to reflect that of the adult population, but the 
percentages in children are lower than that of the adults. Within Africa, the HHV-8 
seroprevalence among children ranges from 13% in Cameroon (Gessain et a!., 1999) 
to 37% in Uganda (Mayama et a/., 1998), and from 36% in Ghana (Nuvor et a/.,
2001) to 47% in Zambia (Olsen et a/., 1998). An HHV-8 prevalence of 4% has been 
reported among Italian children younger than l ly r  (Whitby et a/., 2000). The highest 
prevalence in the Mediterranean area, of up to 45%, has been reported among 
children in Alexandria, Egypt (Andreoni et al., 1999). In the USA, Baillargeon et al. 
(2002) reported the overall prevalence of HHV-8 in South Texas children to be 26% - 
a rate higher than that reported in other studies of children in North America and 
Europe (Blauvelt et al., 1997; Whitby et al., 2000; Martro et al., 2004).
Although US children aged 6 months to 5 yr tend to have higher HHV-8 antibody 
titres than 6 -17 yr old children (Martro et al., 2004), most studies describe an 
increase in seroprevalence with age amongst other populations (Rezza et al., 1998; 
Sitas et al., 1999a; Whitby et al., 2000; Almuneef et al., 2001; Stein et al., 2004; 
Zavitsanou et al., 2007; de Souza et al., 2007b). In African countries with high 
seroprevalence, such as Cameroon (Gessain et al., 1997), French Guiana
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(Plancoulaine et al., 2000), Nigeria (Martro at a!., 2004) and Uganda (Mayama at a!.,
1998), seropositivity increases with age and usually reaches the prevalence of adult 
groups before puberty.
HIV-infected homosexual men have the highest HHV-8 seroprevalence of any risk 
group. A study in the San Francisco area, using serum samples dating to 1984, 
reported a seroprevalence of 48% among homosexual or bisexual men who were 
HIV-positive but did not have KS (Martin at a!., 1998). Another study from the US 
found the seroprevelance of HHV-8 in homosexual and heterosexual United States 
military men with HIV infection to be 35% and 27% respectively (Crum at a!., 2003). 
In Europe and North America, HIV-1-seronegative homosexual men consistently 
show a lower seroprevalence of HHV-8 infection than HIV-1-seropositive homosexual 
men, and higher seroprevalence than observed among blood donors or the general 
population (Kedes at a!., 1996; Melbye at a!., 1998; Martin at a!., 1998; Casper at a!., 
2006; Engels at a!., 2007).
In recent studies of HIV-infected patients without KS, the HHV-8 seroprevalence was 
found to be 19% in Hungary (Szalai at a/., 2005), 28% in Northern Thailand (Chen at 
a!., 2004), 30% in Amsterdam (Dukers at a!., 2000), 45% in Eastern Sicily (Larocca at 
a!., 2005), and up to 52% in Germany (Albrecht at a!., 2004; Lonard at a!., 2007). 
Antibody titres against HHV-8 LANA, assessed by IFA, were found to positively 
correlate with the CD4+ T-cell count of HIV-positive patients with KS, a finding 
important for the interpretation of seroepidemiological studies of HHV-8 infection in 
AIDS patients (de Souza at a!., 2007a). While HHV-8 seropositivity correlated with 
high CD4+ T-cell counts (de Souza at a!., 2007a), clinically manifest KS was more 
likely in patients with low than high CD4+ T-cell counts (Martro at a!., 2007).
The results of serologic studies support the view that infection with HHV-8 is nearly
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universal in patients with KS. For example, 100% of Moroccan patients with classical 
or endemic KS (Hbid et al., 2005), 100% of Tanzanian patients with endemic or 
AIDS-associated oral KS (Mwakigonja at a!., 2007), 83% to 100% of patients with 
African endemic KS (Lennette at a!., 1996; Sitas at a!., 1999a), and 96% of U S 
patients with AIDS-associated KS (Lennette at a!., 1996) were found to be 
seropositive for antibodies against lytic antigens. The geographic association 
between KS prevalence and HHV-8 seroprevalence is significant. Populations in 
Southem Italy, Sardinia and Sicily, where KS rates are high, show HHV-8 
seroprevalences between 25-30% (compared with 10% in Northern Italy), and in the 
rest of Europe and North America the seroprevalence ranged between 1-8% (Whitby 
at a!., 1995; Angeloni at a/., 1998; Antman and Chang, 2000). The seroprevalence in 
Africa also appears to mirror the epidemiology of KS, although high HHV-8 antibody 
titres have been suggested to protect against circulating HHV-8 in PBMC or oral 
fluids and new KS lesions (Cannon at a/., 2003).
HHV-8 seroconversion precedes KS in all populations studied (Gao at a/., 1996a; 
Renwick at a/., 1998; Oksenhendler at a/., 1998a). However, several factors may 
influence the risk of developing KS in patients with prior HHV-8 infection, including 
the ethnic origin of the patients, the seroprevalence rate in their geographic origin, 
gender, age, and degree of immunosuppression (Lennette at a/., 1996; Gao at a/., 
1996b; Penn, 1997; Calabro at a/., 1998). A continued state of immunodeficiency is 
important for the development of KS (Zavos at a/., 2004).
1.9.3 Comparison of HHV-8 seroprevalence and genoprevalence 
The absence of gold standard serological tests and sensitive methods for detecting 
low copy numbers of the HHV-8 genome in PBMCs has contributed to the uncertainty 
over the true prevalence of this virus in the general population of non-KS-endemic 
regions. However, many groups have attempted to improve sensitivity in detecting
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low copy numbers of viral DNA by employing nested PCR, and a wide range of 
approaches have been employed (Cattani et al., 1998; Belec et al., 1998; Min and 
Katzenstein, 1999; Spira et al., 2000). The use of these improved methods to 
determine HHV-8 genoprevalence may better mirror the true prevalence in these 
individuals. Furthermore, a comparison of geno- and sero-prevalence may assist in 
clarifying the specificity and sensitivity of serological methods. Such data may also 
allow for assessment of the stage of HHV-8 infection: primary, latent, or lytic. In 
general, people who are HHV-8 seropositive without detectable DNA in the peripheral 
blood may be considered to be latently infected (Simpson et al., 1996; Gao et al., 
1996a), seronegative people who are only DNA-positive to be hosting an early 
primary infection (Andreoni et al., 2002), and those who are positive in both tests to 
be undergoing reactivated infection or late primary infection.
1.10 Organ transplantation and human herpesvirus infections
Viral infections among renal transplant recipients continue to be a major cause of 
post-transplantation morbidity and mortality despite the availability of effective 
antiviral therapy (Briggs, 2001; Hwang et al., 2004). Human herpesviruses are found 
worldwide, being among the most frequent causes of viral infections in 
immunocompetent as well as immunocompromised patients. In transplant recipients, 
herpesviruses may be acquired via the transplanted organ or blood products or may 
be reactivated as a consequence of the use of powerful immunosuppressive drugs 
(Walker et al., 1982; Smith et al., 2001). Moreover, the persistence of 
immunosuppression greatly favours the clinical expression and severity of virus 
infection. Thus, herpes viruses are frequently involved in both acute and chronic 
deterioration of graft function, in the pathogenesis of post-transplant 
lymphoproliferative disorders and KS, and even in cardiovascular events (Brennan, 
2001 ; Morrone et al., 2002; Gomez et al., 2005).
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HSV infection may occur in renal allograft recipients mainly during or shortly after 
treatment of graft rejection with high-dose steroids (Mosimann et al., 1994; Kang et 
al., 2006). Herpes simplex infections present as mucocutaneous lesions that may 
persist for months with dissemination to internal sites, including the esophagus, 
colon, and bladder. The infection usually responds to aciclovir (Hwang et al., 2004; 
Kang et al., 2006).
Chickenpox caused by VZV infection is a rare infection in adult renal transplant 
recipients; however, it is significant owing to the severity of its clinical features and its 
associated high mortality rate. All renal transplant recipients should be screened for 
VZV immunization prior to transplant irrespective of previous history of VZV infection 
(Lauzurica et al., 2003; Shahbazian and Ehsanpour, 2007). Renal transplant 
recipients with chickenpox can present with atypical symptoms such as acute 
abdominal pain and low back pain (Shahbazian and Ehsanpour, 2007). Early 
diagnosis and treatment with high doses of aciclovir is fundamental in infection 
control (Lauzurica et al., 2003). Vaccination should preferably be administered in 
seronegative recipients several months prior to transplant (Geel et al., 2006; 
Robertson et al., 2006; Shahbazian and Ehsanpour, 2007).
Primary EBV infection is the most important risk factor for development of post­
transplant lymphoproliferative disorder (PTLD) (Smith et al., 2007). Transmission of 
EBV can occur via an allograft with subsequent infection of a previously seronegative 
recipient (Cen et al., 1991; Hague et al., 1996). The PTLD presentation is variable. 
Some patients present asymptomatically; in others, early symptoms can be 
nonspecific. Screening for patients at risk, balancing the intensity of 
immunosuppressive regimens against the risk of rejection and using antiviral agents 
active against EBV can substantially reduce the risk of developing PTLD. Depending 
on the severity of PTLD, treatment may necessitate reduction of immunosuppression
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with or without radiotherapy, interferon-alpha, or additional chemotherapy (Everly et 
al., 2007).
CMV is a significant post-transplant pathogen and continues to be a common cause 
of morbidity and mortality in transplant recipients. The wide incidence of reported 
CMV infection and disease (Hwang at a/., 2004) probably reflects differences in 
immunosuppressive strategies and monitoring protocols for such disease. CMV 
infection can initiate endothelial cell activation and vascular injury that may facilitate 
acute or chronic graft rejection, atherosclerosis, transplant glomerulopathy or 
thrombotic microangiopathy (Brennan, 2001). The clinical manifestations of CMV 
disease in transplant recipients range from asymptomatic infection to mild 
mononucleosis syndromes to severe multisystem involvement (e.g. retinitis, 
pneumonitis and gastrointestinal disease). Several studies have shown that CMV- 
seronegative recipients of an organ from a seropositive donor are at much greater 
risk of acquiring a primary infection and it is generally accepted that primary 
infections are more severe than reactivated infections (Peterson at a/., 1980; Pollard, 
1988). Ganciclovir and valganciclovir are effective in the treatment of CMV disease 
(Pellay at a/., 2005; Luan at a/., 2006) and for CMV prevention (Paya at a/., 2004) in 
high-risk solid organ transplant recipients. Pre-emptive valganciclovir therapy and 
prophylaxis using valganciclovir (Khoury at a/., 2006) or valaciclovir (Reischig at a/.,
2007) have been found to be equally effective in the prevention of CMV disease after 
renal transplantation.
HHV-6 has been described as an immunomodulatory and immunosuppressive virus 
that may facilitate superinfections with other opportunistic organisms in transplant 
recipients, particularly CMV (Flamand ate!., 1995; Dockrell at a!., 1997; Singh, 2000). 
HHV-7 also appears to be an immunomodulatory agent and may facilitate the 
pathogenicity of cytomegalovirus. In a study of renal transplant recipients, patients
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with CMV and HHV-7 coinfection were more likely to have CMV disease than those 
with CMV infection alone (Kidd etal., 2000).
HHV-8 may be transmitted via the transplanted organ (Parravicini at a!., 1997; Luppi 
at a!., 2000a; Kapelushnik at a!., 2001) or may be reactivated in patients who were 
infected before allograft receipt (Cattani at ai, 2001; Bergallo at ai, 2007). The most 
commonly reported clinical manifestation of HHV-8 infection among transplant 
recipients is the development of KS.
1.11 Renal transplantation and KS
latrogenically immunosuppressed individuals, including renal allograft recipients, are 
at risk of developing malignant tumours caused by viral infections (Penn, 1983; 
Farge, 1993). KS was first reported in renal transplant recipients in 1969 and since 
then has been described with increasing frequency in recipients of kidney and other 
solid organ transplants given conventional immunosuppressive therapy (azathioprine 
plus prednisolone) or ciclosporin (Farge, 1993). The prevalence of KS among 
European transplant recipients is about 0.5% and appears to be slightly higher in liver 
(1.2%) compared with kidney (0.5%) and heart (0.4%) transplant recipients (Farge,
1993).
The incidence of KS in renal transplant recipients is 84 to 500-fold greater than in 
control populations (Harwood at ai, 1979; Montagnino at ai, 1994; Montagnino at ai, 
1996; Jensen at a i, 1999; Saadat at ai, 2007) and varies from less than 0.01% to 
5.3% (Hanvood at a/., 1979; Qunibi at ai, 1988; Shmueli at ai, 1989; Qunibi at ai, 
1993; Farge, 1993; al Sulaiman and al Khader, 1994; Penn, 1995; Cathomas at a i, 
1997; Mbulaiteye and Engels, 2006; Garcia-Astudillo and Leyva-Cobian, 2006; 
Bergallo at ai, 2007; Vegso at ai, 2007). Such variation is influenced by whether the 
allograft recipients and donors originate from regions where KS is endemic
90
Chapter 1_____________________________________________________________ Introductory Considerations
(Franceschi and Geddes, 1995), and by the type of regimen used for post­
transplantation immunosuppression (Farge, 1993; Penn, 1996). Amongst allograft 
recipients, KS has been reported to affect men more than women in a 3:1 ratio 
(Penn, 2000), a figure far less than the 9:1 to 15:1 ratio seen with KS in the general 
population (Penn, 1989; Penn, 1994; Penn, 1995).
In Saudi Arabia, the incidence of KS among renal transplant recipients is more than 
10 times higher than among recipients in the United States and western Europe 
(Farge, 1993; Mbulaiteye and Engels, 2006) and accounts for over 70% of all 
neoplasms experienced by renal transplant recipients (Qunibi ef a/., 1988; Qunibi ef 
a/., 1993; al Sulaiman and al Khader, 1994) compared to < 0.4% (aI Suleiman ef a/., 
1987; Qunibi ef al., 1988) of all malignancies in Saudi Arabia. KS is the most 
common post-transplant tumour in Saudi Arabian (Qunibi ef a/., 1988; Qunibi ef a/., 
1993; al Sulaiman and al Khader, 1994), Pakistani (Askari ef a/., 1999), Turkish 
(Ecder ef a/., 1998; Duman ef a/., 2002) and Egyptian (El Agroudy ef a/., 2003) renal 
allograft recipients. The mean period between transplantation and diagnosis of KS 
has been reported to be 12.5 months (Qunibi ef a/., 1988), 13.6 months (aI Suleiman 
ef a/., 1987) and 15.6 months (Qunibi ef a/., 1993) in Saudi Arabia, 15.9 months to 24 
months in Turkey (Ecder ef a/., 1998; Moray ef a/., 2004), 17.1 months in Pakistan 
(Askari ef a/., 1999), 19.6 months in Hungary (Vegso ef a/., 2007) and 33.8 months in 
Spain (Garcia-Astudillo and Leyva-Cobian, 2006). The median duration between 
transplantation and KS onset has been reported to be 7 months in Italy (Parravicini ef 
al., 1997).
HHV-8 DNA has been detected in peripheral blood of allograft recipients (Aluigi ef al., 
1996; Kikuta ef al., 1997a; Zhu ef al., 2008) and the HHV-8 seroprevalence in renal 
transplant recipients has been found to be 50% in the USA (Hudnall ef al., 1998), 
26% in Italy (Cattani ef al., 2001), 41% in China (Zhu ef al., 2008), 25% in Iran
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(Ahmadpoor et al., 2007), 22% in Germany (Lonard et ai., 2007), 0.6% in Spain 
(Garcia-Astudillo and Leyva-Cobian, 2006) and zero in Cuba (Kouri et a!., 2004).
Although haemodialysis patients have been found to be more susceptible to viruses, 
such as HHV-8, and hence in danger of developing KS (Hsu et a/., 2002), the 
connection between dialysis, HHV-8, and KS is not yet well established (Herr et a/., 
2001). However, KS is rarely found in haemodia lysis patients and only a few cases 
have been reported to occur as early as with the onset of dialysis (Herr et al., 2001; 
Metaxa-Mariatou et al., 2004; Yasar et al., 2007). In Switzerland - a well known low- 
risk population - a HHV-8 seroprevalence of 6.4% was found among patients with 
renal failure before transplantation (Regamey ef al., 1998). In Italy, Cattani et al., 
2001, found no significant difference in the HHV-8 seroprevalence between pre­
transplant patients and appropriate control subjects (Cattani ef al., 2001), while 
Bergallo ef al. (2007) observed a higher HHV-8 seroprevalence rate in end-stage 
renal disease (ESRD) patients when compared to their corresponding allograft 
donors. Earlier studies reported a higher pre-transplantation seroprevalence rate 
among Italian females (Andreoni ef al., 2001), while later studies found no difference 
in prevalence by gender (Bergallo ef al., 2007), both not consistent with the higher KS 
incidence previously found among males in Italy (Cotton i etal., 1996). An association 
between HHV-8 seroprevalence and increasing age in ESRD patients has been 
reported from Saudi Arabia (Almuneef ef al., 2001) and Italy (Bergallo ef al., 2007).
In Saudi Arabia, the HHV-8 seroprevalence in renal transplant recipients is high when 
compared to other countries in which such estimates have been made. In a small 
seroprevalence study of Saudi Arabian patients, the seropositivity rate was 93% in 
patients with post-transplantation KS, 28% in transplant recipients without KS, and 
29% in patients with end-stage renal disease (ESRD) on haemodialysis (Qunibi ef al., 
1998). In a larger study of individuals in Saudi Arabia, the same researchers found
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antibodies to HHV-8 in only 7% of ESRD patients (Almuneef et al., 2001), this being 
relatively similar to that detected recently in haemodialysis patients in Greece (7.2%) 
(Zavitsanou at a!., 2006) but less than that of haemodialysis patients in Germany 
(13.7%) (Lonard eta/., 2007). More recently, in Saudi Arabia, 18% of renal transplant 
recipients and seven out of 10 (70%) family members of a renal allograft recipient with 
KS were found to be seropositive for HHV-8 (Alzahrani et a!., 2005). Seropositivity for 
HHV-8 in these transplant patients was not significantly influenced by the existence of 
relatives with kidney failure, the donor’s country of origin, the recipient's home region 
within Saudi Arabia, the haemodialysis centre, the time that elapsed since the renal 
transplantation operation, and the immunosuppressive regimen employed (Almuneef 
etal., 2001; Alzahrani et al., 2005).
Among renal transplant recipients in Saudi Arabia, the skin is the most common 
organ involved with KS, followed by the gastrointestinal tract and the lungs (Qunibi et 
al., 1993; al Sulaiman and al Khader, 1994). Oral KS has also been observed in this 
group of patients (Qunibi et al., 1988; Qunibi et al., 1993). The prognosis in patients 
with KS limited to the skin is favourable (probably because of early detection and 
treatment), while visceral involvement is associated with high mortality (al Sulaiman 
and al Khader, 1994; Zavos et al., 2004; Veroux et al., 2004). Patients with iatrogenic 
KS benefit from reduction or cessation of immunosuppression, but there is a high risk 
of graft loss (Veroux et al., 2004; Moray et al., 2004).
Post-transplantion KS may be caused by two possible mechanisms: HHV-8 
reactivation in patients who were infected before the graft and HHV-8 neo-infection 
either by blood products or from allogeneic transplant tissue (Marcelin et al., 2007). 
However, most cases of post-transplant KS apparently develop as a result of viral 
reactivation. Among patients who are seropositive for HHV-8 before undergoing renal 
transplantation, the risk of post transplant KS is 23% to 28%, as compared with a risk
93
Chapter 1  Introductory Considerations
of 0.7% in patients who are seronegative before receiving a renal transplant (Frances 
et al., 2000; Cattani et ai., 2001), suggesting that infection prior to transplantation is a 
key risk factor for KS (Cattani et ai., 2001). However, not all HHV-8 seropositive 
patients before renal transplant and undergoing immunosuppression develop KS 
(Parravicini et a!., 1997; Frances et a/., 2000; Cattani et a/., 2001; Alzahrani et a/., 
2005; Bergallo et a/., 2007) and the incidence of KS among HHV-8 seropositive 
patients may in some areas be very low (Bergallo et a/., 2007).
The degree of immunosuppression is a critical factor in the likely clinical development 
of iatrogenic KS in renal allograft recipients. It has been demonstrated that renal 
transplant recipients have a higher incidence of KS than non-grafted patients on 
maintenance dialysis (Montagnino et a/., 1996; Qunibi et a/., 1998). While some in 
vitro studies have shown that immunosuppressive agents such as hydrocortisone and 
ciclosporin do not activate the lytic cycle of HHV-8 and do not modify the cell survival 
(Marcelin et ai., 2001), others have found ciclosporin to have a tumour promoting 
activity (Cuba et ai., 2002) and hydrocortisone able to activate the lytic cycle of HHV- 
8 (Hudnall et ai., 1999). Administration of more than 10 corticosteroid pulses has 
been found to be associated with an increased risk of disease (Montagnino et ai., 
1996). However, it still remains unclear as to how the use of these different 
immunosuppressive agents influences the development of KS in renal allograft 
recipients (Cockbum and Krupp, 1989; Hiesse et ai., 1995; Rezeig et ai., 1997; Farge 
et ai., 1999; Eberhard et ai., 1999).
1.12 Importance of research reported in this thesis
Despite recent advances in transplantation techniques, herpesvirus infections remain 
a major cause of morbidity and mortality in transplant recipients. Improvements in 
immunosuppressive drug regimens have decreased the risk of rejection in solid organ 
transplant recipients. However, therapy with all such agents carries an increased risk
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of herpesvirus reactivation. The most commonly reported clinical manifestation of 
HHV-8 infection among transplant recipients is the development of KS. The rate of 
KS among solid-organ transplant recipients varies by geographic location, such that 
countries with endemic KS and higher rates of seropositivity to HHV-8 seem to have 
higher rates of KS among the transplant population. However, this situation may not 
apply to Saudi Arabia.
This study was prompted by the following observations:
1. The reported disparity in HHV-8 prevalence rates between the general population 
and patients with renal disease in Saudi Arabia. This phenomenon has not been 
reported elsewhere in the world, and the reason for the particularly high incidence of 
post-transplantation KS in Saudi Arabia is unknown.
2. Previous epidemiological studies in the Saudi population have relied greatly on 
serological data to estimate the prevalence of HHV-8 infection. In view of the 
uncertain specificity and sensitivity of serological estimations of HHV-8 
seroprevalence, it was considered necessary to test samples for both geno- and 
sero-prevalence to ensure that HHV-8 infection, regardless of its stage, does not go 
undetected. Genoprevalence studies potentially enhance the specificity of, and lend 
sensitivity to, estimations of HHV-8 prevalence in populations at low risk of KS.
3. No studies into the oral shedding of HHV-8 in the Saudi Arabian context, 
particularly involving patients with renal disease, who are at particular risk of KS exist. 
In other geographical populations and other subpopluations that are at high risk of 
HHV-8 infections, there is gathering consensus that HHV-8 is shed predominantly 
from the mouth.
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1.13 Hypothesis
There is evidence that transplant-associated KS is more prevalent among renal 
allograft recipients in Saudi Arabia than some other geographic regions of the world. 
Given the known association between HHV-8 infection and risk of developing KS, it 
was hypothesised that the increased frequency of KS in renal allograft recipients 
results from HHV-8 infection prior to transplantation and reactivation of HHV-8 post 
transplantation when the patients are given intensive immunosuppression.
1.14 Study Aims
The study has been undertaken in an attempt to evaluate the extent of HHV-8 
carriage in saliva, oral mucosal surfaces and peripheral leukocyte subsets and to 
explore the factors that may influence the shedding of the virus in the study groups 
representing populations with different risks of HHV-8 infection, including ESRD 
patients and patients who have undergone renal transplantation. The genetic variation 
of the K1 gene of HHV-8 was analysed and the possibility of multiple infection 
examined.
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2.1 Patients and samples
Samples were collected from eight different groups of participants attending the 
Armed Forces Hospital in Riyadh, Saudi Arabia. These eight groups included: blood 
donors (hereafter designated the “BD” group) (n=178), pregnant women visiting the 
prenatal clinic (the “PW” group) (n=60), patients with chronic renal failure undergoing 
haemodialysis (the “CRF” group) (n=72), renal allograft recipients with no history of 
KS (“RAR”) (n=61), renal allograft recipients with a history of KS (“RAR-KS”) (n=5), 
patients with chronic renal failure undergoing kidney transplant (“CRF-tr”) (n=6), renal 
allograft donors (“RAD”) (n=6), and relatives of renal allograft recipients (“RRAR”) 
(n=3). As the number of females donating blood at the designated study centre was 
found to be low, the inclusion of pregnant women attending the prenatal clinic was 
found to be necessary. The minimum number of participants in each of the four major 
study groups (BD, PW, CRF and RAR groups), required to detect a significant 
difference, was determined on the basis of previously published relevant data, the 
selected statistical power (80%) and P value (<0.05). Ethical approval for the study 
was obtained from the Ethical Committee of the Riyadh Armed Forces Hospital.
The clinical, virological and immunological characteristics determined for each of the 
eight groups are listed in Table 2.1. Oral findings and indices (plaque, gingival and 
bleeding indices) were documented using a standard proforma (Appendix 1).
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Table 2.1 Clinical, virological and immunological characteristics obtained for examined patient groups
Group Clinical Virological immunological
BD ■ Patient age and gender
■ ABO blood group
PBMC HHV-8 DNA Serological evidence of HIV, HBV and HCV infection 
Anti-HHV-8 IgG
PW Patient age and week of pregnancy PBMC HHV-8 DNA Serological evidence of HBV or HCV infection 
Anti-HHV-8 IgG
CRF • Patient age, gender and area of residence (past and current)
■ Dialysis shift and assigned unit location
■ Medical history, medications, previous transplants and 
duration of dialysis
■ Systematic examination for oral lesions and documentation
■ Oral hygiene status and presence or absence of gingival 
disease
■ PBMC HHV-8 DNA
■ Whole mouth and parotid saliva 
HHV-8 DNA
■ Buccal and palatal HHV-8 DNA
■ Serological evidence of HIV, HBV and HCV infection
■ Anti-HHV-8 IgG
RAR&
RAR-KS
■ Patient age, gender and area of residence (past and current)
■ Medical history and medications
■ Date of allograft receipt and type of allograft (live or cadaver 
donor)
■ Location of transplantation and nationality of donor
■ Systematic examination for oral lesions and documentation
■ Oral hygiene status and presence or absence of gingival 
disease
■ Immunosuppressive drug regimen and administered dose
■ Presence or absence of KS or other known malignancies
• PBMC HHV-8 DNA
■ Plasma HHV-8 DNA
■ Whole mouth and parotid saliva 
HHV-8 DNA
• Buccal and palatal HHV-8 DNA
■ Paraffin embedded KS biopsy 
HHV-8 DNA
Serological evidence of HBV or HCV infection 
Anti-HHV-8 IgG
BD, blood donors: PW, pregnant women; CRF, patients with chronic renal failure; RAR, renal allograft recipients with no history of KS; RAR-KS, renal allograft recipients with a history of KS
Table 2.1 Clinical, virological and immunological characteristics obtained for examined patient groups ...continued i
Group Clinical Virological immunological
CRF-tr ■ Patient age, gender and area of residence (past and current)
■ Medical history and medications
■ Type of allograft (live or cadaver donor)
■ Nationality and relation of donor
■ Immunosuppressive drug regimen, dose and duration*
• Systematic examination for oral lesions and documentation*
■ Oral hygiene status and presence or absence of gingival 
disease*
■ Presence or absence of KS or other known malignancies*
RAD ■ Patient age, gender and area of residence (past and current)
■ Medical history and medications
• PBMC HHV-8 DNA*
■ Plasma HHV-8 DNA*
• Whole mouth and parotid 
saliva HHV-8 DNA*
• Buccal and palatal HHV-8 
DNA*
• PBMC HHV-8 DNA
• Plasma HHV-8 DNA
• Whole and parotid saliva 
HHV-8 DNA
■ Buccal and palatal HHV-8 
DNA
Serological evidence of HIV, HBV and HCV infection* 
Anti-HHV-8 IgG*
Serological evidence of HIV, HBV and HCV infection 
Anti-HHV-8 IgG
RRAR ■ Patient age and gender • PBMC HHV-8 DNA 
■ Plasma HHV-8 DNA
Serological evidence of HIV, HBV and HCV infection 
Anti-HHV-8 IgG
CRF-tr, patients with chronic renal failure undergoing kidney transplant: RAD, renal allograft donors; RRAR, relatives of renal allograft recipients
*Undertaken prior to, and at weeks 1, 2, 4, 6 and 8, and 9 months after renal transplant
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2.2 Sample Preparation
2.2.1 Whole blood
Peripheral blood from study individuals was collected in EDTA-treated vacutainers by 
venepuncture, and stored, if necessary, for not more than 24 h at 4°C. Blood 
collection was carried out by assigned nurses in the presence of the researcher. 
Plasma was separated from blood by centrifugation at 3500 rpm for 15 min with 1 ml 
of plasma removed and stored at -20°C for later serological studies. The remaining 
blood was resuspended and immunomagnetic cell separation was achieved using 
Dynabeads (Dynal A.D., Oslo, Nonvay).
Immunomagnetic cell isolation using Dynabeads allows isolation of predefined 
subsets directly from heterogeneous cell suspensions, such as whole blood. 
Dynabeads (Dynal A.D., Oslo, Norway) are small magnetically charged uniformly 
shaped beads coated with a specific monoclonal antibody. The Dynabeads are 
supplied as a suspension containing 4x10® beads/ml in phosphate buffer saline 
(PBS), pH 7.4, containing 0.1% bovine serum albumin (BSA) and 0.02% sodium 
azide (NaNs). Because NaNs is a cytotoxic agent, the beads require to be washed 
before use with a washing buffer (PBS/0.1% BSA).
2.2.1.1 Dynabeads washing procedure
The desired amount of Dynabeads was transferred into a washing tube. The tube 
was then placed on a magnetic particle concentrator (Dynal MPC) for 60 s and the 
fluid was pipetted off carefully. After the tube was removed from the magnetic device, 
1 ml PBS/0.1 % BSA was added and the beads resuspended. This procedure was 
repeated another two times before the Dynabeads were resuspended back into their 
original volume.
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2.2.1.2 Immunomagnetic cell isolation
To separate the different leukocyte fractions from the blood, Dynabeads coated with 
antibodies against CD45+, CD31+, CD19+, CD14+ and CD2+ cell subsets were 
added directly to the cell suspension, where they bind the target cells. The cell types 
targeted in the current investigation and their cell surface cluster of differentiation 
(CD) markers are summarised in Table 2.2.
To 1 ml of whole blood, 50 pi of Dynabeads were added giving an approximate final 
concentration of 2x10^ beads/ml. The whole blood and Dynabead mixture was then 
incubated at 4°C for 1 h providing rotation of the tube every 10 min using a Dynal 
sample mixer (Dynal A.D., Oslo, Norway). The mixture tube was then positioned in 
the magnetic particle concentrator (Dynal MPC) for 3 min to collect the rosetted cells. 
The supernatant was pipetted carefully while the rosetted cells were attached to the 
wall of the tube by the concentrator. The tube was removed from the concentrator, 
after which 1 ml of washing buffer (PBS/0.1% BSA) was added and the rosetted cells 
gently resuspended. The tube was repositioned into the concentrator and the 
supernatant removed. The rosetted cells were washed three times and then 
resuspended in 250 pi of nuclease-free water and stored at -20°C until needed.
2.2.2 Preparation of saliva samples
Whole mouth saliva (WMS) and parotid saliva (PS) specimens were collected into 50 
ml sterile centrifuge tubes (Sarstedt Ltd, Nümbrecht, Germany). WMS was collected, 
unstimulated, by having the study individuals dribble into the sterile centrifuge tubes. 
The cellular and supernate fractions of WMS (WMS^ and WMS®, respectively) were 
separated by low-speed centrifugation at 1500 rpm for 8 min. The cellular fraction 
was then resuspended in 250 pi PBS. Both WMS*" and WMS® were then stored 
separately at -20°C until needed. PS was collected using small buccal collection cups 
(Lashley’s cup) over the parotid duct and saliva stimulated with 5% citric acid fluid
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dropped onto the tongue. The collected parotid saliva was then stored at -20°C until 
needed.
2.2.3 Preparation of oral brush samples
Cells from the buccal mucosa and palate from the study individuals were collected 
using cytology sampling brushes (Cytotak® / Medical Wire and Equipment Co., 
Corsham, Wiltshire, UK). The brush was rotated 10 times against the oral mucosa 
then placed in a sterile container containing 5 ml PBS. The container was then placed 
on the vortex. The brush was removed after vortexing. The container and its content 
were then centrifuged at 3000 rpm for 10 min. Four ml of the supernatant was 
removed and discarded. The pellet along with the remaining 1 ml of PBS was then 
stored at -20°C until needed.
2.2.4 Preparation of Biopsy samples
Paraffin-embedded tissue from KS biopsy samples were sectioned using a sledge 
microtome. Sectioning was carried out by a histopathologist at the Riyadh Armed 
Forces Hospital. Serial 10-pm sections were folded and inserted in 2 ml Eppendorf 
tubes (Sarstedt Ltd, Nümbrecht, Germany).
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Table 2.2 Cluster of Differentiation (CD) markers on the cell surfaces
CD Antigen Other names M.W. Cell types expressing the antigen Functions
CD2 T11, LFA-2 45-58 Thymocytes (95%), mature peripheral I  
cells (almost all), NK cells (80-90%), 
thymic B cells (50%)
Adhesion molecule, binding 
CD58 (LFA-3); can activate T 
cells
CD14 53-55 Macrophages/Monocytes (90%), 
granulocytes (30%), langerhans cells, 
dendritic cells, B cells
Receptor for complex of LPS and 
LPS binding protein
CD19 95 Pre B, B cells, follicular dendritic cells Co- receptor for B cells
CD31 Pecam-1 130-140 Endothelium, platelets, macrophages, 
Kupffer cells, granulocytes, T/NK Cells, 
lymphocytes, megakaryocytes, fibroblasts, 
osteoclasts, neutrophils
Possibly an adhesion molecule
CD45 Leukocyte Common 
Antigen (LCA), 
T200, B220
180-240 All haemopoietic cells, stronger in 
lymphocytes
Tyrosine phosphatase, augments 
signalling through antigen 
receptor of B and T cells
From: 1st International Workshop and Conference on Human Leukocyte Differentiation Antigens (HLDA)
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2.3 Amplification of HHV-8 sub-genomic DNA
2.3.1 Laboratory accommodation
PCR-related procedures were performed in four separate laboratory areas in the 
Virus Reference Division of the Health Protection Agency’s Center for Infections, 
London:
• An extraction room used for processing clinical samples
• A clean room used for preparing reagents (except DNA)
• An amplification room used to run the PCRs
• A gel room for the detection of PGR amplicons by gel electrophoresis
The workflow was strictly unidirectional in order to prevent contamination with PGR 
products.
2.3.2 DNA Extractions
DNA was extracted from 200 pi of the resuspended dynabeads, brushed buccal, 
brushed palatal, and saliva cellular and supematant samples using the QIAamp DNA 
Blood Mini Kit (Qiagen Inc., Venlo, The Netherlands) following the manufacturer’s 
instruction. The DNA was eluted in 50 pi of Elution Buffer AE (lOmM Tris-GL; 0.5 mM 
EDTA; pH 9.0). Paraffin-embedded tissue from KS biopsy samples were sent to 
GenoVar diagnostics Ltd (GenoVar Diagnostics Ltd., Sittingboume, Kent, UK) which 
uses their in-house nucleic acid extraction method applicable to paraffin-embedded 
tissue. This method has been specifically designed to extract total nucleic acid from 
formalin-fixed, paraffin-embedded tissue, and is optimised for extraction of DNA from 
one section of the tissue of up to 20 pm thickness.
2.3.3 PGR amplification of yff-globin DNA
The presence of DNA in the extracts was verified from a number of samples 
randomly selected from each group. This was done by the amplification and detection 
of a 268-bp fragment of the housekeeping yff-globin gene as an indicator for the
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successful extraction. The PCR was carried out in a 25-|jl reaction mixture containing
nuclease-free water, PCR buffer (200 mM Tris-HCL (pH 8.4), SOOmM KOI), 1.5 mM
MgCl2 , 10 mM each dNTP’s, 1 unit Taq DNA polymerase (Invitrogen, CA, USA), 20
pmol of each yff-globin primer (PC04 and GH20) and 2 pi extracted DNA. Single round
PCR was then applied. The sequences of the yff-globin primers were as follows:
PC04: 5'-CAACTTCATCCACGTTCACC-3'
GH20: 5'-GAAGAGCCAAGGACAGGTAC-3'
The thermal cycler (Biometra T3 Thermocycler, Germany) was programmed to 94°C 
for 5 min, followed by 35 cycles of 94 °C for 1 min, 55°C for 1 min, and 72°C for 1 
min, and finally a 5-min extension period at 72®C (Gravitt et al., 1998; Fredricks and 
Reiman, 1999; Sato eta!., 2001).
2.3.4 PCR amplification of the HHV-8 ORF 26 DNA
First-round PCR amplification of HHV-8 ORF 26 (hereafter referred to as "KS330")
was carried out in a 25-pl reaction mixture containing nuclease-free water, PCR
buffer (200 mM Tris-HCL (pH 8.4), 500mM KCI), 4.0 mM MgClg, 10 mM each dNTP,
1 unit Taq DNA polymerase (Invitrogen, CA, USA), 20 pmol of each first round primer
(sequence shown below) and 4 pi extracted DNA. The second-round PCR mix was
identical to the first except 20 pmol of each inner primer (sequence shown below)
was used and 2 pi of the first round product was added as template. The sequences
of HHV-8 ORF-26 primers were as follows (Di Alberti et a/., 1997b):
KS-1 (26): 5'-AGCCGAAAGGATTCCACCAT-3'
KS-2 (26): 5 -TCCGTGTTGTCTACGTCCAG-3'
KS-inn 1 (26): 5'-TTCCACCATTGTGCTCGAAT-3'
KS-inn 2 (26): 5 -TACGTCCAGACGATATGTGC-3'
The PCR thermocycling conditions for the amplification of the region HHV-8 ORF 26 
include heating the samples to 94°C for 5 min, followed by 35 cycles of 94°C for 1 
min, 60°C for 1 min, and 72°C for 1 min, followed by a 5-min extension period at
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72°C. PCR using outer HHV8 ORF-26 primers produces a product 233 bp in length 
from positions 355 to 588 and using the inner primers produces a 211-bp product 
from position 366 to 577. Nucleotide positions are numbered according to the 
sequence deposited in GenBank under accession number U75698.
2.3.5 PCR amplification of the HHV-8 0RF-K1 DNA 
2.3.5. f K1A/1
First-round PCR amplification of the first variable region (VR1) of HHV-8 ORF K1
(hereafter referred to as “K1A/1”) was carried out in a 50-pl reaction mixture
containing nuclease-free water, Stratagene buffer number 8 (containing 35 mM
MgCl2 , 100 mM-Tris HCL (pH 8.8), 750mM KCI) (Stratagene, Amsterdam, The
Netherlands), 10 mM each dNTP, 1 unit Taq DNA polymerase (Invitrogen, CA, USA)
and 20 pmol each outer primer (sequence shown below). To this mixture, 10 pi of
extracted DNA was added. The second-round PCR mix was identical to the first
except 20 pmol of each inner primer (sequence shown below) was used and 2 pi of
the primary product was added as template. The sequences of the HHV-8 K1A/1
primers were as follows (Cook et al., 2002b):
K1 inn 5: 5'-CCCTGGAGTGATTTCAACGC-3'
K1 inn 6: 5 -ACATGCTGACCACAAGTGAC-3'
K1 -1: 5'-GAGTGATTTCAACGCCTTAC-3'
K1 -N: 5'-TGCTGACCACAAGTGACTGT-3'
The PCR thermocycling conditions for the amplification of the region HHV-8 ORF 
K1A/1 include heating the samples to 94°C for 5 min, followed by 35 cycles of 94°C 
for 1 min, 60®C for 1 min, and 72®C for 1 min, and finally 5 min at 72°C.
PCR using the ORF K1 outer primers produces a 255-bp fragment from positions 568 
to 823, while PCR using the inner primers produces a 247-bp fragment from positions 
573 to 820 in the BCBL-1 K1 sequence. Nucleotide positions are numbered
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according to the sequence deposited in GenBank (accession number U86667).
23.5.2 LongKI
A selected number of HHV-8 K1A/1 or KS330 DNA positive samples were amplified
for a longer region of HHV-8 ORF K1 (“long K1”) by nested PCR. This long K1 region
included both HHV-8 ORF K1 variable regions 1 and 2 (VR1 & VR2). First-round
PCR amplification of long K1 was carried out using JumpStart REDTaq ReadyMix
PCR Reaction Mix (Sigma, St. Louis, MO, USA). The mix contains JumpStart Taq
DNA Polymerase, 99% pure dNTPs, buffer, and an inert dye in a 2x optimized
reaction concentrate. 25 pi of this mixture was added to 20 pmol of each outer primer
(sequence shown below), 10 pi of extracted DNA, and nuclease-free water to a final
reaction volume of 50 pi. The second-round PCR mix was identical to the first except
20 pmol of each inner primer (sequence shown below) was used and 5 pi of the first-
round product was added as template. The sequences of the HHV-8 long K1 primers
(Cook et al., 1999; Whitby et ai., 2004) are as follows:
K1 a-f: 5-ATGTTCCTGTATGTTGTCTGC-3'
Kla-r: 5 -AGTACCAATCCACTGGTTGCG -3'
K1 b-f: 5-GTCTGCAGTCTGGCGGTTTGC -3'
K1 b-r: 5-CTGGTTGCGTATAGTCTTCCG -3'
The PCR thermocycling conditions for the amplification of the HHV-8 long K1 region 
include heating the samples to 95°C for 1 min 45 s, followed by 35 cycles of 96°C for 
1 min, 51 ®C for 45 s, and 72®C for 1 min. The annealing temperature for the second- 
round assay was 58°C for 30 cycles. Both assays ended with a 5-min extension 
period at 72®C (Mbulaiteye et a!., 2006). PCR using the long K1 outer primers 
produces a 867-bp fragment from positions 485 to 1352, while PCR using the inner 
primers produces a 840-bp fragment from positions 500 to 1340 in the BCBL-1 K1 
sequence. Nucleotide positions are numbered according to the sequence deposited 
in GenBank under accession number U86667.
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2.3.6 Detection of the PCR product
Eight pi of the PCR product was mixed with 2 pi of Blue/Grange 6X loading dye 
(Promega, Wisconsin, USA) and electrophoresed through a 2% agarose gel along 
with 1 pg of 1-kb ladder molecular weight marker (Invitrogen, CA, USA) on either side 
of the test samples to assess the size of the amplified product. Positive and negative 
controls were also added. Electrophoresis took place in a 1X TRIS-borate EDTA 
buffer (TBE supplied as 10X stock) (Invitrogen, CA, USA). The gels were then 
stained with ethidium bromide solution (Invitrogen, CA, USA) in TBE buffer 
(concentration of 5pg/ml). DNA fragments were visualized using a short wave ultra­
violet trans-illuminator (Biorad Gel doc System) and photographed using a photo 
printer (Mitsubishi P91 Video Copy Processor).
2.3.7 Procedures to minimize contamination
To minimize contamination during PCR, DNA extraction, PCR reagent preparation, 
thermocycling and post-PCR procedures were conducted in dedicated rooms. 
Appropriate negative control specimens were also included in each PCR. In addition, 
DNA extraction and PCR were repeated for those samples showing intra-individual 
HHV-8 subgenomic sequence variation.
2.3.8 Purification of PCR products for sequencing
In order to efficiently recover DNA and remove gel, primers and free nucleotides, 
which can interfere with subsequent downstream applications, the PCR products 
were purified directly from the second-round PCR product using GE GFX PCR DNA 
Purification kit (GE Healthcare Bio-Sciences AB, Uppsala, Sweden) following the 
manufacturer’s instructions, or from agarose gels by the use of the Qiagen QIAquick 
Gel Extraction kit (Qiagen Inc., Venlo, The Netherlands). The latter technique 
involved loading the PCR products onto a 2% composite agarose gel and 
electrophoresis, as described in Section 2.3.6. Alternate wells were used to allow
109
Chapter 2__________________________________________________________ Patients. Materials and Methods
adequate area for cutting out each band from the gel without risk of contamination 
from other products. Short wave transillumination was used to visualize the bands so 
that they could be carefully cut out with a scalpel, and transferred to separate 1.5 ml 
Eppendorfs. The Eppendorfs were then weighed and the appropriate amount of 
buffer QG (containing a pH indicator) added. Buffer QG solubilizes the agarose gel 
slice and provides the appropriate conditions for binding of DNA to the silica 
membrane in preparation for DNA purification, as detailed by the manufacturer’s 
instructions.
In addition, plasmid DNA was purified using Qiagen QIAprep Spin Miniprep Kit 
(Qiagen Inc., Venlo, The Netherlands) when needed. This technique involves alkaline 
lysis of bacterial cells followed by adsorption of DNA onto a silica membrane in the 
presence of high salt in an attempt to obtain an optimum combination of DNA quality, 
yield and concentration.
To confirm that the purification had been successful and to estimate the quantity of 
DNA recovered, 1 pi of the supematant was taken and run on a 2% agarose gel 
alongside a 1pg of 1-kb ladder (Invitrogen, CA, USA), stained and visualised before 
subsequent cloning or sequencing.
2.3.9 Cloning
Second-round K1A/1 PCR products of some positive samples were cloned prior to 
DNA sequencing using the TORO TA cloning kit (Invitrogen). This resulted in better 
quality sequencing results, and allowed multiple clones from one sample to be 
compared, thereby ensuring sequence fidelity.
The PCR4-T0P0 vector is supplied linearised with the addition of a 3’ thymidine (T) 
overhang to complement the 3’ terminal A of the PCR product. During PCR, Taq
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polymerase adds a single adenosine (A) to 3’ end of the PCR product through its 
non-template dependent terminal transferase activity (Marchuk et al., 1991; Shuman, 
1994). Ligation of vector and PCR product occurs through the activity of 
topoisomerase I, covalently bound to the vector (Shuman, 1994). Chemically 
competent E. coil are used to transform the cloning reaction and are grown overnight 
on L agar (Luria agar: 1.0% tryptone, 5.0% yeast extract, 1.0% 0.17 M NaCI, 1.5% 
agar, pH 7.0) containing 50 mg/ml ampicillin. PCR using second-round primers was 
performed directly on the resulting colonies and prior to sequencing.
2.3.10 DNA sequencing
The samples were sequenced using the Beckman CEQ2000 automated capillary 
array sequencer. Purified DNA was added to the PCR sequencing reaction consisting 
of the following components: 5 pi of sterile water, 3 pi of inner PCR primers (2 pmol), 
and 8 pi of Beckman Coulter sequencing kit mix (Beckman Coulter Inc, CA, USA), to 
a total volume of 20 pi. Sequencing PCR reactions were purified using the 
CleanSEQ® Sequencing Reaction Clean-Up System (Agencourt Bioscience Corp., 
MA, U.S.A). CleanSEQ® contains magnetic particles in an optimized binding buffer to 
selectively capture sequencing extension products.
The CleanSEQ® procedure (Figure 2.1) is performed in three stages:
1. Selective binding of sequencing extension products to paramagnetic beads and 
separation of the beads with a magnetic field;
2. Washing of the beads with 85% ethanol to remove unincorporated dyes, 
nucleotides, salts and other contaminants;
3. Elution of the purified sequencing product from the paramagnetic beads using 
forma mide.
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Figure 2.1 CleanSEQ® Process overview
1. Agencourt CleanSEQ reagent and ethanol addition to sequencing reaction; 2. sequencing 
products binding to magnetic beads; 3. Separation of sequencing products from contaminants 
with magnetic field; 4. Washing with ethanol; 5. Elution from magnetic particles 6. Transfer 
away from magnetic beads.
[Adapted from: http://www.agencourt.com/poducts/spri_reagents/cleanseq]
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The sequencing products were then immediately loaded onto the automated 
sequencer. The Beckman CEQ-2000 uses a capillary system to electrophorese the 
samples through a polyacrylamide gel contained in a capillary tube. In the 
sequencing PCR mix, chain terminating nucleotide bases with different fluorescent 
tags are present and are incorporated into the DNA during PCR amplification. During 
electrophoresis a laser reads these fluorescent bases to determine the sequence of 
the sample.
2.3.11 Analysis of sequence data
Raw chromatograph data were analysed using the SeqMan sequence analysis 
software, and multiple alignments were made in Megalign. Both programmes were 
from the LASERGENE sequence analysis package (DNAstar Inc., Madison, Wl, 
USA). The Megalign programme allowed the degree of similarity between different 
sequences to be analysed by comparing nucleotides and/or amino acids. The 
alignments were viewed in four different formats: the Alignment Report, Sequence 
Distances, Residue Substitution and Phylogenetic Tree using the UPGMA method of 
clustering analysis. Genetic distances were expressed as a percent nucleotide 
divergence over the entire tree. Further analysis was performed after all sequence 
data had been collected. Alignments were entered into the PHYLogeny /nference 
Package (PHYLIP version 3.6, Seattle, USA). The following programmes were used 
to analyse sequence data in PHYLIP: DNADIST and NEIGHBOR. Alignments were 
first analysed using SEQBOOT to create 1000 multiple data sets, resampled from the 
input data set using random sampling methods with replacement. Trees generated in 
SEQBOOT were entered into the CONSENSE program and the branching patterns 
that occurred most frequently were reflected on the consensus tree. Values at each 
node indicated the percentage of trees containing each branching pattern and could 
be used to interpret the robustness of the resulting tree.
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2.4 Quantitative PCR
Selected WMS^ extracts, showing positive results for K1A/1 and KS330 DNA, were 
sent to Dr 8 Dollard, the National Centre for Infectious Diseases, Centres for Disease 
Control and Prevention, Atlanta, GA, where a quantitative, fluorescence-based, real­
time PCR assay targeting ORF 25, was applied as previously described (Stamey et 
al., 2001). Each 50 pi reaction contained extracted DNA, 600 nM each primer, and 
200 nM probe. The samples were tested in duplicate.
2.5 Serological detection of HHV-8
An ELISA (Advanced Biotechnologies Inc., Columbia, MD, USA) was used for the 
detection of HHV-8 IgG antibodies in the participants' plasma samples. This uses, as 
antigen, a whole viral extract from the KS-1 cell line which was derived from a PEL of 
an EBV/HIV-uninfected patient. The test detects antibody to the majority of HHV-8 
structural proteins (Said eta!., 1996b; Chatlynne eta!., 1998).
The plasma was first diluted in a provided sample diluent (1:101), and 100 pi applied 
to each well, with the positive control (in duplicate), the negative control (in triplicate) 
and the reagent blank (100-pl sample diluent) in another well. The test procedure 
involves three incubation steps: In the first, the plasma (at a 1:101 dilution) is 
incubated in the antigen-coated microtitre wells. The wells are then washed to 
remove any unbound sample components. The second step involves the addition of 
horseradish peroxidase conjugated anti-human IgG (Fc-specific) to the wells. The 
conjugate binds to the antibody immobilized on the wells. The wells are then washed 
to remove unreacted conjugate. The final incubation step involves the incubation of 
the microtitre wells containing immobilized peroxidase conjugate with a peroxidase 
substrate (tetramethylbenzidine). Enzyme-mediated cleavage of the substrate results 
in a colour change of positive samples to blue. After 30 min the reaction is stopped by 
adding a sulphuric acid stop solution. The colour of the positive samples then
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changes from blue to yellow, and the colour intensity is measured 
spectrophotometrically. The colour intensity of the solution is proportional to the 
antibody concentration in the test sample. Optical Density (CD) ratios were calculated 
by dividing the reading of each sample well by the cut-off value (the average of the 
three negative control readings multiplied by 3). The CD ratios were then interpreted 
as follows:
OD Ratio
Negative samples <0.75
Positive samples >1.00
Equivocal (borderline) 0.76 -  0.99
2.6 Screening for inter- and intra- sample K1/V1 sequence differences 
by denaturing gradient gel electrophoresis (DGGE)
2.6.1 K1A/1 Expand high-fidelity PCR and cloning
Selected samples that amplified positively for K1A/1 were subjected again to nested 
PCR using same conditions as in Section 2.3.5.1 except that 0.7 units of the EXPAND 
High Fidelity PCR System (Roche Diagnostics, Penzberg, Germany) were used 
instead of Taq DNA polymerase. The PCR products were then purified directly from 
the second-round PCR product using GFX PCR DNA Purification kit (GE Healthcare 
Bio-Sciences AB, Uppsala, Sweden) following the manufacturer’s instructions. 
Clones were generated from each K1A/1 PCR product by use of the TOPO TA 
Cloning System (Invitrogen, CA, USA) as detailed in Section 2.3.9.
2.6.2 GC-clamp colony PCR
For at least 15 clones from each amplificate, another round of PCR was done under 
conditions identical to the second-round high-fidelity PCR, except that a "clamping" 
primer was used in place of the forward inner sense primer. The clamping primer 
contains a guanine-cytosine rich domain with a high melting temperature, to prevent
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complete dénaturation of the PCR product (Sheffield et al., 1989; Woodward et al.,
1994). This primer, K1-1 clamp, has the following sequence:
5’CGCCCGCCGCGCCCCGCGCCCGTCCCGCCGCCCCCGCCCGGAGTGATTTCA
ACGC-3’
The sequence for the reverse inner sense primer is as described in Section 2.3.5.1. 
Colony PCR products were separated and visualised on an agarose gel as described 
in Section 2.3.6.
2.6.3 Preparing denaturing gradient polyacrylamide gels
Stock solutions of each acrylamide mix were prepared beforehand and cooled to 4°C 
prior to use. For the K1A/1 colony PCR product, a gel gradient of 30% to 50% 
dénaturants was necessary to achieve discrimination to a 1 base pair mutation. The 
50% solution contained 10% acrylamide, 0.6% TAE buffer, 20% forma mide and 3.5 
M urea. The 30% solution contained 10% acrylamide, 0.6X TAE, 12% forma mide, 
and 2.1 M urea. Using a gravity-driven gradient maker with pump drive (GRI, 
Braintree, UK), the gradient gel was poured using 30 ml of each solution. To allow the 
gel to polymerise 13 pi of N, N, N’, N’ -tetramethylethylenediamine (TEMED) 
(Invitrogen) and 250 pi of 10% ammonium persulfate per each 30 ml of stock solution 
were added prior to pouring. A gradient gel was pumped between glass plates. A 48- 
well comb was inserted and the gel was left to polymerise for at least 6 h.
2.6.4 Loading and electrophoresis
Clamped colony PCR products (4 pi) generated as described in Section 2.6.2 were 
mixed with 2 pi of Blue/Orange 6X loading dye (Promega, Wisconsin, USA). After all 
the samples were loaded into the wells, electrophoresis in 0.6X TAE buffer at 60°C 
and 100 V took place over 16 h. The electrophoresis apparatus allowed for 
continuous flow of buffer to maintain a constant temperature of 60°C throughout the
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run (Igeny PhorU).
2.6.5 Staining of gels
Gels were stained in a solution of ethidium bromide (Invitrogen) in 200 ml of 0.6X 
TAE buffer (concentration of 1.25|jg/ml) for 1 h. Bands were visualised by a short 
wave ultraviolet transilluminator (Biorad Gel doc System) and photographed using a 
photo printer (Mitsubishi P91 Video Copy Processor). K1A/1 inserts in clones 
corresponding to bands that migrate to disparate gel positions were sequenced for 
genotypic and subgenotypic differences as described in Section 2.3.10 and raw 
chromatograph data analysed as described in Section 2.3.11.
2.7 Screening for inter- and intra- sample long K1 sequence 
differences by cloning and DNA sequencing
2.7.1 Isolation of DNA band from agarose gel
Selected PCR products that amplified positively for long K1 were loaded onto a 2% 
composite agarose gel and underwent electrophoresis. The bands were carefully cut 
out with a scalpel, and transferred to separate 1.5 ml Eppendorfs, after which DNA 
purification was performed using Qiagen QIAquick Gel Extraction kit (Qiagen) as 
descrit>ed in Section 2.3.8. Purified DNA fragments were visually verified by gel 
examination before cloning.
2.7.2 Cloning
The long K1 gene fragment was cloned into vectors by use of the TOPO-TA Cloning® 
kit (Invitrogen, CA, USA) as described in Section 2.3.9. Colonies were screened by 
PCR using HHV-8 long K1 second-round primers as described in Section 2.3.5.2. 
DNA of at least ten clones of each amplificate was purified using GE GFX PCR DNA 
purification kit or Qiagen QIAprep Spin Miniprep Kit when needed. Purified DNA 
fragments were visually verified by gel examination before sequencing.
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2.7.3 Sequencing
The selected clones were sequenced using forward and reverse M13 and long K1 
inner primers. Sequencing was performed using the Beckman-Coulter CEQ2000 
automated capillary array sequencer as described in Section 2.3.10. Raw DNA 
sequence data were analyzed using Seqman software (DNAstar) (Section 2.3.11).
2.8 Statistical analysis
Data entry and analysis were performed using the SPSS for Windows (Statistical 
Package of Social Science) software, version 12.0. Frequency distributions and 
cross-tabulation tables were constructed in order to analyze the demographic, clinical 
and virological information. In an attempt to detect possible risk factors, both logistic 
regression and chi-squared testing (the P value for statistical significance was set at 
<0.05) were used. The independent samples f-test, ANOVA and Bivariate correlation 
(Spearman’s rank correlation) were used as appropriate.
118
Chapter 3
HHV-8 Geno- and Sero-prevalence in the General 
Population, Patients with Renai Failure, and Renal
Allograft Recipients
Chapter 3__________________________________________ HHV-8 Geno- and Sero-prevalence in Saudi Arabia
3.1 Introduction
Serological studies reveal that the prevalence of HHV-8 in populations varies widely 
throughout the world (Whitby et al., 1995; Gao et al., 1996b; Kasolo et al., 1997; 
Whitby et al., 1998; Rezza et al., 1998; OIsen et al., 1998; Perna et al., 2000; 
Iscovich et al., 2000; Chokunonga et al., 2000; Schulz, 2000a; He et al., 2007). The 
prevalence of KS also varies widely. With regard to post-transplantation KS, the rate 
of KS among solid-organ transplant recipients varies by geographic location. 
Generally, countries with higher rates of seropositivity to HHV-8 also have higher 
rates of KS among the transplant population. However, this situation does not seem 
to apply to Saudi Arabia, where KS is particularly prevalent among renal allograft 
recipients compared to other geographic regions. Previous studies have suggested 
that HHV-8 seroprevalence is relatively low (ranging between 1.7% and 7%) in the 
general Saudi Arabian population (Qunibi et al., 1998; Almuneef et al., 2001; 
Alzahrani et al., 2005), yet high (ranging between 18% and 28%) in renal allograft 
recipients without KS (Qunibi et al., 1998; Alzahrani et al., 2005). Such a disparity in 
HHV-8 prevalence rates between the general population and renal transplant 
recipients has not been reported elsewhere and the reason for the particularly high 
incidence of post-transplantation KS in this geographic area is unknown.
Saudi Arabian patients with ESRD, unlike those from other regions (Cattani et al., 
2001) were reported to have an increased risk of HHV-8 infection (7% to 29%) 
(Qunibi et al., 1998; Almuneef et al., 2001) compared with subjects without renal 
disease (ranging between 1.7% and 7%) (Qunibi et al., 1998; Almuneef et al., 2001; 
Alzahrani et al., 2005). The finding by Almuneef et al. (2001), in the later and larger 
study, of antibodies to HHV-8 in only 7% of ESRD patients is comparable in 
magnitude to the incidence reported in patients in Greece receiving haemodialysis 
(7.2%) (Zavitsanou et al., 2006).
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Most previous studies of orally shed HHV-8 have been conducted in Western gay 
men and in people who live in KS-hyperendemic areas such as Africa. No studies 
appear to have involved patients with renal disease in another group at particular risk 
of KS -  those from the Middle East (Penn, 1983; El Agroudy et al., 2003).
Given the issues outlined above with regard to HHV-8 infection and disease relating 
to post solid-organ transplant patients in Saudi Arabia, an investigation into the extent 
of serologic as well as genomic prevalences of HHV-8 infection in the Saudi Arabian 
general population, patients with end-stage renal disease receiving haemodialysis, 
and renal allograft recipients was conducted. Additionally, the shedding of HHV-8 via 
saliva and the possibility of HHV-8 infection in different anatomical compartments in 
patients with renal disease was determined to define the most likely sites of HHV-8 
shedding.
3.2 Patients and samples
3.2.1 Study population
Samples were collected from four different groups of participants (BD, PW, CRF and 
RAR) attending the Armed Forces Hospital in Riyadh, Saudi Arabia (Table 3.1). All 
participants were of Saudi nationality. Clinical data on BD, PW, CRF and RAR 
patients were obtained from computer-based and standard medical records and 
documented onto standardized forms, which were linked to patient samples by 
numerical code. The clinical, virological and immunological characteristics determined 
for each of the four groups are listed in Table 2.1. Oral findings and indices were 
documented using a standard proforma (Appendix 1).
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Table 3.1 Demographic features of the four study groups
Group n . Male Female Age
mean (yr) SO median (yr) range (yr)
BD 178 176 2 30 7 30 18-51
PW 60 0 60 27 7 28 17-43
CRF 72 43 29 57 14 60 23-83
RAR 61 37 24 40 13 41 19-72
BD, blood donors: PW, pregnant women; CRF, patients with chronic renal failure; RAR, renal allograft recipients 
with no history of KS
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3.2.2 Sample collection
Blood samples were obtained from the BD and PW groups as described in Section 
2.2.1, while matched oral and blood samples were obtained from the CRF and RAR 
groups as described in Sections 2.2.1, 2.2.2 and 2.2.3.
3.2.3 Sample processing
After separation of plasma from the blood, the CD45+, CD31+ and CD 19+ cell 
subsets were immunomagnetically fractionated as described in Sections 2.2.1.1 and 
2.2.1.2. The cellular and supemate fractions of WMS (WIVIS^  and WMS®, respectively) 
were separated by low-speed centrifugation. BE and PE were similarly pelleted. 
Following aspiration of the supemate, WIVIF ,^ BE and PE were resuspended in 1 ml 
of PBS, and stored at -20®C until required. DNA was extracted from blood cell 
subsets and oral samples as described in Section 2.3.2. The presence of DNA in 
randomly selected extracts was verified by amplifying a fragment of the /ff-globin gene 
as described in Section 2.3.3.
3.2.4 Anti HHV-8 IgG detection
The Advanced Biotechnologies ELISA was applied to all plasma samples as detailed 
in Section 2.5.
3.2.5 Sequencing analysis of DNA amplified from KS330 and K1
The 211-bp KS330 segment was amplified from sample extracts by use of nested 
PGR (Section 2.3.4). The 247-bp K1A/1 segment was amplified from sample extracts 
by nested PGR (Section 2.3.5.1). PGR products were sequenced, raw DNA 
sequence data analyzed and phylogenetic analyses performed as detailed in Sections 
2.3.10 & 2.3.11.
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3.2.6 Study of demographic, clinical and virological characteristics 
Data entry and analysis were performed using the SPSS for Windows (Statistical 
Package of Social Science) software, version 12.0. Frequency distributions and 
cross-tabulation tables were constructed in order to analyze the demographic, clinical 
and virological information. In an attempt to detect possible risk factors, both logistic 
regression and chi-squared testing (the P value for statistical significance was set at 
<0.05) were used to determine the effect of general and specific characteristics on 
HHV-8 genoprevalence, seroprevalence and K1A/1 genotypes. When investigating 
potential differences in age between groups, the independent samples f-test and 
AN OVA were used as appropriate. Bivariate correlation (Spearman’s rank 
correlation) was used to test for WMS® viral load interaction with oral health.
The general and specific variables examined are listed below:
3.2.6.1 General Variables
Age, gender, area of origin (area of birth and childhood according to the 
administrative area; Fig 3.1), viral infections (hepatitis B and hepatitis C) and oral 
indices (plaque index, gingival index and bleeding index).
3.2.6.2 Specific Variables
For the CRF group, these were history of previous transplant and duration of dialysis. 
For the RAR group, these were history of previous transplant, type of renal allograft, 
nationality of allograft donor, relation of donor, location of transplant, time elapsed 
since transplant, and medications administered (ciclosporin, prednisolone, tacrolimus, 
mycophenolate mofetil and antivirals).
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Figure 3.1 Map of Saudi Arabia showing the 13 administrative regions
[Adapted from: httpV/www.geocities.com/brianjamesdunn/saud i4.jpg]
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3.2.7 Quantitative PCR
All WMS®, showing positive results for both K1A/1 and KS330 DNA, were referred to 
the National Centre for Infectious Diseases, Centres for Disease Control and 
Prevention, Atlanta, G A, where a quantitative, fluorescence-based, real-time PCR 
was applied as described in Section 2.4.
3.2.8 Investigation of Taq polymerase-induced misincorporation
In this study, 1239 samples were tested by nested PCR for 2 HHV-8 ORFs. Taq 
polymerase was the preferred polymerase used for PCR, being the most cost- 
effective for large-scale reactions. However, Taq polymerase does not have 3’ to 5’ 
exonuclease activity and cannot therefore excise misincorporated nucleotides during 
polymerisation. This may lead to the presence of artefactual mutation errors in a 
proportion of the PCR amplicons. It has been estimated that Taq polymerase will 
introduce an error at a rate of approximately 0.85 x 10"^errors/base pair/cycle.
In order to estimate the impact of Taq polymerase-induced mutations on the clonal 
diversity displayed by DGGE, clones produced from an ORF K1A/1 PCR product, 
amplified from the HHV-8 infected cell line, BCBL-1, were analysed. From each PCR 
product amplified using either Taq polymerase or the EXPAND system, 11 clones 
were produced and amplified in colony PCR. Previous single-strand conformational 
polymorphism (SSCP) studies on BCBL-1 KW1 clones, amplified using the high- 
fidelity EXPAND DNA polymerase system, had indicated no viral diversity was 
present in this cell line (C. Bez, personal communication). EXPAND contains a 
mixture of both Taq polymerase and Pwo polymerase. Pwo polymerase possesses 3’ 
to 5’ exonuclease proofreading activity and as a result the EXPAND system will 
produce errors at a rate of only 8.5 x lO"® errors/base pair/cycle. Another 11 clones 
using Taq polymerase to amplify ORF K1A/1 PCR product followed by the use of 
EXPAND during the screening PCR (colony PCR) were also examined.
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3.2.9 Intra-person K1A/1 sequence differences as revealed by DGGE 
Two CRF patients (CRF24 and CRF57), from whom non-identical ORF K1A/1 
sequences were recovered and K1A/1 amplification using EXPAND was possible, 
were chosen for DGGE analysis. From CRF 24 and CRF 57, oral and blood samples, 
which amplified positively for both examined regions, were subjected again to nested 
PCR by use of the EXPAND (Section 2.6.1). The PCR products were then purified 
directly from the second-round product (Section 2.3.8) and clones generated (Section 
2.3.9). From approximately 22 colonies from each amplificate, another round of PCR 
was done using a clamping primer as described in Section 2.6.2, and the products 
were visualised by agarose gel electrophoresis. The PCR products from 16 selected 
colonies were subjected to DGGE as detailed in Sections 2.6.3, 2.6.4 and 2.6.5, 
followed by nucleotide sequencing (Section 2.3.10).
3.3 Results
3.3.1 Anti HHV-8 detection
IgG antibodies to HHV-8 were detected in the plasma of one person in the BD group 
(0.6%) (Table 3.2), none in the PW group, 12 in the CRF group (16.7%) (Table 3.3), 
and four in the RAR group (6.6%) (P <0.001, Pearson Chi-square) (Table 3.5). 
Although the Chi-square test results showed that there was a statistical significant 
difference, this result should be treated with caution, as the number of cells employed 
in the statistical analysis, with an expected count less than 5 was 37.5%.
HHV-8 IgG was found significantly more frequently in CRF patients (12/72; 16.7%) 
than in healthy control individuals (1/238; 0.4%) (P <0.001, Fisher’s exact test). HHV- 
8 IgG was also found to be more frequent in renal transplant recipients (4/61; 6.6%) 
than in healthy control individuals (1/238; 0.4%) (P = 0.007, Fisher’s exact test). 
However, no significant difference in HHV-8 IgG was found between CRF and RAR 
patients (P = 0.108, Fisher’s exact test)
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3.3.2 HHV-8 DNA detection
The rate of HHVB-subgenomic DNA detectability varied according to the sample 
group, type of sample collected (blood, saliva or oral brushes) and the target of 
amplication within the HHV-8 genome.
3.3.2.1 Blood donors and pregnant women
HHV-8 subgenomic DNA was detected in the CD45+ blood cells from nine blood 
donors (5.1%) and from none of the pregnant women. All HHV-8-genopositive blood 
donors were male, with a mean age of 28.7 yr (SD= 7.7) and median age of 29 yr 
(range: 1 9 - 4 0  yr). One donor’s blood sample was concordantly positive for KS330 
and K1 A/1, three were positive for KS330 alone and five were positive for K1/V1 only 
(Table 3.2).
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Table 3.2 Saudi blood donors with HHV-8 geno- or sero-positivity
Donor
Age
(yr)
KS330 K1/V1
Anti-
HHV-8
1 27 PCS pos neg
2 40 pos neg neg
3 22 neg pos neg
4 29 pos neg neg
5 29 neg pos neg
6 33 neg pos neg
7 32 neg neg pos
8 39 neg I  . pos neg
9 20 neg pos neg
10 19 pos neg neg
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3.3.2.2 Chronic renal failure group
The detectability rates according to the amplifiable subgenomic DNA segments were 
as follows: concordantly positive for KS330 and K1A/1: 1/72 (1.4%) for CD19+ cells, 
none for CD31+ cells, 3/72 (4.2%) for CD45+ cells, 5/69 (7.3%) for WMS", 5/69 
(7.4%) for WMS", none for PS, 1/69 (1.5%) for BE, 1/69 (1.5%) for PE; positive for 
KS330 alone: 1/72 (1.4%) for GDI9+ cells, 1/72 (1.4%) for CD31+ cells, none for 
CD45+ cells, 1/69 (1.5%) for WMS", 4/69 (5.8%) for WMS", none for PS and for BE, 
2/69 (2.9%) for PE; and, positive for K1/V1 alone: 1/72 (1.4%) for CD19+ cells, 8/72 
(11.1%) for CD31+ cells, 1/72 (1.4%) for CD45+ cells, 3/69 (4.4 %) for WMS", 3/69 
(4.4 %) for WMS", 2/41 (4.9%) for PS, 5/69 (7.3%) for BE, and 5/69 (7.3%) for PE 
(Table 3.3). For 4 people, HHV-8 DNA could be amplified from >4 samples. For 2 
people, HHV-8 DNA could be amplified from three samples. For 4 people, HHV-8 
could be amplified from two samples, and for nineteen patients only one sample 
amplified positively for HHV-8.
For CRF patients from whom tx)th oral and blood samples were collected (n= 69), 
solitary or concordantly positive results for HHV-8 K1 and/or KS330 DNA were 
detected in one or more oral samples from 22 (31.9%) patients and in at least one 
blood sample from 11 (15.9%) patients. HHV-8 DNA was significantly more 
detectable in the oral samples of CRF patients than in their blood (P = 0.043, 
McNemar’s test). Table 3.4 and Figure 3.2 compare oral (WMS", WMS", PS, BE and 
PE) and blood (CD19+, CD31+ and CD45+ cells) HHV-8 detection in CRF patients.
Nearly one third of CRF patients (20/69) were HHV-8 geno positive but not 
seropositive, while three CRF patients were seropositive but not genopositive (3/69, 
4.4%) and nine were both HHV-8 geno- and sero-positive (9/69, 13%) four of whom 
were positive for HHV-8 DNA in their oral samples only and two positive in their blood 
samples alone. Three (25%) out of the 12 HHV-8 seropositive CRF patients had
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detectable HHV-8 DNA in both their blood and oral compartments. HHV-8 K1A/1 
DNA in her blood sample.
Among all CRF HHV-8-antibody positive patients (n=12), 7/12 (58.3%) were solitary 
or concordantly positive for HHV-8 K1 or/and KS330 DNA PCR in their oral samples 
and 5/12 (41.7%) were solitary or concordantly positive for HHV-8 K1 or/and KS330 
DNA PCR in their blood samples. The results based on the logistic regression 
analysis (the odds ratios (OR) and their corresponding 95% confidence intervals) 
revealed that CRF patients with detectable antibodies have 6.1 times the odds of 
having HHV-8 in blood (95% Cl; 2.3, 23.6), and 4 times the odds of having HHV-8 in 
their oral samples (95% Cl: 1.1, 14.2) compared to CRF patients without detectable 
antibodies.
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Table 3.3 ELISA and HHV-8 DNA PCR findings in oral a n d blood sa m p le s  o f CRF patients
HHV-8 PCR RESULTS
U)NJ
CRF 
ID number
24
57
56
23
10
43 
15 
46 
11 
48
44 
54 
37
CD19 CD31
2 neg neg neg ^ s
7 neg neg neg pos
34 neg neg neg [p o s
65 neg neg [ pos neg
58 neg neg neg neg
60 neg neg neg neg
61 neg neg neg neg
32 neg neg neg neg
41 neg neg neg neg
45 neg neg neg neg
12 neg neg neg neg
62 neg neg neg neg
9 neg neg neg neg
72 neg neg neg neg
69 neg neg neg neg
3 neg neg neg neg
33 neg neg neg neg
64 neg neg neg neg
CD45
neg
neg
neg
neg
neg
neg
neg
neg
neg
neg
neg
neg
neg
neg
neg
neg
neg
neg
neg
neg
neg
neg
neg
neg
neg
neg
neg
neg
neg
neg
neg
neg
neg
neg
neg
WMS*
pos
pos
pos
pos
pos
neg
neg
neg
neg
neg
neg
neg
pos
neg
neg
neg
neg
neg
neg
neg
neg
neg
neg
neg
neg
neg
neg
neg
neg
neg
neg
neg
pos
pos
pos
pos
pos
pos
neg
neg
neg
neg
neg
neg
neg
neg
neg
neg
neg
neg
neg
pos
neg
neg
neg
neg
neg
neg
neg
neg
neg
neg
neg
WMS*
pos
pos
pos
pos
pos
neg
neg
neg
neg
neg
pos
pos
pos
neg
neg
neg
neg
neg
neg
neg
neg
pos
pos
pos
pos
pos
neg
neg
neg
neg
neg
neg
neg
neg
neg
neg
neg
neg
pos
pos
neg
neg
neg
neg
neg
neg
neg
neg
neg
neg
neg
neg
PS
neg
neg
neg
neg
neg
neg
neg
neg
neg
neg
NA
neg
neg
NA
NA
neg
NA
NA
NA
neg
neg
neg
neg
NA
NA
neg
neg
neg
neg
neg
neg
neg
NA
neg
neg
NA
NA
neg
neg
NA
NA
neg
NA
neg
neg
NA
NA
pos
NA
NA
NA
neg
neg
neg
neg
NA
NA
neg
neg
neg
neg
neg
neg
neg
NA
neg
neg
NA
NA
pos
neg
NA
NA
neg
neg
CE]
neg 
neg
pos
neg
neg
neg
neg
neg
neg
neg
neg
neg
neg
neg
neg
neg
neg
neg
neg
neg
neg
neg
neg
neg
neg
neg
neg
neg
neg
neg
neg
neg
neg
neg
pos
pos
neg
neg
neg
neg
pos
neg
neg
neg
neg
neg
neg
neg
neg
neg
neg
neg
neg
neg
neg
neg
neg
pos
neg
neg
neg
PE
1 1
pos pos
neg pos
p“ neg
neg neg
neg pos
neg neg
neg neg
neg neg
neg neg
neg neg
neg neg
neg neg
pos neg
neg neg
neg neg
neg neg
neg neg
neg neg
neg neg
neg neg
neg neg
neg neg
neg neg
neg neg
neg pos
neg pos
neg pos
neg neg
neg neg
neg neg
neg neg
neg neg
HHV-8
Seropositlvlty
pos
pos
pos
pos
pos
neg
neg
neg
neg
neg
neg
neg
neg
neg
neg
neg
neg
neg
neg
neg
neg
neg
neg
neg
neg
pos
pos
pos
CD45+, CD31+ and CD19+; PBMC subsets; WMS®, whole mouth saliva supemate fraction; WMS®, whole mouth saliva cellular fraction; PS, parotid saliva; 
BE, buccal exfoliate; PE, palatal exfoliate; pos, HHV-8 DNA amplified; neg, HHV-8 DNA not amplified; NA, sample not available
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Table 3.4 Oral and blood HHV-8 shedding in CRF patients
Non­
infected
Oral
infection
only
Blood
infection
only
Oral and 
blood 
infection Total
No. (%) No. (%) No. (%) No. (%) No. (%)
CRF
Patients 40 (58) 18(26) 7(10) 4(6) 69 (100)
Figure 3.2 Venn diagram illustrating oral and blood shedding of HHV-8 in CRF 
patients
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3.3.2.3 Renal allograft recipient group
The detectability rates according to the amplifiable subgenomic DNA segments were 
as follows: concordantly positive for KS330 and K1A/1: 2/61 (3.3%) for CD19+ cells, 
none for CD31+ cells, CD45+ cells, WMS®, WMS®, PS, BE and PE; positive for 
KS330 alone: 1/61 (1.6%) for CD19+ cells, none for CD31+ cells, CD45+ cells, 
WMS®, WMS®, PS, BE and PE; and, positive for K1A/1 alone: 8/61 (13.1%) for 
GDI9+ cells, 1/61 (1.6%) for CD31+ cells, 3/61 (4.9%) for CD45+ cells, 6/60 (10%) 
for WMS®, 5/60 (8.3%) for WMS®, none for PS, 3/60 (5%) for BE, and none for PE 
(Table 3.5). For one person, HHV-8 DNA could be amplified from three samples. For 
three people, HHV-8 DNA could be amplified from two samples and for twenty 
patients only one sample amplified positive for HHV-8.
For RAR patients, from whom both oral and blood samples were collected (n=60), 
solitary or concordantly positive results for HHV-8 K1 and/or KS330 DNA were 
detected in an oral sample from 12 (20%) patients and in a blood sample from 14 
(23.3%) patients. HHV-8-DNA-positivity rate was not significantly different between 
blood and oral samples (P = 0.824, McNemar’s test). Table 3.6 and Figure 3.3 
compare oral (WMS®, WMS®, PS, BE and PE) and blood (CD19+, CD31+ and CD45+ 
cells) HHV-8-DNA detection rates in RAR patients.
A third of RAR patients (20/60) were HHV-8 genopositive but not seropositive, while 
three patients were both HHV-8 geno- and sero-positive (3/60, 5%), two of who were 
solitarly positive for HHV-8 K1/V1 DNA in their oral samples and one solitarly positive 
for HHV-8 K1/V1 DNA in her blood sample.
In this study, 9/178 (5.1%) of CD45+ cell samples from blood donors, none (0/60) 
from the PW group, 4/72 (5.6%) from the CRF group, 3/61 (4.9%) from the RAR 
group yielded HHV-8 subgenomic amplicons (P = 0.352, Pearson Chi-square).
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Moreover, no statistically significant difference was observed in HHV-8 subgenomic 
detection rates in CD45+ cell samples between patients with renal disease and 
healthy control individuals (P = 0.596, Fisher’s exact test) or between CRF and RAR 
patients (P = 1, Fisher’s exact test). The detectability rates in the four study groups 
are summarised in Table 3.7.
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Table 3 .5  ELISA and HHV-8 DNA P C R  findings in oral and  blood s a m p le s  o f RAR p atients
HHV-8 PCR RESULTS
CD19 CD31 CD45 WMS» W M S' PS BE PE
U»o\
CD45+, CD31+ and CD 19+: PBMC subsets 
WMS®, whole mouth saliva supemate fraction: WMS°, 
HHV-8 DNA amplified; neg, HHV-8 DNA not amplified
RAR 
ID number 1 7:1 1 1 I 1 1 7^1 1 7^1 1 7^1 I 1 1 7^1 HHV-8Seroposltivity
61 neg neg neg neg neg neg neg pos neg pos NA NA neg pos neg neg pos
10 neg neg neg neg neg pos neg neg neg neg NA NA neg pos neg neg neg
72 neg neg neg neg neg pos neg pos neg neg neg neg neg neg neg neg neg
17 neg neg neg neg neg pos neg neg neg neg NA NA neg neg neg neg neg
23 neg 1 pos 1 neg neg neg neg neg neg neg pos neg neg neg neg neg neg neg
63 neg neg neg 1 1 neg neg neg neg neg neg NA NA neg neg neg neg pos
58 neg pos neg neg neg neg NA NA NA NA NA NA NA NA NA NA pos
13 neg pos neg neg neg neg neg neg neg neg neg neg neg neg neg neg neg
24 neg pos neg neg neg neg neg neg neg neg neg neg neg neg neg neg neg
66 neg pos neg neg neg neg neg neg neg neg NA NA neg neg neg neg neg
70 neg pos neg neg neg neg neg neg neg neg NA NA neg neg neg neg neg
8 pos pos neg neg neg neg neg neg neg neg NA NA neg neg neg neg neg
9 pos pos neg neg neg neg neg neg neg neg neg neg neg neg neg neg neg
11 neg pos neg neg neg neg neg neg neg neg neg neg neg neg neg neg neg
20 neg pos neg neg neg neg neg neg neg neg NA NA neg neg neg neg neg
31 pos neg neg neg neg neg neg neg neg neg neg neg neg neg neg neg neg
56 neg neg neg neg neg neg neg pos neg neg NA NA neg neg neg neg neg
34 neg neg neg neg neg neg neg pos neg neg neg neg neg neg neg neg neg
16 neg neg neg neg neg neg neg pos neg neg neg neg neg neg neg neg neg
36 neg neg neg neg neg neg neg pos neg neg NA NA neg neg neg neg neg
32 neg neg neg neg neg neg neg neg neg neg neg neg neg pos neg neg neg
27 neg neg neg neg neg neg neg neg neg pos NA NA neg neg neg neg neg
14 neg neg neg neg neg neg neg neg neg pos neg neg neg neg neg neg neg
21 neg neg neg neg neg neg neg neg neg pos neg neg neg neg neg neg i pos
whole mouth saliva cellular fraction; 
; NA, sample not available
PS, parotid saliva; BE, buccal exfoliate; PE, palatal exfoliate; pos.
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Table 3.6 Oral and blood HHV-8 shedding in RAR patients
Non-infected
Oral
infection
only
Blood
infection
only
Oral and 
blood 
infection Total
No. (%) No. (%) No. (%) No. (%) No. (%)
Parents 9(15) 11(18) 3(5) 60 (100)
neg = 37
Figure 3.3 Venn diagram illustrating oral and blood shedding of HHV-8 in RAR 
patients
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oTable 3.7 Patients with solitary or concordantly positive results for HHV-8 K1A/1 or/and KS330 DNA
Tested
Samples BD PW
Group
CRF patients RAR patients
Total bbod 
genoprevalence
saliva
Total oral J 
genoprevalence
^CD19+ NA NA
J CD31+ NA NA
CD45+
V
9/178
(5.1%)
0/60
(0%)
fwMS* NA NA
[WMS" NA NA
PS NA NA
BE NA NA
PE NA NA
Seroprevalence.{ IgG AS 1/178(0 .6%) 0/60(0%)
22/69 
(31.9%)
11/72 
(153%) <
16/69
(23.2%)
3/72 (4.2%) 
9/72 (12.5%)
4/72 (56%)
9/69 (13%) 
12/69(17.4%,)
2/41 (4.9%,) 
6/69 (8.7%) 
8/69 (11.6%)
12/72(16.7%)
15/61 
(24.6% )<
11/61(18%) 
1/61 (1.6%)
3/61 (4.9%)
^10/60 r  6/60(10%)
(1 6 -7 % ^  5/60 (8.3%)
12/60
(20%) 0/33 (0%) 
3/60 (5%) 
0/60 (0%)
4/61 (6.6%)
BD, blood donors; PW, pregnant women; CRF, patients with chronic renal failure; RAR, renal allograft recipients with no history of KS; WMS®, whole mouth saliva 
supemate fraction; WMS°, whole mouth saliva cellular fraction; PS, parotid saliva; BE, buccal exfoliate; PE, palatal exfoliate; NA, sample not available; CD45+, 
CD31+ and CD19+, PBMC subsets.
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3.3.3 Demographic, clinical and virological characteristics in relation to HHV- 
8 geno- and sero-positivity
Demographic characteristics as well as general and specific risk factors in relation to
HHV-8 geno- or sero-prevalence are summarised in Tables 3.8, 3.9, 3.10 & 3.11.
3.3.3.1 Gender
All HHV-8 geno- or sero-positive individuals from the combined BD and PW group 
were male, with 1/176 (0.6%) of the male participants found to be seropositive 
compared to none of females (P = 1.0, Fisher’s exact test) and 9/176 (5%) of males 
genopositive compared to none of females (P = 0.117, Fisher’s exact test).
There was no statistically significant difference in the proportion of seropositive 
females compared to seropositive males in the CRF group (7/29 [24.1%] vs. 5/43 
[11.6%]; P = 0.204, Fisher’s exact test), and seropositive females compared to 
seropositive males in the RAR group (2/24 [8.3%] vs. 2/37 [5.4%]; P = 0.643, Fisher’s 
exact test).
More than half (15/27; 55.6%) of females in the CRF group were found to be HHV-8 
genopositive in one or more sample compared to 14/42 (33.3%) of males (P = 0.084, 
Fisher’s exact test). There was no significant difference in HHV-8 genopositivity rate 
between males (16/36; 44.4%) and females (7/24; 29.2%) in the RAR group (P = 
0.285, Fisher’s exact test).
3.3.3.2 Age
The single seropositive individual from the combined BD and PW group was 32 yr. All 
HHV-8 genopositive individuals from the combined BD and PW group were below the 
age of 40 yr. However, no statistically significant association was observed between 
the ages in these two groups in terms of geno- or seropositivity.
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None of the CRF patients <50 yr or >81 yr were HHV-8 seropositive. None of the 
RAR patients ^ 0  yr or >71 yr were seropositive. Seropositivity rate for all other age 
groups varied between 22.2% and 33.3% amongst CRF patients and between 5% 
and 33.3% amongst RAR patients.
Two CRF patients aged between 21 yr and 30 yr were HHV-8 genopositive in at least 
one sample. Less than 50% of CRF patients aged between 30 yr and 60 yr and more 
than 61% of CRF patients aged between 61 yr and 80 yr were HHV-8 genopositive. 
In the RAR group, 8/13 (61.5%) aged between 21 yr and 30 yr were genopositive, 
while patients aged within the age groups 31-40 yr, 41-50 yr, 51-60 yr and 61-70 yr 
showed a genopositivity rate between 25% to 40%. No CRF patients older than 80 yr 
or RAR patients older than 71 yr or younger than 21 yr were genopositive.
3.3.3.3 Area of origin
Anti-HHV-8 IgG was detected in: 4/34 (11.8%) of CRF and 0/17 of RAR patients from 
Riyadh; 1/7 (14.3%) of CRF and 0/3 of RAR patients from Makkah; 0/2 of RAR 
patients from Madinah; 1/6 (16.7%) of CRF and 0/10 of RAR patients from Qaseem; 
1/1 (100%) of CRF and 0/3 of RAR patients from the Eastern province; 3/9 (33.3%) of 
CRF and 1/7 (14.3%) of RAR patients from Aseen 0/1 of CRF patients from Tabouk; 
1/5 (20%) of CRF and 0/1 of RAR patients from Hail; 1/6 (16.7%) of CRF and 0/6 of 
RAR patients from Jizan; 1/3 (33.3%) of RAR patients from Najran; 0/1 of CRF and 
1/4 (25%) of RAR patients from Alba ha; 0/1 of CRF and 1/2 (50%) of RAR patients 
from Aljouf; and, 0/1 of CRF and 0/3 of RAR patients born outside the Kingdom of 
Saudi Arabia.
HHV-8 DNA was detected in at least one sample from: 14/34 (41.2%) of CRF and 
8/17 (47.1%) of RAR patients from Riyadh; 2/7 (28.6%) of CRF and 2/3 (66.7%) of 
RAR patients from Makkah; 1/2 (50%) of RAR patients from Madinah; 1/5 (20%) of
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CRF and 4/10 (40%) of RAR patients from Qaseem; 1/1 (100%) of CRF and 1/3 
(33.3%) of RAR patients from the Eastern province; 6/7 (85.7%) of CRF and 0/6 of 
RAR patients from Aseer; 0/1 of CRF patients from Tabouk; 4/5 (80%) of CRF and 
0/1 of RAR patients from Hail; 1/6 (16.7%) of CRF and 2/6 (33.3%) of RAR patients 
from Jizan; 1/3 (33.3%) of RAR patients from Najran; 0/1 of CRF and 3/4 (75%) of 
RAR patients from Albaha; 0/1 of CRF and 1/2 (50%) of RAR patients from Aljouf; 
and, 0/1 of CRF and 0/3 of RAR patients born outside the Kingdom of Saudi Arabia.
3.3.3.4 Duration of dialysis
CRF patients receiving haemodialysis for a period of 5 yr or less showed a HHV-8 
seropositivity rate of 4/36 (11.1%) compared to 8/36 (22.2%) seropositivity rate 
amongst patients on haemodialysis for more than 5 yr (P = 0.343, Fisher’s exact 
test). CRF patients receiving haemodialysis for a period of 5 yr or less showed a 
HHV-8 genopositivity rate of 14/35 (40%) compared to a 15/34 (44.1%) seropositivity 
rate amongst patients on haemodialysis for more than 5 yr (P = 0.809, Fisher’s exact 
test).
3.3.3.5 Previous renal transplant
Anti-HHV-8 IgG was not detected in any of the CRF (n=8) or RAR patients (n=5) with 
a history of a previous transplant, compared to 12/64 (18.8%) of CRF (P = 0.337, 
Fisher’s exact test) and 4/56 (7.1%) of RAR patients (P = 1.000, Fisher’s exact test), 
respectively, without a history of a previous transplant.
HHV-8 DNA was detected in 3/8 (37.5%) of CRF and 1/5 (20%) of RAR patients with 
a history of a previous transplant compared to 26/61 (42.6%) of CRF (P = 1.000, 
Fisher’s exact test) and 22/55 (40%) of RAR patients (P = 0.640, Fisher’s exact test), 
respectively, without a history of a previous transplant.
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3.3.3.6 Location of transplant
RAR patients who underwent allograft transplant in the city of Riyadh (KSA) showed 
a seropositivity rate of 2/17 (11.8%) and the single RAR patient who received the 
allograft in Jeddah (KSA) was seronegative. One out of six (16.7%) RAR patients 
who undenvent allograft transplant in the Philippines and 1/3 (33.3%) of patients who 
received an allograft in the USA were seropostive. None of those who underwent 
allograft transplant in Pakistan (n=30), Egypt (n=3) or India (n=1 ) were seropositive.
RAR patients who undenvent allograft transplant in the city of Riyadh (8/16) or the 
Philippines (3/6) showed a 50% genopositivity rate. The single RAR patient who 
received the allograft in Jeddah was genonegative and the single RAR patient who 
received the allograft in India was genopositive. One out of three (33.3%) RAR 
patients who received an allograft in Egypt or the USA were HHV-8 genopositive 
compared to 9/30 (30%) of patients who received an allograft in Pakistan.
3.3.3.7 Nationality of donor
Anti-HHV-8 IgG was detected in 2/13 (15.4%) of RAR patients receiving allografts 
from Saudi donors; 1/6 (16.7%) from Philipino donors; 1/3 (33.3%) from American 
donors; and none in RAR patients with donors from Pakistan (n=30), India (n=1), 
Egypt (n=2) or Sudan (n=2), or those whose origin was unknown (n=4).
HHV-8 DNA was detected in 8/12 (66.7%) of RAR patients receiving allografts from 
Saudi donors; 9/30 (30%) from Pakistani donors; 1/1 (100%) from Indian donors; 3/6 
(50%) from Philipino donors; 1/2 (50%) from Egyptian donors; 1/3 (33.3%) from 
American donors; and none in RAR patients with donors from Sudan (n=2), or those 
whose origin was unknown (n=4).
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3.3.3.8 Allograft donor status
Patients receiving an allograft from a cadaver donor showed a 1/7 (14.3%) 
seropositivity rate compared to 2/14 (14.3%) for those receiving an allograft from a 
live related donor and 1/40 (2.5%) from a live unrelated donor.
Patients receiving an allograft from a cadaver donor showed a 1/7 (14.3%) 
genopositivity rate compared to 8/13 (61.5%) for those receiving an allograft from a 
live related donor and 14/40 (35%) from a live unrelated donor.
3.3.3.9 Time elapsed since transplant
Anti-HHV-8 IgG was detected in 2/33 (6.1%) of RAR patients who had received the 
allograft within the past 2 years compared to 2/28 (7.1%) of RAR patients who had 
received the allograft two or more years ago (P = 1.000, Fisher’s exact test).
HHV-8 DNA was detected in 13/33 (39.4%) of RAR patients who had received the 
allograft within the past 2 years compared to 10/27 (37%) of RAR patients who had 
received the allograft two or more years ago (P = 1.000, Fisher’s exact test).
3.3.3.10 Hepatitis B serostatus
None of the four known hepatitis-B-positive BD or four known hepatitis-B-positive 
(HBsAg) CRF patients were found to be HHV-8 sero- or geno-positive. One of the 
two known hepatitis-B-seropositive RAR patients was found to be HHV-8 
genopositive but not sero-positive.
3.3.3.11 Hepatitis C serostatus
None of the two known hepatitis-C-seropositive BD were found to be HHV-8 sero- or 
geno-positive. Out of the known hepatitis-C-positive CRF patients, 1/11 (9.1%) was
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found to be HHV-8 seropositive œmpared to 11/61 (18%) of hepatitis-C-negative 
CRF patients (P = 0.677, Fisher’s exact test). None of the 6 hepatitis-C-seropositive 
RAR patients were found to be HHV-8 seropositive while 4/55 (7.3%) of hepatitis-C- 
negative RAR patients were seropositive (P = 1.000, Fisher’s exact test).
Out of 10 hepatitis-C-seropositive CRF patients, 3 (30%) were HHV-8 genopositive 
compared to 26/59 (44.1%) of hepatitis-C-seronegative patients (P = 0.502, Fisher’s 
exact test). Four of 6 hepatitis-C-seropositive RAR patients (66.7%) were HHV-8 
genopositive compared to 19/54 (35.2%) of hepatitis-C-seronegative patients (P = 
0.191, Fisher’s exact test).
3.3.3.12 Systemic drug therapy
No CRF patients were administered ciclosporin or tacrolimus. Out of 3 CRF patients 
receiving low doses of prednisolone, 2 (66.7%) were HHV-8 genopositive. The single 
CRF patient receiving a high dose of prednisolone and another receiving a high dose 
of mycophenolate mofetil (MMF) were HHV-8 genonegative. However, all CRF 
patients receiving prednisolone or MMF were seronegative.
At the time of sampling, all RAR patients were being administered a therapeutic 
regimen consisting of: prednisolone and ciclosporin (n=51), or prednisolone and 
tacrolimus (n=9), or prednisolone alone (n=1). Some patients were additionally 
administered a low (n=4) or high (n=26) dose of MMF. The administered dosage of 
each of these drugs was carefully adjusted by their attending physician as 
necessitated by their clinical status.
Anti-HHV-8 IgG was detected in the single RAR patient receiving prednisolone alone. 
Anti-HHV-8 IgG was detected in 3/51 (5.9%) of RAR patients receiving a 
prednisolone and ciclosporin regimen compared to none of 9 patients receiving a
144
Chapter 3________________________________________  HHV-8 Geno- and Sero-prevalence in Saudi Arabia
prednisolone and tacrolimus regimen (P = 1.0, Fisher’s exact test).
Anti-HHV-8 IgG was detected in 3/50 (6%) of RAR patients receiving high doses of 
ciclosporin compared to 1/10 (10%) of patients not receiving ciclosporin (P = 0.1, 
Fisher’s exact test). Anti-HHV-8 IgG was detected in 2/44 (4.5%) of patients receiving 
a low dose and in 2/17 (11.8%) of those receiving a high dose of prednisolone (P = 
0.308, Fisher’s exact test). Anti-HHV-8 IgG was not detected in any RAR patient 
administered a low (n=7) or high (n=2) dose of tacrolimus. Anti-HHV-8 IgG was 
detected in 1/4 (25%) of RAR patients administered a low dose MMF, none of 26 
patients administered a high-dose MMF (total 1/30; 3.3%), compared to 3/31 (9.7%) 
of RAR patients not administered MMF (P = 0.612, Fisher’s exact test). No HHV-8 
DNA or Anti-HHV-8 IgG was detected in the three RAR patients receiving antiviral 
therapy (valaciclovir).
HHV-8 DNA was detected in the single patient receiving prednisolone alone. HHV-8 
DNA was detected in 22/51 (43%) of patients receiving a prednisolone and 
ciclosporin regimen compared to 1/9 (11.1%) of those receiving a prednisolone and 
tacrolimus regimen (P= 0.134, Fisher’s exact test).
HHV-8 DNA was detected in the single RAR patient receiving a low dose of 
ciclosporin and in 21/50 (42%) of patients receiving high doses of ciclosporin (total 
22/51; 43.1% administered ciclosporin) compared to 1/9 (11.1%) of patients not 
receiving ciclosporin (P = 0.134, Fisher’s exact test). HHV-8 DNA was detected in 
17/43 (39.5%) of RAR patients receiving a low dose of prednisolone and in 6/17 
(35.3%) of those receiving a high dose of prednisolone (P =1.000, Fisher’s exact 
test). HHV-8 was detected in 1/7 (14.3%) of RAR patients administered a low dose of 
tacrolimus and in none of 2 patients administered a high dose of tacrolimus. HHV-8 
was detected in 25% (1/4) of RAR patients administered a low dose of MMF, 50%
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(13/26) administered a high dose of MMF (total 14/30; 46.7% administered MMF), 
compared to 30% (9/30) of RAR patients not administered the MMF (P = 0.288, 
Fisher’s exact test).
The results based on the logistic regression analysis revealed that there was no 
statistical evidence to suggest that any of the general characteristics (age, gender, 
area of origin, medication, HBV infection, HCV infection, dental Indices, relation of 
donor, location of transplant, months since transplant, type of renal allograft, duration 
of dialysis and previous transplant) increased the likelihood of the patients having 
detectable HHV-8 in either blood or saliva, or being anti-HHV-8-seropositive.
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T a b le  3.8 Demographic and virological factors vs HHV-8 detection in Saudi blood 
donors
Genopositivity Seropositivity
Characteristic +ve 
No. (%)
-ve 
No. (%)
+ve 
No. (%)
-ve 
No. (%)
Gender
Female
Male
0/2 
9/176 (5.1)
2/2(100)
167/176(94.9)
0/2 
1/176 (0.6)
2/2(100)
175/176(99.4)
Age (years)
18-20
21-30
31-40
41-50
51-60
2/12(16.7) 
4/86 (4.7) 
3/62 (4.8) 
0/16 
0/2
10/12(83.3) 
82/86 (95.3) 
59/62 (95.2) 
16/16(100) 
2/2(100)
0/12
0/86
1/62(1.6)
0/16
0/2
12/12(100) 
86/86(100) 
61/62 (98.4) 
16/16(100) 
2/2(100)
Hepatitis B
Positive
Negative
0/4
9/174(5.2)
4/4(100)
165/174(94.8)
0/4 
1/174 (0.6)
4/4(100)
173/174(99.4)
Hepatitis C
Positive
Negative
0/2 
9/176 (5.1)
2/2(100) 
167/176 (94.9)
0/2 
1/176 (0.6)
2/2(100)
175/176(99.4)
Blood group
A
B
AB
0
2/47 (4.3) 
1/28 (3.6) 
0/6 
6/97 (6.2)
45/47 (95.7) 
27/28 (96.4) 
6/6(100) 
91/97 (93.8)
0/47
0/28
0/6
1/97(1.1)
47/47(100) 
28/28(100) 
6/6(100) 
96/97 (98.9)
Total 9/178(5.1) 169/178 (94.9) 1/178 (0.6) 177/178 (99.4)
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T ab le  3.9 Demographic and virological factors vs HHV-8 detection in Saudi blood 
donors and pregnant women combined
Genopositivity Seropositivity
Characteristic +ve 
No. (%)
-ve 
No. (%)
+ve 
No. (%)
-ve 
No. (%)
Gender
Female
Male
0/62
9/176(5.1)
62/62(100) 
167/176 (94.9)
0/62
1/176(0.6)
62/62(100)
175/176(99.4)
Age (years)
17-20
21-30
31-40
41-50
51-60
2/17(11.8) 
4/119(3.4) 
3/80 (3.8) 
0/20 
0/2
15/17(88.2) 
115/119(96.6) 
77/80 (96.2) 
20/20(100) 
2/2(100)
0/17
0/119
1/80(1.3)
0/20
0/2
17/17(100) 
119/119(100) 
79/80 (98.7) 
20/20(100) 
2/2(100)
Hepatitis B
Positive
Negative
0/4 
9/234 (3.9)
4/4(100) 
225/234 (96.1)
0/4 
1/234 (0.4)
4/4(100) 
233/234 (99.6)
Total 9/238 (3.8) 229/238 (96.2) 1/238 (0.4) 237/238 (99.6)
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T ab le  3.10 Demographic, clinical and virological factors vs HHV-8 seroprevalence
CRF RAR
Characteristic +ve 
No. (%)
-ve 
No. (%)
+ve 
No. (%)
-ve 
No. (%)
Gender
Female
Male
7/29(24.1)
5/43(11.6)
22/29 (75.9) 
38/43 (88.4)
2/24 (8.3) 
2/37 (5.4)
22/24(91.7) 
35/37 (94.6)
Age (years)
18-20
21-30
31-40
41-50
51-60
61-70
71-80
81-90
0/2 
0/9 
0/11 
4/18(22.2) 
5/21 (23.8) 
3/9 (33.3) 
0/2
2/2(100) 
9/9(100) 
11/11 (100) 
14/18(77.8) 
16/21 (76.2) 
6/9 (66.7) 
2/2(100)
0/3 
0/13 
0/14 
1/20(5) 
2/6 (33.3) 
1/4(25) 
0/1
3/3(100) 
13/13(100) 
14/14(100) 
19/20(95) 
4/6 (66.7) 
3/4 (75) 
1/1 (100)
Area of origin
Riyadh
Makkah
Madlnah
Qaseem
E.P.
Aseer
Tabouk
Hail
Jlzan
Najran
AIBaha
Aljouf
Other*
4/34(11.8)
1/7(14.3)
1/6(16.7) 
1/1 (100) 
3/9 (33.3) 
0/1 
1/5(20) 
1/6(16.7)
0/1
0/1
0/1
30/34 (88.2) 
6/7 (85.7)
5/6 (83.3) 
0/1 
6/9 (66.7) 
1/1 (100) 
4/5(80) 
5/6 (83.3)
1/1 (100) 
1/1 (100) 
1/1 (100)
0/17
0/3
0/2
0/10
0/3
1/7(14.3)
0/1
0/6
1/3(33.3)
1/4(25)
1/2(50)
0/3
17/17(100) 
3/3(100) 
2/2(100) 
10/10(100) 
3/3(100) 
6/7 (85.7)
1/1 (100) 
6/6(100) 
2/3 (66.7) 
3/4 (75) 
1/2(50) 
3/3(100)
Duration of 
dialysis
<5years
>5years
4/36(11.1) 
8/36 (22.2)
32/36 (88.9) 
28/36 (77.8)
Previous renal 
transplant(s)
yes
no
0/8
12/64(18.8)
8/8(100)
52/64(81.2)
0/5
4/56(7.1)
5/5(100) 
52/56 (92.9)
Location of 
transplant
KSA/Riyadh
KSA/Jeddah
Philippines
Pakistan
USA
Egypt
India
2/17(11.8)
0/1
1/6(16.7)
0/30
1/3(33.3)
0/3
0/1
15/17(88.2) 
1/1 (100) 
5/6 (83.3) 
30/30 (100) 
2/3 (66.7) 
3/3(100) 
1/1 (100)
Nationality of 
donor
Saudi
Pakistani
Indian
Philipino
Egyptian
American
Sudanese
Unknown
2/13(15.4) 
0/30 
0/1 
1/6(16.7) 
0/2 
1/3 (33.3) 
0/2 
0/4
11/13(84.6) 
30/30(100) 
1/1 (100) 
5/6 (83.3) 
2/2(100) 
2/3 (66.7) 
2/2(100) 
4/4(100)
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Table 3.10 Demographic, clinical and virological factors vs HHV-8 seroprevalence... 
cont’d
CRF RAR
Characteristic +ve 
No. (%)
-ve 
No. (%)
+ve 
No. (%)
-ve 
No. (%)
Allograft 
Donor status
Cadaver
Live-related
Live-unrelated
1/7(14.3) 
2/14(14.3) 
1/40 (2.5)
6/7 (85.7) 
12/14(85.7) 
39/40 (97.5)
Time since 
transplant
<2 years 
^  years
2/33(6.1)
2/28(7.1)
31/33 (93.9) 
26/28 (92.9)
Hepatitis B
positive
negative
0/4
12/68(17.6)
4/4(100) 
56/68 (82.4)
0/2 
4/59 (6.8)
2/2(100) 
55/59 (93.2)
Hepatitis 0
positive
negative
1/11 (9.1) 
11/61 (18)
10/11(90.9) 
50/61 (82)
0/6 
4/55 (7.3)
6/6(100) 
51/55 (92.7)
Ciclosporin
not
administered 
low dose 
(<75 mg OD) 
high dose 
(>75 mg OD)
12/72(16.7) 60/72 (83.3) 1/10(10) 
0/1 
3/50 (6)
9/10(90) 
1/1 (100) 
47/50 (94)
Prednisolone
not
administered 
low dose 
(<10 mg OD) 
high dose 
(>10 mg OD)
12/68(17.6)
0/3
0/1
56/68 (82.4) 
3/3(100) 
1/1 (100)
2/44 (4.5) 
2/17(11.8)
42/44 (95.5) 
15/17(88.2)
Tacrolimus
not
administered 
low dose 
(<10 mg OD) 
high dose 
(>10 mg OD)
12/72(16.7) 60/72 (83.3) 4/52 (7.7) 
0/7 
0/2
48/52 (92.3) 
7/7(100) 
2/2(100)
MMF
not
administered 
low dose 
(<1 gOD) 
high dose 
(>1 gOD)
12/71 (16.9) 
0/1
59/71 (83.1) 
1/1 (100)
3/31 (9.7) 
1/4 (25) 
0/26
28/31 (90.3) 
3/4 (75) 
26/26(100)
Valaciclovir
not
administered
administered
12/72(16.7) 60/72 (83.3) 4/58 (6.9) 
0/3
54/58 (93.1) 
3/3(100)
Total 12/72 (16.7) 60/72 (83.3) 4/61 (6.6) 57/61 (93.4)
outside the Kingdom of Saudi Arabia: OD, once daily
E.P, Eastern Province; *, born
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Table 3.11 Demographic, clinical and virological factors vs HHV-8 genoprevalence
CRF RAR
Characteristic +V0
No. (%)
-ve 
No. (%)
+ve 
No. (%)
-ve 
No. (%)
Gender
Female 15/27(55.6) 12/27(44.4) 7/24 (29.2) 17/24(70.8)
Male 14/42(33.3) 28/42 (66.7) 16/36 (44.4) 20/36 (55.6)
Age (years)
18-20 - - 0/3 3/3(100)
21-30 2/2(100) 0/2 8/13(61.5) 5/13(38.5)
31-40 2/9 (22.2) 7/9 (77.8) 5/14(35.7) 9/14(64.3)
41-50 5/11 (45.5) 6/11 (54.5) 7/20 (35) 13/20 (65)
51-60 3/18(16.7) 15/18(83.3) 2/5 (40) 3/5 (60)
61-70 11/18(61.1) 7/18(38.9) 1/4 (25) 3/4 (75)
71-80 6/9 (66.7) 3/9 (33.3) 0/1 1/1 (100)
81-90 0/2 2/2(100) - -
Area of origin
Riyadh 14/34 (41.2) 20/34 (58.8) 8/17(47.1) 9/17(52.9)
Makkah 2/7 (28.6) 5/7(71.4) 2/3 (66.7) 1/3(33.3)
Madinah - - 1/2 (50) 1/2(50)
Qaseem 1/5 (20) 4/5 (80) 4/10(40) 6/10(60)
Eastern 1/1 (100) 0/1 1/3(33.3) 2/3 (66.7)
province
Aseer 6/7 (85.7) 1/7(14.3) 0/6 6/6(100)
Tabouk 0/1 1/1 (100) - -
Hail 4/5 (80) 1/5(20) 0/1 1/1 (100)
Jizan 1/6(16.7) 5/6 (83.3) 2/6 (33.3) 4/6 (66.7)
Najran - - 1/3(33.3) 2/3 (66.7)
AIBaha 0/1 1/1 (100) 3/4 (75) 1/4(25)
Aljouf 0/1 1/1 (100) 1/2(50) 1/2 (50)
Other* 0/1 1/1 (100) 0/3 3/3(100)
Duration of 
dialysis
<5years
>5years
14/35 (40) 
15/34 (44.1)
21/35 (60) 
19/34 (55.9)
Previous renal 
transplant(s)
yes 3/8 (37.5) 5/8 (62.5) 1/5 (20) 4/5 (80)
no 26/61 (42.6) 35/61 (57.4) 22/55 (40) 33/55 (60)
Location of 
transplant
KSA/Riyadh
KSA/Jeddah
Philippines
Pakistan
USA
Egypt
India
8/16(50) 
0/1 
3/6 (50) 
9/30 (30) 
1/3(33.3) 
1/3 (33.3) 
1/1 (100)
8/16(50) 
1/1 (100) 
3/6 (50) 
21/30(70) 
2/3 (66.7) 
2/3 (66.7) 
0/1
Nationality of 
donor
Saudi
Pakistani
Indian
Philipino
Egyptian
American
Sudanese
Unknown
8/12(66.7) 
9/30 (30) 
1/1 (100) 
3/6 (50) 
1/2(50) 
1/3 (33.3) 
0/2 
0/4
4/12(33.3) 
21/30(70) 
0/1 
3/6 (50) 
1/2 (50) 
2/3 (66.7) 
2/2(100) 
4/4(100)
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Table 3.11 Demographic, clinical and virological factors vs HHV-8 genoprevalence.. 
cont’d
CRF RAR
Characteristic +ve 
No. (%)
-ve 
No. (%)
+ve 
No. (%)
-ve 
No. (%)
Allograft 
Donor status
Cadaver
Live-related
Live-unrelated
1/7(14.3) 
8/13(61.5) 
14/40 (35)
6/7 (85.7) 
5/13(38.5) 
26/40 (65)
Time since 
transplant
<2 years 
^  years
---------
13/33 (39.4)
10/27 (37)
20/33 (60.6) 
17/27 (63)
Hepatitis B
positive
negative
0/4 
29/65 (44.6)
4/4(100) 
36/65 (55.4)
1/2 (50) 
22/58 (37.9)
1/2(50)
36/58(62.1)
Hepatitis C
positive
negative
3/10(30) 
26/59 (44.1)
7/10(70) 
33/59 (55.9)
4/6 (66.7) 
19/54 (35.2)
2/6 (33.3) 
35/54 (64.8)
Ciclosporin
not
administered 
low dose 
( <75 mg OD) 
high dose 
(>75 mg OD)
29/69 (42) 40/69 (58) 1/9(11.1) 
1/1 (100) 
21/50 (42)
8/9 (88.9) 
0/1 
29/50 (58)
Prednisolone
not
administered 
low dose 
(<10 mg OD) 
high dose 
(>10 mg OD)
27/65 (41.5) 
2/3 (66.7) 
0/1
38/65 (58.5) 
1/3(33.3) 
1/1 (100)
17/43 (39.5) 
6/17(35.3)
26/43 (60.5) 
11/17(64.7)
Tacrolimus
not
administered 
low dose 
(<10 mg OD) 
high dose 
(>10 mg OD)
29/69 (42) 40/69 (58) 22/51 (43.1) 
1/7(14.3) 
0/2
29/51 (56.9) 
6/7 (85.7) 
2/2(100)
MMF
not
administered 
low dose 
(<1 gOD) 
high dose 
(>1 gOD)
29/68 (42.6) 
0/1
39/68 (57.4) 
1/1 (100)
9/30 (30) 
1/4 (25) 
13/26 (50)
21/30(70) 
3/4 (75) 
13/26(50)
Valaciclovir
not
administered
administered
29/69 (42) 40/69 (58) 23/57 (40.4) 
0/3
34/57 (59.6) 
3/3(100)
Total 29/69 (42) 40/69 (58) 23/60 (38.3) 37/60 (61.7)
outside the Kingdom of Saudi Arabia: OD, once daily
E.P, Eastern Province; *, born
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3.3.4 Whole saliva supernate viral load
The HHV-8 viral load of WMS®, showing positive results for both K1A/1 and KS330 
DMA, ranged between 8.6 x 10  ^and 12x10^ genome-copies/ml (Table 3.12). HHV-8 
was detected in PE samples from patients only when their WMS® viral load exceeded 
80,000 genome-copies/ml and from BE samples only when their WMS® viral load 
exceeded 200,000 genome-copies/ml. The load in WMS® obtained from CRF24, in 
whom HHV-8 DMA was also found in both BE and PE, was particularly high.
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Table 3.12 WMS® HHV-8 viral loads compared to sample genopositivity
CRF 
ID number
0019 0031 0045 WMS* WMSc PS BE PE HHV-8 viral 
load 
WMS/PS 
(coples/ml)0 5 1 53 I 5 0 5 1 5 0 55 0 53 1 5§
10 neg neg neg neg neg neg pos pos pos pos NA NA neg neg neg pos 151500
23 neg neg neg pos pos pos pos pos pos pos NA NA neg neg neg neg 8641
24 pos pos neg pos pos pos pos pos pos pos NA NA pos pos pos pos 119562500
56 neg neg neg neg neg neg pos pos pos pos neg neg neg pos pos neg 241050
57 pos neg neg neg pos pos pos pos pos pos neg neg neg neg neg pos 83225
CRF, patients with chronic renal failure; WMS®, whole-mouth saliva supernate fraction; WIVIS^ , whole-mouth saliva cellular fraction; PS, parotid saliva; BE, buccal exfoliate; 
PE, palatal exfoliate; NA, sample not available
a .
Is
8
Ia
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3.3.5 Association between oral inflammation and salivary HHV-8 viral load 
No association was observed between salivary viral load and oral inflammation, as 
indicated by the plaque, gingival and bleeding oral indices (P > 0.05, Spearman’s 
rank correlation coefficient) (Table 3.13).
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Table 3.13 Patient oral health in relation to HHV-8 WMS® viral loads
Sample WMS’  viral load copies/ml Plaque Index Gingival index Bleeding Index
CRF10* 151,500 2.25 - -
CRF23 8,641 1.88 1.25 0.50
CRF24 119,562,500 1.04 0 0
CRF56 241,050 1.06 0.63 0
CRF57 83,225 1.42 1.54 1.08
* Examination during dialysis session; hence no gingival or bleeding index obtained. 
CRF, patients with chronic renal failure
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3.3.6 Sequence diversity
3.3.6.1 KS330
A dendrogram displaying the diversity of consensus KS330 sequences among the 
samples, and their genotypic assignments is shown in Fig 3.4. The KS330 genotype 
of blood and oral samples obtained from the three groups that showed positive 
results belonged to four different subgroups (A/C, B/C, B and F), with a maximum 
divergence of 4.3%. All positive blood samples of renal allograft recipients and the 
majority of blood donors (3/4) belonged to the F genotype. HHV-8 amplified from the 
blood samples of the CRF group belonged to either A/C or F genotype, while those 
amplified from the oral samples of this same group belonged to any one of the four 
genotypes (Fig 3.4, Tables 3.15, 3.16 and 3.17). Amongst the six CRF patients with 
multiple KS330-positive samples, four (given patient assignments CRFs 10, 23, 24 
and 57) had identical intra-person KS330 sequences. Intra-person sequence 
diversities of up to 1.2% were detected between CRF 56 s saliva samples and PE, 
and up to 1.8% between CRF 37 s WMS^ and PE. The genotype assignments of 
saliva and PE samples from these two CRF patients were consequently different: 
genotype F for the sequences obtained from saliva and genotypes B/C for PE 
obtained from CRF56 and B from that obtained from CRF37.
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Figure 3.4 Diversity of consensus KS330 sequences. Bootstrapping for 1000 
replicates is noted as a percentage at major branch points.
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3.3.6.2 K1/V1
A dendrogram displaying the diversity of BD, CRF and RAR consensus K1A/1 
sequences, and their genotypic assignments is shown in Fig 3.5. The K1A/1 
genotypes obtained from these three groups blood and oral samples belonged to five 
different subgroups (A1, A2, A5, B and 02) with a maximum divergence of 28.3%.
HHV-8 amplified from blood samples obtained from blood donors belonged to one of 
three genotypes: A1 (n=1), A2 (n=1) and 02 (n=4). HHV-8 amplified from the ORF 
group’s oral or blood samples belonged to any of the five genotypes: A1 (n=21), A2 
(n=1), A5 (n=2), B (n=1) and 02 (n=19), while those amplified from the RAR group’s 
oral or blood samples belonged to three genotypes: A1 (n=20), A5 (n=2) and 02 
(n=6) (Table 3.14).
For 12 people (8 ORFs and 4 RARs), K1A/1 DNA could be amplified from 2 or more 
samples. Nonidentical intra-person sequences were found amongst all 12 people, 
with intraperson divergences ranging from 0.5% (between WMS® and PE of ORF 10 
and ORF 24, WMS" and PE of ORF10, WMS7BE and OD45 of ORF 24, BE and PE 
of ORF 24, WMS" and BE of ORF 54 and ORF 56, WMS" and BE of ORF 56, WMS" 
and WMS'  ^of ORF 57, WMS" and OD45+ cells of ORF 24, ORF 57 and RAR 72) to 
21.7% among the ORF group (between 0D19+ cell subsets and PE of ORF 24), and 
21.1% among the RAR group (between OD45+ cell subsets and PE of RAR 10).
Amongst the 8 ORF patients with multiple K1A/1 positive samples, four (ORFs 8, 23, 
24 and 57) carried sequences belonging to 2 genotypes (A1 and A2, or A1 and 02). 
These were the 0D19+ and 0D31+ cells of ORF 8 (A1 and A2, respectively); 0D31 + 
cells and 0D45+ cells/saliva (WMS® and WIVIS^ ) of ORF 23 (A1 and 02, respectively); 
OD19+/OD31+ cells and OD45+ cells/saliva/BE/PE of ORF 24 (A1 and 02, 
respectively); and PE and saliva/OD45+ cell samples of ORF 57 (A1 and 02,
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respectively).
Amongst the 4 RAR patients with multiple K1 A/1-positive samples, three (RARs 10, 
23 and 61) carried sequences belonging to 2 genotypes (A1 and C2, or A1 and A5). 
These were the CD45+ cells and BE of RAR 10 (A1 and C2, respectively): CD19+ 
cells and WMS'  ^of RAR 23 (C2 and A1, respectively); WMSVBE and WIVIS^  of RAR 
61 (A1 and A5, respectively).
For the 4 CRF and 1 RAR patient whose samples were found to carry nonidentical 
sequences of the same genotype, intra person/intersample sequences were >5% 
divergent in the case of only one patient: CRF 43 BE and PS (5.9%); WMS® and PS 
(5.4%).
Identical intra-person sequences could be identified: between WMS® and WIVIS^  of 
both CRF 10 and CRF 56, WMS^ and BE of CRF 24, and WIVIS^  and CD45+ cells of 
CRF 57, all belonging to the C2 genotype (Figure 3.5, Table 3.16).
There was no evidence that the genotype profile (Table 3.14) was different between 
the oral and blood samples of CRF patients (P = 0.084, Pearson Chi-Square) or 
between the oral and blood samples of RAR patients (P = 0.039, Pearson Chi- 
Square). Although the Chi square test results revealed that there was a statistically 
significant difference, this result should be treated with caution, as the number of 
cells, employed in the statistical analysis, with an expected count less than 5 were as 
high as 67%.
The phylogenetic tree in Figure 3.5, shows a number of CRF patients exhibiting 
identical K1/V1 sequences, some of whom were dialyzed during the same shift and in 
the same room (CRF7-CD31/CRF8-CD19 and CRF2-CD31/CRF15-BE) while others
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were dialyzed during the same shift but in different rooms (CRF46-WMS7CRF48- 
CD31 and CRF7-CD31 & CRF8-CD19/ CRF61-WMS‘^ ). In addition, sequences from a 
number of other CRF patients differed by 1 to 3 nucleotides and were identical at the 
amino acid level (CRF2-CD31 & CRF15-BE/CRF43-BE: CRF7-CD31, CRF8-CD19 & 
CRF61-WMS7CRF24-CD19 & CRF12-PE; CRF43-WMS7CRF57-WMS7 CRF60- 
WMS7 CRF24- WIVIS^ ), some of whom were dialyzed during the same shift and in the 
same room (CRF61-WMS7CRF24-CD19 & CRF12-PE), while others were dialyzed 
during different shifts (CRF2-CD31 & CRF15-BE/CRF43-BE; CRF43-WMS7CRF57- 
WMS"; CRF60- WMS7 CRF24- WMS^).
Possible linkages between the KS330 and K1/V1 genotypes (as determined by direct 
sequencing) were analyzed (Table 3.15, 3.16 and 3.17). No obvious patterns of 
linkage were observed.
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Figure 3.5 Diversity of consensus K1A/1 sequences. Bootstrapping for 1000 
replicates is noted as a percentage at major branch points.
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Table 3.14 K1 A/1 genotype assignments according to study groups
Genotype
Group Sample A1 A2 A5 B 02 Total
BD
Blood 1 1 4 6
CRF
Oral 11 2 1 16 30
Blood 10 1 - - 3 14
RAR
Oral 7 2 5 14
Blood 13 - - - 1 14
Total 41 1 4 1 25 78
BD, blood donors; CRF, patients with chronic renal failure; RAR, renal allograft recipients
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Table 3.15 Linkage analysis of KS330 and K1A/1 amongst BD CD45+ cells
Patient 
ID number
KS330 genotype K l/V I genotype
BD16 F A1
BD64 F -
BD82 A/C -
BD80 - 02
BD93 - 02
BD94 - 02
BD103 - A2
BD157 - 02
BD163 F -
BD, blood donor
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Table 3.16 Linkage analysis of KS330 and K1 A/1 amongst CRF patients
Patient 
ID number
Patient sample KS330 genotype K1/V1 genotype
CRF2 CD31 - A1
CRF7 CD31 - A1
CRF8 GDI 9 A1
CD45 - A2
CRF9 PE - A1
CRF10 WMS® A/G G2
WMS'" A/G G2
PE - G2
CRF11 CD31 - A1
CRF12 PE - A1
CRF15 BE - A1
CRF23 CD31 A1
CD45 A/G G2
WMS® A/G G2
WMS'" A/G G2
CRF24 GDI 9 A/G A1
GD31 - A1
GD45 A/G G2
WMS* A/G G2
WMS^ A/G G2
BE A/G G2
PE A/G G2
CRF32 WMS'" A/G -
CRF34 GD31 - A1
CRF37 WMS" F
PE B -
CRF41 WMS" A/G -
CRF43 WMS® A1
PS - A1
BE - A1
CRF44 GD31 A1
WMS'" A/G _
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Table 3.16 Linkage analysis of KS330 and K1A/1 amongst CRF patients... cont’d
Patient 
ID number
Patient sampie KS330 genotype K1/V1 genotype
CRF45 WMS'" B/C -
CRF46 WMS'^ - A1
CRF48 CD31 - A1
CRF54 WMS" . A5
BE - A5
CRF56 WMS® F C2
WMS'" F C2
BE - C2
PE B/C -
CRF57 CD19 F
CD45 F C2
WMS® F C2
WMS'^ F C2
PE - A1
CRF58 WMS'" - C2
CRF60 WMS'^ - C2
CRF61 WMS^ - A1
CRF62 PE - A1
CRF65 CD31 F -
CRF69 BE - B
CRF72 PS
\A / lk i l^ ^ ^  kail
- A1
mouth saliva cellular fraction; PS, parotid saliva; BE, buccal exfoliate; PE, palatal exfoliate; -, not 
detected
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Table 3.17 Linkage analysis of KS330 and K1A/1 amongst RAR patients
Patient 
ID number
Patient sample KS330 genotype K1/V1 genotype
RAR8 CD19 F A1
RAR9 CD19 F A1
RAR10 CD45 A1
BE - C2
RAR11 CD19 - A1
RAR13 CD19 - A1
RAR14 WMS^ " - C2
RAR16 WMS® - A1
RAR17 CD45 - A1
RAR20 CD19 - A1
RAR21 WMS'" - A1
RAR23 CD19 C2
WMS'" - A1
RAR24 CD19 - A1
RAR27 WMS'" - C2
RAR31 CD19 F -
RAR32 BE - A1
RAR34 WMS® - C2
RAR36 WMS^ - A5
RAR56 WMS® - C2
RAR58 CD19 - A1
RAR61 WMS" A1
WMS'" - A5
BE - A1
RAR63 CD31 - A1
RAR66 CD19 - A1
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Table 3.17 Linkage analysis of KS330 and K1A/1 amongst RAR patients., cont’d
Patient 
ID number
Patient sampie KS330 genotype K1/V1 genotype
RAR70 CD19 - A1
RAR72 CD45 A1
WMS^ - A1
RAR, renal allograft recipient; WMS , whole mouth saliva supernate fraction; WMS , whole mouth 
saliva cellular fraction; BE, buccal exfoliate; - ,  not detected
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3.3.7 Relation between HHV-8 K1A/1 genotype and selected variables 
The majority of CRF and RAR HHV-8 genopositive patients were found to carry the 
A1 genotype (36/47%; 76.6), with seven patients carrying more than one genotype 
(Table 3.18).
All CRF and RAR genopositive patients originating from the Eastern province (n=2), 
Madina (n=1) and Aljouf (n=1), in addition to the majority of the patients originating 
from Riyadh (15/24), Aseer (4/7), Makkah (3/4), Hail (3/4), Alba ha (2/3), Jizan (2/3) 
and Qaseem (2/3) carried the K1/V1 genotype A1, with three patients from Riyadh, 
two from Aseer and one from both Hail and Najran carrying two genotypes each. The 
two patients from Aseer, the single patient from Hail and two of the three patients 
from Riyadh carried both A1 and C2 genotypes, while the third patient from Riyadh 
carried both A1 and A2 genotypes. The single patient from Najran carried both A1 
and A5 genotypes. Only one patient from Riyadh was found to carry B genotype 
(Figure 3.6).
Patients with A1 genotype varied in age from 21 yr to 72 yr. Patients with A5 
genotype were <36 yr and those with C2 genotype >39 yr. The single patient 
exhibiting genotype B was 65 yr. All patients carrying more than one genotype were 
>53 yr, with the exception of one patient, who was 26 yr (Figure 3.7). However, no 
statistically significant association (P = 0.529, ANOVA) was found between K1/V1 
genotype and the mean age of CRF and RAR patients.
The percentage of male patients carrying A1 genotype solely was 18/27 (66.7%) 
compared to 11/20 (55%) of female patients carrying A1 genotype (P = 0.546, 
Fisher’s exact test). The percentage of male patients carrying A5 genotype solely 
was 1/27 (3.7%) compared to 1/20 (5%) of female patients carrying A5 genotype (P = 
0.567, Fisher’s exact test), while the percentage of male patients carrying C2
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genotype solely was 4/27 (14.8%) compared to 4/20 (20%) of female patients 
carrying C2 genotype (P = 0.707, Fisher’s exact test). The single patient carrying B 
genotype was male. The percentage of male patients carrying two HHV-8 genotypes 
was 3/27 (11.1%) compared to 4/20 (20%) of females (P = 0.438, Fisher’s exact test) 
(Figure 3.8).
All amplifiable HHV-8 K1/V1 from CD31+ cells (n=9) and PS (n=2) were found to 
carry the A1 genotype. Additionally, A5 HHV-8 K1/V1 genotype was detected in oral 
samples only (WMS and BE), while detection of A2 genotype was limited to CD45+ 
cells. However, WMS, BE and CD45+ cells obtained from other patients could also 
carry another genotype (A1, B, or C2) (Table 3.19, Figure 3.9).
All three patients with a history of a previous transplant carried A1 genotype 
compared to 26/44 (59%) of patients without a previous transplant (P = 0.921, 
Pearson Chi-Square). None of the CRF or RAR patients with more than one HHV-8 
K1/V1 genotype (0/7) had a history of a previous transplant compared to 3/40 (7.5%) 
of patients with only one HHV-8 K1/V1 genotype (P = 1, Fisher’s Exact test). The 
mean age of the seven patients with more than one HHV-8 K1/V1 genotype was 54.6 
yr, while the the mean age of the forty patients with only one genotype was 47.9 yr (P 
= 0.304, independent samples t -test). All three RAR patients carrying more than one 
genotype compared to 9/20 (45%) of RAR patients with one genotype had received 
the kidney allograft within the past 2 yr (P = 0.217, Fisher’s Exact test). 2/3 (66.7%) of 
RAR patients carrying more than one genotype received the allografts from a relative 
compared to 7/20 (35%) of RAR patients carrying a single genotype {P= 0.538, 
Fisher’s Exact test). However, these differences were not statistically significant. All 
Hep-C-positive CRF and RAR patients with positive HHV-8 K1/V1 were found to 
carry an A genotype (A1 : 1 CRF patient and 3 RAR patients, A5:1 RAR patient).
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Table 3.18 HHV-8 K1A/1 genotypes amongst CRF and RAR patients (combined)
K1/V1
genotype Frequency Percent (%)
A1 only 29 61.7
A5 only 2 4.3
B only 1 2.1
02 only 8 17.0
A1+A2 1 2.1
A1+C2 5 10.6
A1+A5 1 2.1
Total 47 100
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Figure 3.6 Stacked column chart illustrating the distribution of K1A/1 genotypes in 
CRF and RAR patients according to area of origin
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Figure 3.7 Stacked column chart illustrating the distribution of K1A/1 genotypes 
according to age
K1A/1 genotype
□  A1+A2
A1+C2
A1+A5
21-30 31-40 41-50 51-60 61-70 71-80
age group
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Figure 3.8 Stacked column chart illustrating the distribution of K1A/1 genotypes 
according to gender
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Table 3.19 Distribution of HHV-8 K1A/1 genotypes in relation to sample type
Sample Total
WMS* WMS« PS BE PE GDI 9 CD31 CD45
Genotype
A1 count 5 3 2 4 4 11 9 4 42
% within 
sample 35.7% 23.1%
100.0
% 44.4% 66.7% 91.7% 100.0% 30.8% 53.8%
A2 count 0 0 0 0 0 0 0 2 2
% within 
sample 0% 0% 0% 0% 0% 0% 0% 15.4% 2.6%
A5 count 2 1 0 1 0 0 0 0 4
% within 
sample 14.3% 7.7% 0% 11.1% 0% 0% 0% 0% 5.1%
B count 0 0 0 1 0 0 0 0 1
% within 
sample 0% 0% 0% 11.1% 0% 0% 0% 0% 1.3%
02 count 7 9 0 3 2 1 0 7 29
% within 
sample 50.0% 69.2% 0% 33.3% 33.3% 8.3% 0% 53.8% 37.2%
Total count 14 13 2 9 6 12 9 13 78
% within 
sample 100% 100% 100% 100% 100% 100% 100% 100% 100%
<1LA exfoliate; CD19, CD31 and CD45, PBMC subsets
X
!
e
9
ga
1s
a
I01
Chapter 3 HHV-8 Geno- and Sero-prevalence in Saudi Arabia
Figure 3.9 Stacked column chart illustrating the distribution of K1A/1 genotypes in 
CRF and RAR patients according to sample type
K1A/1 genotype
■  A1
□  A2
■  A5
□  B
■  C2
WMS° WMS" PS BE PE GDI9 CD31 CD45
Sample
WMS®, supernate fraction of whole-mouth saliva; WMS'", cellular fraction of whole-mouth saliva; PS, 
parotid saliva; BE, buccal exfoliate; PE, palatal exfoliate; CD19, CD31& CD45, PBMC subsets.
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3.3.8 Extent of Taq polymerase-induced misincorporation 
DGGE of 11 Taq polymerase and 11 Taq polymerase + EXPAND -amplified BCBL-1 
clones (using Taq polymerase to amplify ORF K1A/1 PCR product followed by the 
use of EXPAND during the screening PCR) revealed that 6/11 (54.5%) and 5/11 
(45.5%) of the clones, respectively, had a sequence which was divergent from the 
majority sequence (denoted by * in Figure 3.10(A)). On the other hand, DGGE of 11 
EXPAND-amplified BCBL-1 clones revealed that only 1/11 (9%) had a sequence 
which was divergent from the majority sequence (denoted by * in Figure 3.10(A)). 
Figure 3.10(B) is a dendrogram of the 13 different groups (I to xn i) of sequences, 
originating from the amplified BCBL-1 clones. The clones, differing by 1 to 3 bp, 
exhibited a maximum of 1% sequence divergence from the majority sequence.
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Figure 3.10 (A) DGGE results from PCR BCBL-1 ORF K1A/1 products generated
using Taq DNA polymerase and the EXPAND system; Arabic numerals represent 
assigned clone numbers, coinciding with lane positions in the gel; colony products 
are assigned different Roman numerals. Lanes marked with a * indicate those 
products with a divergent sequence from the majority sequence (I), (B) A comparison 
of nucleotide sequences derived from the 13 different groups (I to X III) of colony 
products. Dots indicate residues occupying positions aligned to those of the majority 
sequence (I) at top.
A)
I I  I I I I I I I  I I I  I I I I I I  IV  I I I V  V I V I I  I I V I I I  IX  X  I I I X I X I I  X I I I
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3.3.9 Intra-person K1A/1 nucleotide sequence differences as studied by 
DGGE
3.3.9.1 CRF 24
High-fidelity PCR of sample extracts from CD45+ cells, WMS®, BE and PE of CRF 24 
yielded K1A/1 DNA. Clones were generated from which differences in nucleotide 
sequence could be analyzed by the combined DGGE-sequencing approach. Figure 
3.11 is a composite of representative DGGE gel pictures showing migration distances 
attained by amplicons generated from clonal inserts; each gel accommodates two 
samples with K1A/1 DNA (16 clones/sample). All PCR products that yielded minority 
bands and some products representing the majority were sequenced (denoted by * in 
Figure 3.11(A); Arabic numerals correspond to clone numbers). Figure 3.11(B) is a 
dendrogram depicting the extent of inter- and intra-sample K1A/1 nucleotide 
sequence diversity. A total of 11 different groups (I to XI) of sequences originating 
from CD45+ cells, WMS®, BE and PE of CRF 24 were detected. A comparison of the 
nucleotide sequences is shown in Figure 3.11(C). The consensus ORF K1A/1 
sequence from CD45+ cells was identical to the majority sequence, while the 
consensus ORF K1A/1 sequences from WMS® and BE were identical to sequence 
group IV. The consensus ORF K1A/1 sequence from PE was not identical to any of 
the 11 sequence groups and was 0.9% divergent from the majority sequence.
Analysis of clones from minority sequences permitted intrasample K1A/1 variability to 
be further characterized from individual samples. An intra-sample sequence 
divergence was observed amongst the CD45+ (<  1.4%), WMS® (<  0.5%), BE 
(<  20.4%), PE (<  0.9%) clones. DGGE and nucleotide sequencing analyses 
confirmed findings from direct K1A/1 PCR sequencing that CRF 24 carried >1 
genotype. For the BE sample, direct sequencing of K1A/1 generated sequences 
assignable to genotype C2, but clonal analysis revealed carriage of minority 
sequences VI and VII generated from clones 4 and 15 which belong to another
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genotype (A1), with a sequence diversity of up to 19.8% from the majority sequence. 
This A1 sequence was also detected, by direct sequencing, in his CD19+ and CD31 + 
blood cells (Figure 3.5).
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Figure 3.11 (A) Composite of representative DGGE gel photographs accommodating 
K1A/1 amplicons from 16 clones generated from CD45+ cells, WMS^, BE and PE 
amplificates of CRF24; Arabic numerals represent assigned clone numbers, 
coinciding with lane positions in the gel; colony products with unique sequences are 
assigned different Roman numerals. (B) Dendrogram showing phylogenetic 
distribution of K1A/1 consensus derived from (*) indicated clones; Roman numerals in 
parenthesis denote unique sequences found within specimen; Bootstrapping for 1000 
replicates is noted as a percentage at major branch points. (0) A comparison of 
nucleotide sequences; Roman numerals denote unique sequences and numbers in 
the parenthesis denote the number of sequenced clones with the unique sequences. 
Dots indicate residues occupying positions aligned to those of the majority sequence 
(I) at top.
A)
CRF24
WMS® CD45+
V I  I VI  V  I I V I  I I V  I I VI I  I V III I I I I IX  I I X  I I X I X I V  I I
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3 3.9.2 CRF 57
High-fidelity PCR of sample extracts from CD45+ cells and WMS^of CRF 57 yielded 
K1A/1 DNA. Clones were generated from which differences in nucleotide sequence 
could be analyzed by the combined DGGE-sequencing approach. Figure 3.12(A) is a 
DGGE gel photographic image showing migration distances attained by amplicons 
generated from clonal inserts; the gel accommodates the two samples with K1A/1 
DNA (16 clones/sample). All PCR products that yielded minority bands and some 
products representing the majority were sequenced (denoted by * in Figure 3.12(A); 
Arabic numerals correspond to clone numbers). Figure 3.12(B) is a dendrogram 
depicting the extent of intra- and inter-sample K1 A/1 nucleotide sequence diversity. A 
total of 8 different groups (I to vni) of sequences were detected. A comparison of the 
nucleotide sequences is shown in Figure 3.12(C). The consensus ORF K1/V1 
sequence from CD45+ cells and WIVIS^  were identical to the majority sequence group 
(n), while the consensus ORF K1/V1 sequences from WMS^and from PE were 0.5% 
and 15.2% divergent from the sequence group (n), respectively.
Analysis of clones from minority sequences permitted intrasample K1/V1 variability to 
be further characterized from individual samples. An intra-sample sequence 
divergence was observed amongst the CD45+ cell (<3.4%) and WMS® (<1.9%) 
clones. DGGE and nucleotide sequencing analyses detected only one genotype (C2), 
similar to that detected by direct K1A/1 PCR sequencing of these two samples. 
Therefore, none of these two samples examined by DGGE carried the minority 
sequence (A1) previously detected in this patient’s PE by direct K1/V1 PCR 
sequencing.
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Figure 3.12 (A) DGGE photograph accommodating K1A/1 DNA amplified from 16 
clones generated from CD45+ and WMS^ amplificates of CRF57; Arabic numerals 
represent assigned clone numbers, coinciding with lane positions in the gel; colony 
products with unique sequences are assigned different Roman numerals, (B) 
Dendrogram showing phylogenetic distribution of K1A/1 consensus derived from (*) 
indicated clones; Roman numerals in parenthesis denote unique sequences found 
within specimen; Bootstrapping for 1000 replicates is noted as a percentage at major 
branch points, (C) A comparison of nucleotide sequences; Roman numerals denote 
unique sequences and numbers in the parenthesis denote the number of sequenced 
clones with the unique sequences. Dots indicate residues occupying positions 
aligned to those of the majority sequence (II) at top.
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3.4 Discussion
Epidemiological studies to date have greatly relied on serological data to estimate the 
prevalence of HHV-8 infection in populations and to study patterns of transmission. 
In North America and Europe, serological data point to a link between sexual 
behaviour and risk of HHV-8 infection (Martin et al., 1998; Dukers et al., 2000). 
However, there is limited seroprevalence and no genoprevalence data relative to 
HHV-8 in the Saudi Arabian general population and patients with renal disease.
Existing seroprevalence studies from Saudi Arabia have suggested that HHV-8 is not 
ubiquitous in the Saudi general healthy population: antibodies to HHV-8 were 
detected in serum samples from 7% of a total of 15 (Qunibi et al., 1998), 3.9% of 258 
(Almuneef et al., 2001) and 1.7% of 577 (Alzahrani et al., 2005) people tested. In the 
present study, IgG antibodies to HHV-8 were detected in the plasma of only 0.6% of 
the blood donors and none of the pregnant women (0.4% in groups BD and PW 
combined), proportions that are consistent with the other findings in Saudi Arabia 
(Table 3.20).
The HHV-8 seroprevalence detected in Saudi Arabian blood donors in this study was 
also less than that detected in different groups of blood donors from the USA, 
Southeast Asia, Caribbean (1.3% - 5.2%) and Africa (37.5% - 42%) (Ablashi et al.,
1999) tested using the whole virus enzyme-linked immunosorbent assay (ELISA; 
Advanced Biotechnologies Inc, Columbia, MD, USA) as what is used here, and less 
than that detected using other assays in healthy controls and blood donors from 
African countries such as Zambia (ranging between 48% to 71%) (Olsen et al., 1998; 
He et al., 1998), Congo (up to 82%) (Engels et al., 2000), Botswana (up to 87%) 
(Engels et al., 2000) and central Africa (22%) (Belec et al., 1998), and from Germany 
(3.9%) (Lonard et al., 2007), Sweden (20%) (Enbom et al., 2000), Brazil (<79%) 
(Biggar et al., 2000; Freitas et al., 2002; Ishak et al., 2007; de Souza et al., 2007b),
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Peru (56%) (Mohanna et al., 2007), Argentina (4%) (Perez et a!., 2004), Chile (3%) 
(Perez et a!., 2004), Cuba (1.2%) (Kouri et a!., 2004), Taiwan (19%) (Huang et a!.,
2000), northwest China (47%) (Dilnur et a!., 2001), USA (up to 26%) (Lennette et a/., 
1996; Gao et a/., 1996b; Baillargeon et a/., 2002; Pellett et a/., 2003; Martro et a!., 
2004; Casper et a/., 2006) and Mediterranean countries (7.6% to 20%) (AngeIoni et 
a/., 1998; Whitby et a/., 1998; Calabro et a/., 1998; Chatlynne and Ablashi, 1999; 
Schulz, 2000b; Davidovici et a/., 2001; Vitale et a/., 2001; Zavitsanou et a/., 2007). 
However, the HHV-8 seroprevalence in Saudi Arabian blood donors, as detected by 
this study, is more than that detected in one study of blood donors from Japan 
(0.2%), identified by antibodies against HHV-8 latency-associated nuclear antigen 
(LANA) using an indirect immunofluorescent assay (Fujii et a/., 1999).
When investigating the association in blood donors between HHV-8 seroprevalence 
and gender, age, blood group, and hepatitis B and hepatitis C infection, no 
associations were found. Similar findings in relation to hepatitis C infection and 
gender were observed in other populations (Angeloni et a/., 1998; Olsen et a/., 1998; 
Plancoulaine et a/., 2000; Iscovich et a/., 2000; Hudnall et a/., 2003; Perez et a/., 
2004; Zavitsanou et a/., 2007; de Souza et a/., 2007b). However, in many 
populations, especially those in northern Europe, Brazil and North America, the HHV- 
8 seroprevalence is 2 to 10 times higher in men than women (Whitby et a/., 1995; 
Cesarman et a/., 1995b; Lennette et a/., 1996; Kedes et a/., 1997; Chatlynne and 
Ablashi, 1999; Greenblatt et a/., 2001; Perez et a/., 2004). A recent study has 
however reported a higher HHV-8 seroprevalence amongst Brazilian Amerindian 
women than men (Ishak et a/., 2007).
Studies involving 258 blood donors from Saudi Arabia (Almuneef et a/., 2001), 306 
blood donors from South Africa (Stein et a/., 2004), 339 Amerindians from Brazil (de 
Souza et a/., 2007b), 955 healthy urban employees from Greece (Zavitsanou et a/..
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2007), 1337 individuals from French Guiana (Plancoulaine et al., 2000), and 100 
blood donors from the USA (Hudnall at a!., 2003) describe an increase in 
seroprevalence with age, the latter study also detecting a significant association with 
ABO blood group B. However, in the current study, despite a sample size of 238, no 
association was found.
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Table 3.20 Summary of Saudi Arabian HHV-8 seroprevalence studies involving healthy volunteers
Study Nature of controls* n Age (yr) Male(%) HHV-8 seroprevalence
Mean Range Std.
deviation
(%) Technique used
Qunibi et 
al, 1998
Healthy volunteers at 
King Faisal Specialist 
Hospital and Research 
Center, Riyadh, Saudi 
Arabia
15 32.3 NA 10.2 40 7 Immunoblotting assays to 
detect antibodies to two lytic 
cycle HHV-8 antigens; p40 
and sVCA**
Almuneef 
et al, 2001
Serum submitted to 
hospital clinical 
chemistry laboratory 
and/or blood bank in 
Riyadh (central region) 
and Jizan (southern 
region)
258 47.5 NA NA 55 3.9 Indirect immuno­
fluorescence (lytic HHV-8 
antigen) technique and 
confirmation by immunoblots 
using acetate induced BC-3 
cell extract and the 
recombinant small viral 
capsid antigen ORF65
Alzahrani
e fa /,2005
Women attending 
obstetrics clinics and 
couples seeking pre­
marital genetic 
counseling at King 
Fa had Military Medical 
Complex, Dhahran 
(Eastern region)
577 27 18-44 NA 20 1.7 Immunofluorescence assay 
testing for antibodies to the 
latent HHV-8 antigen 
(LANA)
Present
study
Blood donors 
(accepted and 
deferred) and pregnant 
women at the Armed 
Forces Hospital,
Riyadh
238 29.8 17-51 7.1 74 0.4 ELISA for detecting anti­
body to the majority of HHV- 
8 structural proteins
All were Saudis
* p40, an antigen found in infected cells; sVCA, an HHVS-encoded small viral capsid antigen expressed in Escherichia coli
X
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In the present study, IgG antibodies to HHV-8 were detected in 16.7% of Saudi 
Arabian CRF patients, a proportion slightly less than the 29% reported by Qunibi et 
al. (1998), but greater than the 7% reported by Almuneef et al. (2001) (Table 3.21). 
The HHV-8 seroprevalence presently observed is also greater than that in ESRD 
patients reported from a number of other countries such as Switzerland (6.4%) 
(Regamey et al., 1998), Greece (7.2%) (Zavitsanou et al., 2006) and Germany 
(13.7%) (Lonard et al., 2007).
Contrary to the finding of Almuneef et al. (2001) that the differences in HHV-8 
antibody prevalence between 201 Saudi ESRD patients (7.0%) and 258 individuals 
without renal disease (3.9%) were not significant, HHV-8 IgG was found in this study 
to be significantly more frequent in CRF patients than in healthy control individuals. A 
difference in HHV-8 seroprevalence has similarly been reported recently between 
ESRD patients prior to transplantation and their corresponding healthy allograft 
donors, from northwestern Italy (Bergallo et al., 2007), while earlier studies from 
northern (Luppi et al., 1999), south eastern (Di Stefano et al., 2006), central and 
south (Cattani et al., 2001) Italy failed to find any significant difference in the HHV-8 
seroprevalence between pretransplant patients and controls. The difference of 
seroprevalence between CRF patients and those without renal disease (BD and PW 
combined), observed in this study could be attributable to the level and intensity of 
health care given to CRF patients. Haemodialysis requires regular visits in dialysis 
units resulting in an increasing rate of nosocomial infections. Uraemic 
immunodeficiency, exacerbated by the dialysis procedure, may additionally contribute 
to an increased risk of HHV-8 infection (Haag-Weber and Horl, 1993; Descamps- 
Latscha and Chatenoud, 1996).
In relation to gender, age, area of origin, duration of dialysis, previous history of organ 
transplantation, hepatitis B, hepatitis C, therapeutic regimens and oral indices, no
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significant associations were found with anti HHV-8 seropositivity in the CRF group. 
These results are similar to those reported by previous studies (Almuneef et al., 
2001; Di Stefano at a!., 2006). Other studies found a higher seroprevalence among 
pre-transplant females (Andreoni at a!., 2001) and increasing age (Almuneef at a/., 
2001 ; Bergallo at a!., 2007).
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Table 3.21 Summary of Saudi Arabian HHV-8 seroprevalence studies involving patients with chronic renal failure
Study Male
(%)
Age (yr)
^Seroprevalence
(%)Unit location n Mean Range Std.
deviation
Qunibi et al, 
1998
King Faisal Specialist 
Hospital and Research 
Center, Riyadh
14 50 43.9 NA 14.6 29
Almuneef et 
al, 2001
Three centres;
1. King Faisal Specialist 
Hospital in Riyadh (Central 
region)
2. King Fahad Hospital in 
Riyadh (Central region)
3. King Fahad Central 
Hospital in Gizan (southern 
region)
201 49 47.1 NA NA 6.97
Present
study
Armed Forces Hospital, 
Riyadh
72 59.7 57 23-83 14 16.7
Q.
(A
1s
2
I
OL
* The methods used by each research group are the same as those described in Tabie 3.20
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In Saudi Arabian renal allograft recipients, IgG antibodies to HHV-8 were detected in 
6.6%, less than that previously reported in Saudi Arabian renal allograft recipients by 
Qunibi et al. (1998) (28%) and later by Alzahrani et ai. (2005) (18%) (Table 3.22) and 
in renal allograft recipients from other countries such as USA (50%) (Hudnall et a/., 
1998), Italy (26%) (Cattani et a/., 2001), Iran (25%) (Ah mad poor et a/., 2007) and 
Germany (22%) (Lonard et a/., 2007). However, the detected seroprevalence is 
greater than that reported from Spain (0.6%) (Garcia-Astudillo and Leyva-Cobian, 
2006) and Cuba (0%) (Kouri et a/., 2004).
HHV-8 IgG was found to be more frequent in renal transplant recipients than in 
healthy control individuals. The detection of a higher HHV-8 seroprevalence in Saudi 
renal allograft recipients when compared to the general population may render them 
at risk to develop KS and makes it possible that in addition to reactivation of 
serologically silent opportunistic infections secondary to immunosuppression, specific 
routes of transmission including infection from the transplanted organ (Luppi et a/., 
2000a; Kapelushnik et a!., 2001; Becuwe et a!., 2005) and transfusion of blood or 
blood products (Blackboum et a!., 1997; Dollard et a/., 2005; Hladik et a/., 2006; 
Lefrere et a/., 2007) may be potentiated, although transmission via blood transfusion 
remains controversial and may not apply to non-endemic countries such as Saudi 
Arabia.
The HHV-8 seropositivity in renal transplant recipients according to age, area of 
origin, previous history of organ transplantation, location of transplant, nationality of 
donor, allograft donor status, time that elapsed since the renal transplantion surgery, 
hepatitis infection, immunosuppressive therapeutic regimens or oral indices, showed 
no significant differences. These findings support previous studies from Saudi Arabia 
reporting no significant association between HHV-8 seropositivity in renal transplant 
patients and the donor's country of origin, the recipient's home region within Saudi
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Arabia and the time elapsed since renal transplantation (Almuneef et al., 2001; 
Alzahrani et a!., 2005). The lack of any statistically significant associations between 
the type or dose of immunosuppressive drugs and the seroprevalence of HHV-8, 
supports findings from other studies (Alzahrani et a/., 2005; Ahmad poor et a!., 2007), 
but the cross-sectional design of this study had limitations in this regard. Of 
importance, Anti-HHV-8 IgG was not detected in any RAR patient administered low­
er high-dose tacrolimus or in those administered valaciclovir.
The differences between the seroprevalence detected in this study and previous 
published reports from Saudi Arabia may be explained by the variation in sensitivity 
and specificity between the different seroprevalence detection techniques used. 
Whereas the LANA immunofluorescence assay for antibodies against HHV-8 used in 
the study by Alzahrani et ai. (2005) has been reported to have lower sensitivity but 
higher specificity as compared with the immunoblot assay for ORF65 antigen, as 
used by Qunibi et ai. (1998). A whole-virus ELISA, as used in this study, has 
advantages over using individual viral proteins as a source of antigen since the viral 
lysate contains a broad spectrum of seroreactivity compared to that detected by a 
single viral protein in ELISA, I FA, or immunoblots.
In conclusion, the results of the present study confirmed high HHV-8 seroprevalence 
in renal disease patients relative to its prevalence in the general population. This 
result supports previous data showing the comparatively high prevalence of HHV-8 
antibodies in hemodialysis patients (Qunibi et a/., 1998; Regamey et a/., 1998; Hsu et 
ai., 2002) and renal transplant recipients (Qunibi et a/., 1998; Hudnall et a/., 1998; 
Alzahrani et a/., 2005) when compared to blood donors from the same country. This 
association may be confounded by age, as, in the present study, the mean ages of 
CRF (57 yr) and RAR patients (40 yr) were higher than that of the healthy controls 
(30 yr). However, in the present study the seroprevalence of HHV-8 in the CRF and
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RAR groups was much higher (>40-fold and > 16-fold, respectively) relative to the 
healthy controls. Therefore, it is highly unlikely that such an increase could be 
attributed to the age factor. Nonetheless, the effect of age cannot be completely 
excluded. In contrast, the effect of renal disease and induced immunosuppression 
seem to be more prominent factors.
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Table 3.22 Summary of Saudi Arabian HHV-8 seroprevalence studies involving renal allograft recipients
Study Unit location n Male
Age
(yr) Seroprevalence Immunosuppresives(%) mean range Std.
deviation
(%)
QunibI etal, 
1998
King Falsa! 
Specialist 
Hospital and 
Research 
Center, Riyadh
18 56 39.6 NA 15.6 28 prednisolone plus ciciosporin 
and azathioprlne
Alzahrani et al, 
2005
King Fahad 
Military Medical 
Complex, 
Dhahran 
(Eastern region)
150 50.7 41 17-72 NA 18 ciciosporin and prednisolone 
In combination with either 
azathioprlne or 
mycophenoiate mofetii
Present study Armed Forces 
Hospital, Riyadh
61 60.7 40 19-72 13 6.6 prednisolone In combination 
with either ciciosporin or 
tacrolimus. Some patients 
were additionally 
administered mycophenoiate 
mofetii
The methods used by each research group are the same as those described In Table 3.20
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Current serologic assays may be insufficiently sensitive to detect low titre antibodies 
associated with remote HHV-8 infection. This insensitivity raises the possibility that 
HHV-8 infection is more widespread than can be appreciated from 
seroepidemiological studies. Thus the necessity for studying genoprevalence arises.
HHV-8 subgenomic DMA was detected in the CD45+ blood cells from nine of the 
blood donors (9/178; 5.1%) and from none of the pregnant women. The detectability 
rate in the combined BD and PW group (9/238; 3.8%) was less than that detected by 
PGR in blood samples of healthy individuals from Japan (12/15; 80%) (Kikuta et al., 
1997a), central and southern regions of Italy (3/13; 23%) (Cattani et a!., 1998), 
Central Africa (11/49; 22.5%) (Belec et a/., 1998) and Greece (77/800; 9.6%) (Zavos 
et a/., 2005), but more than that reported from France (0/25) (Dupon et a/., 1997) and 
Texas, USA (0/100) (Hudnail et a/., 2003). The marked variability in HHV-8 
genopositivity between the present study and others may be related to the low copy 
number of viral DMA present in PBMCs and the differing sensitivity levels achievable 
in detecting small amounts of HHV-8 DMA (Decker et a/., 1996; Blackboum et a/., 
1997) or due to the fact that immunocompetent individuals may be able to suppress 
better the HHV-8 viral load in their blood. It is also possible that detection of HHV-8 
DMA in PBMC may be intermittent even in HHV-8 seropositive individuals (Laney et 
a/., 2004). In addition, unlike this study, which included the amplification of both the 
K1/V1 and KS330 HHV-8 DMA segments, the previous studies cited involved the 
amplification of ORF26 or ORF72 HHV-8 DMA segments. Moreover, in the present 
study, blood samples were processed within 24 h after being collected from study 
participants and were stored at -20°C until DNA extraction was performed. CD45+ 
cells had been separated from whole blood using a biomagnetic cell separation 
technique and extracted using a simple commercially available DNA extraction kit 
(Section 2.3.2). This technique has been previously applied to successfully detect 
HHV-8 DNA in the CD45+ blood fraction of HIV-1 infected men, blood donors.
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patients with KS and their first degree relatives (Leao et al., 2000; Cook et al., 2002a; 
Cook et al., 2002b; Beyari et al., 2003; Kumar et al., 2007) and is not likely to have 
resulted in the low levels of K1A/1 DNA detection in the blood samples from the 
control groups. For these reasons, the low HHV-8 DNA detection rate found in the BD 
and PW groups very likely reflects very low HHV-8 prevalence in the study groups.
None of the HHV-8 DNA positive blood donors were HHV-8 seropositive and the 
single donor who was seropositive was not HHV-8 genopositive. The lack of 
concordance observed between HHV-8 seropositivity and genome detection 
suggests that low-risk carriers may not mount antibody responses detectable by 
current serological assays. Hence HHV-8 genome testing may, complementary to 
serological testing, provide an estimate that more closely mirrors the true prevalence 
of this virus in low risk populations.
Although haemodialysis patients have been found to be more susceptible to viruses, 
such as HHV-8 (Hsu et al., 2002), only a few cases of KS have been reported in this 
group of patients (Herr et al., 2001; Metaxa-Mariatou et al., 2004; Yasar et al., 2007) 
and studies investigating HHV-8 genoprevalence and the connection between 
dialysis, HHV-8 DNA, and KS in such patients has not yet been well established (Herr 
et al., 2001). Therefore, in this study we examined HHV-8 genoprevalence amongst 
this high-risk group of patients. CRF patients and renal allograft recipients showed 
positive results for HHV-8 DNA in one or more sample: 22/69 (31.9%) and 11/72 
(15.3%) in oral and blood samples of CRF patients, and 12/60 (20.0%) and 15/61 
(24.6%) in oral and blood samples of RAR patients. Four CRF (5.8%) and three RAR 
(5%) patients had detectable HHV-8 in both blood and oral compartments. These 
genoprevalences of HHV-8 in the blood cell subsets and oral samples of CRF and 
RAR patients point to a relatively high rate of detection of HHV-8 DNA, which may be 
related to reactivation due to immune dysfunction.
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After adjusting for the unavailable oral samples, HHV-8 DNA was found to be more 
detectable in the oral samples of CRF patients than in blood, while RARs showed no 
significant difference in detection rates. A higher detection rate from the oral 
compartment has been similarly reported in HHV-8-seropositive Egyptian children 
with acute fever not due to a specific viral exanthema (Andreoni et al., 2002), Kenyan 
female prostitutes (Taylor et a!., 2004) and homosexual men from California (Pauk et 
a!., 2000) with or without KS. In another study, of asymptomatic family members of 
Malawian patients with KS, HHV-8 genome detection rate was found to be 
significantly higher in oral than in blood samples: HHV-8 DNA sequences could be 
detected in mouth-rinses of 18 (27%) out of 67 family members but not in any blood 
samples (Cook et a/., 2002b), probably reflecting the high load of shedding into the 
oral cavity and the possible lower replicative activity of the virus systemically in the 
studied groups.
The results based on logistic regression analysis revealed that the detection of HHV- 
8 DNA in the oral cavity of CRF and RAR patients, in the present study, was not 
significantly associated with its detection in the blood samples. Similarly, a previous 
study involving seropositive Zimbabwean women with KS found no significant 
association between HHV-8 DNA detection in PBMC with its detection in oral 
samples (Lampinen et a/., 2000). Therefore, the oral cavity seems to represent an 
independent focus of viral residency and perhaps of viral replication.
Reports from different countries have detected HHV-8 DNA in the saliva and the non- 
lesional oral mucosa of patients with KS or impaired immunity, with or without HIV co- 
infection. The presence of HHV-8 DNA has been demonstrated in 37% of mouth 
rinses from 38 Zimbabwean women with KS (Lampinen et a/., 2000), 10% of saliva 
and 40% of oral scrapes from 10 Greek patients with HIV infection and 10 with 
haematologic malignancies (Triantes et al., 2004), 11.6% of oral epithelial cell
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samples from 77 Swiss HIV-infected patients with or without KS (Widmer et al., 
2006), 46% of palatal-exfoliate samples, 26% of throat-gargle samples, 21% of 
mouth-rinse samples from 22 KS patients in Malawi and 67 of their first-degree 
relatives (Beyari ef a!., 2003), and in 15% to 75% of saliva and oral swabs from HHV- 
8 seropositive homosexual American men with and without KS (Koelle at a!., 1997; 
Pauk at a!., 2000; Casper at a!., 2007). However, the detection rate may be less in 
immunocompetent individuals, whereas no HHV-8 DNA was detected in whole 
unstimulated saliva and scrapes from the lingual and buccal mucosa of healthy 
controls from Greece (Triantes at a!., 2004), in oral rinse samples from HIV-negative 
Zimbabwean women without KS (Lampinen at a!., 2000), in saliva from healthy adult 
volunteers from the USA (Koelle at a!., 1997), or in oral tissues of general dental 
patients from the UK (Di Alberti at a!., 1997a). Of note is that this study is the first to 
examine saliva and oral cells for HHV-8 shedding in ESRD and renal transplant 
recipients. However, similar samples were not collected from the healthy control 
group to allow comparison.
The palate has consistently been shown in HIV-coinfected people to be the most 
common site of development for KS (Flaitz at a/., 1997; Gorsky and Epstein, 2000), 
suggesting that HHV-8 might be particularly tropic for this anatomical site. Moreover, 
previous studies have detected HHV-8 DNA in the palate in addition to the buccal 
mucosa of patients with KS (Cook at a!., 2002a; Cook at a!., 2002b; Beyari at a/.,
2003), and those with haematologic malignancies or HIV infection (Triantos at a/.,
2004). The present study supports these findings, but in the context of ESRD patients 
on haemodialysis and renal allograft recipients. The number of CRF and RAR 
patients with detectable HHV-8 DNA in their whole saliva (supernate or cellular) 
samples (16 and 9, respectively) exceeded those with detectable HHV-8 DNA in their 
buccal (6 and 3, respectively) or palatal (8 and 0, respectively) exfoliates, with 
samples from whole saliva of CRF patients showing more K1A/1 and KS330
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concordantly positive results than other oral samples, implicating a higher copy 
number of viral DNA. HHV-8 could be detected in both cellular and cell-free salivary 
fluid, although sometimes disconcordantly, coinciding with previous reports 
(Blackboum et al., 1998). Moreover, the limited number of CRF and RAR patients (2 
and 0, respectively) with detectable HHV-8 DNA in saliva collected from the parotid 
duct, supports previous findings indicating that major and minor salivary glands are 
not important contributors to HHV-8 shedding (Pauk at a/., 2000; Corey at a!., 2002).
The lower HHV-8 DNA detection rate in BE and PE compared to whole saliva in 
patients with renal disease, as detected in this study, probably reflects active HHV-8 
replication in the oral epithelium other than the buccal mucosa or hard palate or in 
areas of the palate or buccal mucosa further away from the selected sampling sites. 
PCR in situ hybridization studies have previously demonstrated a higher 
concentration of HHV-8-positive cells in the buccal mucosa, with evidence of HHV-8 
lytic replication, compared to saliva and scrapings of the lingual epithelial cells from 
HIV-seronegative and seropositive MSM (Pauk at a/., 2000). Moreover, HHV-8 DNA 
has been detected in a greater number of buccal scrapes than saliva samples from 
HIV-seropositive and haematologic malignancies patients (Triantos at a!., 2004). 
Additionally, the particularly high WMS® viral load DNA (119,562,500 genome-copies/ 
ml) detected in patient CRF 24, whose BE and PE were concordantly positive for 
both K1A/1 and KS330 HHV-8 DNA, may indicate that HHV-8 in his buccal and 
palatal cells contributed to the increased WMS® HHV-8 viral load, supporting the 
hypotheses that HHV-8 persists and replicates in oral epithelial cells and that these 
cells are a principal source of the virus in saliva (Vieira at a/., 1997; Duus at a!., 2004; 
Johnson at a/., 2005).
The rates of detectable HHV-8 DNA in saliva, in the present study (58.3% of 
seropositive CRF and 66.7% of seropositive RARs), are greater than that reported by
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previous studies involving HHV-8 seropositive American MSM (Pauk et al., 2000), 
Kenyian female prostitutes (Taylor et a!., 2004), Brazilian Amerindians (de Souza et 
a!., 2007b) and Ugandan children (Mbulaiteye et a!., 2004), which revealed a salivary 
HHV-8 detection rate of 39%, 32%, 23.7% and 17% respectively. Recently, Casper et 
al. (2007) found 27 of 44 (61%) American HHV-8-seropositive MSM to have 
detectable HHV-8 in saliva, a proportion higher than that previously reported by 
others. These differences in HHV-8 DNA detection rates amongst HHV-8 seropositive 
individuals may be attributed to the difference in the examined study populations, 
sample size, PCR conditions and target of amplication within the HHV-8 genome.
In the current study, HHV-8 DNA was detected in 35% of both seronegative CRF 
(20/57) and RAR (20/57) patients, a proportion higher than that detected in the saliva 
or buffy-coat samples from 87 seronegative Ugandan children (7%) or 102 
seronegative mothers (1%) (Mbulaiteye et al., 2004). In other studies, 12% of 24 
Malawian KS patients (Beyari et al., 2003) and 34% of 9 Swiss HIV patients (Widmer 
et al., 2006) with detectable HHV-8 DNA were found to be HHV-8 seronegative. It is 
most likely that these samples were obtained at the early phase of primary HHV-8 
infection (before anti-HHV-8 is mounted to a detectable extent). Follow-up testing of 
the anti-HHV-8 serostatus would need to be done to monitor for HHV-8 
seroconversion.
The results based on the logistic regression analysis revealed that CRF patients with 
detectable antibodies have 6 times the odds of having HHV-8 in their blood samples 
and 4 times the odds of having HHV-8 in their oral samples than CRF patients 
without detectable antibodies. This comparison of geno- and sero-prevalences may 
allow for assessment of the stage of HHV-8 infection: primary, latent, or lytic, as 
described earlier. Moreover, in the case of CRF and RAR patients, where a number 
of patients were both geno- and sero-positive, these individuals may be considered to
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be undergoing reactivated or late primary infection. Therefore, testing samples for 
both geno- and sero-prevalence may be necessary to ensure that HHV-8 infection, 
regardless of its stage, does not go undetected.
The HHV-8 genopositivity in CRF patients in relation to gender, age, area of origin, 
duration of dialysis, previous history of organ transplantation, hepatitis B, hepatitis C, 
therapeutic regimens or oral indices, showed no statistically significant differences 
between the different groups, although there was a tendency for a higher 
genoprevalence among female CRF patients than males but this association was not 
statistically significant.
On the other hand, when investigating possible differences in HHV-8 genoprevalence 
rates in RAR patients in regard to gender, age, area of origin, previous history of 
organ transplantation, location of transplant, allograft donor status, time elapsed 
since the renal transplantation surgery, hepatitis B, hepatitis C, use of 
immunosuppressive therapeutic regimens, or oral indices, no statistically significant 
associations were found.
In the present study, there was a tendency for a higher genoprevalence among RAR 
patients receiving an allograft from a live related donor (61.5%) than among those 
receiving the allograft from a live unrelated (35%) or cadaver (14.3%) donor; 
however, this finding was not of statistical significance (P > 0.05). The findings of no 
significant differences in salivary genoprevalence by gender or age are consistent 
with the results of a recent study reported by Casper et al. (2007) who found no 
association with age, contrary to another study showing a higher salivary HHV-8 DNA 
detection rate among Amerindian men in Brazil and showing a decrease with age (de 
Souza at a/., 2007b).
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The association between malignancy and immunosuppressive therapy is mediated 
through several mechanisms. Indirectly, immunosuppressive drugs greatly increase 
the post-transplant risk of malignancy by impairing immunosurveillance and 
facilitating the action of oncogenic viruses. However, the direct pro- and anti- 
oncogenic actions of immunosuppressants also play an important role. The cancer- 
promoting effect of calcineurin inhibitors, independently of depressed 
immunosurveillance, has been revealed in recent years (Ecder et al., 1998; Guba et 
al., 2002), and currently, only mammalian target of rapamycin (mTOR) inhibitors have 
shown simultaneous immunosuppressive and antitumour properties (Guba et al., 
2002; Gutierrez-Dalmau and Campistol, 2007).
In this study, two out of three (66.7%) CRF patients receiving low doses of 
prednisolone were found to be HHV-8 genopositive. This finding may be of 
importance or merely a coincidence, especially that none of these two patients was 
seropositive and the single CRF patient receiving a high dose of prednisolone was 
HHV-8 genonegative. As for the renal allograft recipients, anti-HHV-8 IgG and HHV-8 
DNA were respectively detected in 5.9% (3/51) and 43% (22/51) of RAR patients 
receiving a prednisolone and ciciosporin immunosuppressive regimen compared to 
0% and 11.1% (1/9) of those receiving a prednisolone and tacrolimus regimen, 
suggesting a possibe important role for ciciosporin in HHV-8 infection. However, this 
association was not statistically significant and the sample sizes were small, therefore 
further studies comparing groups with a larger number of patients and including other 
factors, such as the length of exposure to immunosuppressive therapy, may be 
required to confirm such associations. These lines of study are important as the 
mechanism by which these different immunosuppressive agents influence the 
development of KS remains unclear (Cockburn and Krupp, 1989; Hiesse et al., 1995; 
Rezeig et al., 1997; Farge et al., 1999; Eberhard et al., 1999). Previous studies from 
Saudi Arabia and Iran failed to find any association between the type and dose of
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immunosuppressive drugs and the seroprevalence of HHV-8 (Alzahrani et al., 2005; 
Ahmadpoor et al., 2007).
Studying the possible link between HHV-8 sero- or geno-prevalence and the patient’s 
area of origin is of importance, as three separate reports from Saudi Arabia indicated 
that 75% (al Suleiman et al., 1987), 64% (Qunibi et al., 1988) and 32% (Qunibi et al., 
1993), of post-transplantation KS cases occurred in patients from the southwestern 
region of the country, an area in close proximity to Yemen and Africa. However, 
previous seroprevalence studies from Saudi Arabia did not find an association 
between HHV-8 seroprevalence and area of residence (Riyadh vs south) amongst a 
group of Saudi Arabian ESRD patients (Almuneef et al., 2001) and renal allograft 
recipients (Alzahrani et al., 2005). When comparing the groups of CRF and RAR 
patients in the current study, with different areas of origin and including only those 
groups with >1 patient, no statistically significant association between the area of 
origin and sero- or geno-positivity were found. However, the results do highlight the 
fact that CRF patients from another area (Hail) located in the north of the country may 
have a high HHV-8 geno- and sero-prevalence compared to other regions and this 
finding could be further explored.
At the time of sampling, the majority of RAR patients participating in this study still 
lived in their area of origin and travelled to Riyadh only to attend hospital follow-up 
appointments. On the other hand, all participating CRF patients, not originally from 
Riyadh, had moved to this city, where they have been regularly attending the dialysis 
unit at the Armed Forces hospital. So, in order to accurately assess the differences in 
CRF patients HHV-8 sero- or geno-prevalence rates according to the different areas 
of the country, obtaining samples from CRF patients attending their local dialysis 
units in their respective area of origin may be more useful.
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Although studies of the general population from the USA (Engels et al., 2007) and 
Greece (Zavitsanou et a!., 2007), of children from Uganda (Mayama et ai., 1998) and 
of ESRD patients from Saudi Arabia (Almuneef et a!., 2001) found HHV-8 
seropositivity to be positively associated with hepatitis B virus infection, a statistically 
significant association between hepatitis B virus infection and HHV-8 sero- or geno­
positivity in either the control or renal disease groups was not found. However, this 
may be attributed to the low number of participants with hepatitis B in each of the 
three groups.
To evaluate the sub-cellular distribution of HHV-8 DNA detection and to assure broad 
representation of the blood subpopulations, a variety of which have previously been 
reported to support HHV-8 persistence (Table 1.4), immunomagnetic fractioning of 
CD45+, CD31+ and CD 19+ cell subsets was conducted and all fractions tested for 
HHV-8 infection. A variation in the rate of HHV-8 subgenomic DNA detection in the 
different blood subsets and in the target of amplication within the HHV-8 genome was 
observed. A greater number of CRF patients (n=9) had detectable HHV-8 DNA in 
their CD31+ cells than those with detectable HHV-8 DNA in their CD45+ (n=4) or 
CD19+ (n=3) cells, which supports previous findings implicating HHV-8 persistence in 
circulating KS-like spindle cell progenitors (Sirianni et a!., 1997a). However, all 
positive CRF CD31+ cells showed only a single-region positivity, possibly implicating 
a low copy number of viral DNA in such cells (Decker et a!., 1996; Blackboum et a/., 
1997). The sub-cellular distribution of HHV-8 DNA differed for the RAR group, where 
a greater number of RAR patients (n=11) had detectable HHV-8 DNA in their CD 19+ 
cells than those with detectable HHV-8 DNA in their CD45+ (n=3) or CD31+ (n=1) 
cells. Previous studies have reported HHV-8 DNA detection in CD19+ cells of 
patients with Castleman’s disease (Kikuta et a/., 1997b) or with or without KS 
(Ambroziak et a/., 1995; Harrington et a/., 1996; Henry et a/., 1999; Monini et a/..
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1999; Pellet et al., 2006). However, none of these studies included patients with renal 
disease.
CD45 antigen is the most common leucocyte marker and is expressed in all cells of 
haematopoietic origin except erythrocytes. However, in the present study, a 
discordant result was observed between the detection of HHV-8 in CD 19+ or CD31 + 
and CD45+ cell subsets in both the CRF and RAR patient groups. This may be owing 
to the relative paucity of HHV-8 infected B lymphocytes and endothelial cells isolated 
from whole blood using dynabeads coated with antibodies against CD45+.
In this study, 7/133 (5.3%) of CD45+ cell samples from patients with renal disease 
yielded HHV-8 subgenomic amplicons compared to 9/238 (3.8%) of CD45+ cell 
samples from blood donors and pregnant women. This difference was not statistically 
significant and is contrary to previous findings indicating a higher molecular evidence 
of HHV-8 activation in the renal transplant population compared with healthy adults 
(Hudnail at a!., 1998). However, the blood genoprevalence comparison was limited to 
CD45+ cell subsets, as other cell subsets (CD19+ and CD31+ cell subsets) were 
isolated from whole blood samples of CRF and RAR patients only but not from the 
BD and PW groups.
None of the 61 renal allograft recipients (including 3 who were both HHV-8 sero- and 
geno-positive patients) in this study developed KS, although some of the RAR 
patients had been given immunosuppressive agents for extended periods of time, 
exceeding 18 years in some cases. Similar findings were detected by Alzahrani at a/., 
2005, who found none of 150 renal transplant recipients (including 27 HHV-8- 
seropositive patients) developed KS. That three patients were administered antivirals 
and nine were administered tacrolimus rather than ciciosporin may have played some 
role. Moreover, it should be taken into consideration that approximately half of the
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RARs in this study were referred from different parts of the country to the Armed 
Forces Hospital in Riyadh, where renal transplant surgeries were performed, 
therefore representing many diverse geographic areas and genetic backgrounds.
Previous studies have explored the possible role of genetic and geographic factors. 
HLA DRB family (mainly HLA DRB1 and HLA DRB5) were found to be important in 
classic and epidemic forms of KS (Friedman-Kien et al., 1982; Pollack et ai., 1983; 
Gaya et al., 2004; Masala et al., 2005; Dorak et al., 2005), but not in Saudi Arabia 
(Qunibi et al., 1988). In initial studies, it appeared that KS was associated with the 
HLA A2 genotype (Qunibi et al., 1988), but this association was not confirmed in 
additional patients (Qunibi et al., 1993). Another possiibiity is that the increased 
incidence of KS in Saudi Arabian transplant recipients may be related to variations in 
locally circulating strains of HHV-8. The ORF K1 region, which exhibits a high degree 
of sequence diversity, facilitates subtyping. These subtypes correlate with ethnicity 
and geography (Zong et al., 2002). However, the significance that this diversity brings 
to the virus is not yet known, but may reflect a positive selection leading to immune 
selection or evasion (Zong et al., 1999). Moreover, this variation within the genome 
has not yet been useful clinically. Although strain-specific peptide vaccines are 
discussed, clinical trials have not been undertaken because the effects of these 
viruses are often thought to be a secondary consequence of immunosuppression as 
opposed to primary viral infection (Stebbing et al., 2006).
Direct sequencing studies of the highly variable gene ORF K1 yield data that 
discriminate between variants better than one that is more conserved, such as 
KS330. KS330 sequence polymorphism does not provide sufficient resolution for 
inferences of HHV-8 genotype and strain variation to be made, unless variations are 
sufficiently wide. Nevertheless, interpreting ORF 26 DNA sequence information may 
provide considerable value for epidemiological studies and clinical diagnostic
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purposes (Zong et al., 2007b). However, because no obvious patterns of linkage 
were observed in this study between the KS330 and K1A/1 genotypes, direct 
sequencing of the highly variable region (K1A/1) was chosen when analysing 
possible association with the various variables.
The majority of HHV-8 K1A/1 amplified from samples obtained from blood donors 
(C=4, A=2) belonged to C genotype, while the majority of HHV-8 K1A/1 amplified 
from CRF (A=24, B=1, 0=19) and RAR patients (A=22, 0=6) belonged to A 
genotype. These differences were not statistically significant. Subtypes A and 0  have 
been known to be the most related (Hayward, 1999; Hughes and Hughes, 2007) with 
a wide distribution throughout Europe, USA, Asia and the Middle East. In previous 
studies from Saudi Arabia involving renal transplant patients with associated KS, only 
A l and 0  (02, 04 and 05) genotypes were detected (Hayward, 1999; Zong et ai., 
1999). The 02 variant has also been reported to be predominant in classic KS from 
the USA and Scandinavia (Zong et a/., 2002), while the 05 variant has been recently 
identified in Morrocan classical, post transplant and AIDS-associated KS (Duprez et 
a/., 2006). The current study is the first to report the detection of A2, A5 and B HHV-8 
K1 genotypes in the Saudi population. The B ORF K1 subtype has previously been 
found predominantly in sub-Saharan Africa or in persons of African heritage, while 
the A5 subtype sequence has been detected in African (Zong et a/., 2002; Treurnicht 
et a/., 2002; Hayward and Zong, 2007) and Brazilian samples (Nascimento et a/., 
2005). The single patient with B genotype ORF K1 sequence was a ORF patient 
living in a small town outside the capital city Riyadh (appx 500 km) and belonging to 
an ancient Arabian bedouin tribe; hence, he is unlikely to have any African ancestors. 
Four patients (ORF23, ORF24, ORF57 and RAR72) had detectable HHV-8 in both 
their OD45+ cells and WMS, and all of them carried the same genotype in both these 
two specific samples, regardless of the HHV-8 genotype presented in any of their 
other genopositive samples. The reason behind this remains unclear.
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Although there is constant mixing of cellular components and secreted fluids from 
various anatomical compartments, the samples obtained in this study may be 
considered to hold cells and fluids that originate from different compartments. This 
study determined that some of the compartments sampled can harbour distinct HHV- 
8 strains, whereas all amplifiable HHV-8 K1A/1 from CD31+ cells (n=9) and PS (n=2) 
were found to carry A1 genotype. Additionally, A5 HHV-8 K1A/1 genotype was 
detected only in oral samples (WMS and BE), while detection of A2 genotype was 
limited to CD45+ cells. However, WMS, BE and CD45+ cells obtained from other 
patients were found to also carry other genotypes (A1, B, or C2).
For 2 RAR patients, intraperson genotypic differences, arising from nucleotide 
sequence variations in K1A/1, were found between the oral cavity and blood, while 
for 3 CRF patients intraperson genotypic differences were found in blood alone. For 1 
CRF and 1 RAR patient, intra person genotypic differences were found in the oral 
cavity only. These findings support those detecting more than one HHV-8 genotype in 
the oral cavity and blood (Beyari et al., 2003), reflecting multiple infection. Whether 
for these 7 people the distinct but closely related variants originated from founder 
strains that underwent genetic drift after infection or were introduced at different 
exposure time points cannot be determined due to the cross-sectional nature of this 
study. Because HHV-8 genomic sequences carried in blood and oral samples from 
these 7 patients could be either genotypically identical or different, conclusions 
cannot also be drawn about the selective tropism of HHV-8 strains. Current evidence 
from other studies suggests that HHV-8 exhibits broad tropism (Dupin et a!., 1999; 
Pauk et a/., 2000; Blackboum et a/., 2000).
To detect possible intra-unit HHV-8 transmission in CRF patients, the hypervariable 
region (K1A/1) was analysed and compared between patients undergoing 
haemodialysis. Previous studies have documented intra-unit hepatitis C virus
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transmission in haemodialysis units using a similar phylogenetic analysis approach, 
with phylogenetic analysis revealing clustering between patients who were dialyzed 
during the same shift and in the same area (Hmaied et al., 2007). In the current 
study, phylogenetic analysis showed a number of CRF patients exhibiting identical 
K1A/1 sequences. Two pairs of patients were dialyzed during the same shift and in 
the same room (CRF7/CRF8 and CRF2/CRF15), while others were dialyzed during 
the same shift but in different rooms (CRF46/CRF48 and CRF7&8/CRF61). These 
findings suggest possible nosocomial spread of HHV-8 among patients undergoing 
haemodialysis. Spread could have been facilitated by sharing articles between 
patients and/ or via nurses and medical staff, especially that these patients were 
accommodated at close quarters housing patients who are infectious for the virus 
with those who are unprotected from primary infection, re-infection or super-infection. 
That this mode of transmission occurred is further supported by the finding that CRF 
patients were found to have high HHV-8 seropositivity and oral genopositivity rates.
The finding that the three RAR patients carrying more than one HHV-8 K1/V1 
genotype had undergone only one renal transplant surgery and received the kidney 
allograft within the past 2 yr was unexpected. The patients may have been exposed 
to simultaneous pre- or post- transplant primary infection with different HHV-8 strains 
or were infected with only one strain prior to transplant after which they became 
exposed post-transplant to HHV-8 superinfection with a different strain due to 
immunosuppression or via the transplanted organ. However, as this was a cross- 
sectional study and no pre-transplantation samples were available for analysis, no 
definitive conclusions can be reached. Surprisingly, two of the three RAR patients 
carrying more than one genotype received the allograft from a relative and assuming 
that the superinfection was transmitted via the transplanted organ, it could be 
considered that relatives were more likely to carry the same HHV-8 genotype, 
especially if they had contracted infection from one another.
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Immunocompetent individuals infected with multiple viral strains have been identified 
for CMV and EBV (Meyer-Konig et al., 1998; Srivastava et ai., 2000; Walling et al., 
2003). Multiple infection with HIV-1 and HIV-2 is also possible (Steain et al., 2004). 
Although it is unclear how immunological responses generated by the host after first 
exposure protect against HHV-8 infection from subsequent exposures, it would 
appear that humoral responses may not be neutralizing, because HHV-8 can actively 
replicate in people who are seropositive for the virus (Tedeschi et al., 2001). 
Accordingly, people growing up and living in regions where HHV-8 is hyperendemic 
are potential hosts to multiple HHV-8 strains. However, few studies have reported 
multiple infection of HHV-8 (Gao et al., 1999; Beyari et al., 2003).
The present study focuses on whether intrahost HHV-8 subgenomic sequence 
polymorphism exists among and within oral and blood samples of Saudi patients with 
renal disease and the extent of such polymorphism. Because direct PCR sequencing 
will not identify minor populations of the virus, it was necessary to study a large 
number of cloned PCR products to investigate the level of intra-individual diversity 
present. The DGGE approach was selected. DGGE was developed primarily for the 
detection of genetic mutations in human disease and can reliably detect single base 
pair mutations. The technique is based on variations in the electrophoretic mobility of 
double-stranded DNA through a gradient of increasing concentrations of formamide 
or urea dénaturants (Myers et al., 1987). The DNA fragment will migrate through the 
gradient gel until it reaches a point where the concentration of dénaturants is equal to 
the melting temperature, Tm, of its lowest melting domain. This will cause the 
fragment to unravel, thus retarding its progress through the gel. The Tm of any 
domain is dependent on its nucleotide composition and mutations in low melting point 
domains and as few as one nucleotide will affect the fragment’s mobility and ultimate 
position in the gel. However, distinct electrophoretic patterns are not only determined 
by the number of different nucleotides between molecules, but they are also affected
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by the type of base involved and its position in the fragment (Harris and Teo, 2001). 
Use of a ‘GC Clamp’, a high GO rich domain introduced during PCR to one end of the 
fragment, increases sensitivity by preventing the DNA from becoming completely 
denatured under DGGE conditions (Sheffield et al., 1989; Fodde and Losekoot, 
1994). This process will occur on a different position in the gel, when one or more 
base pairs are substituted or deleted.
In this study, DGGE was used to rapidly screen a large number of cloned PCR 
products derived from the K1A/1 region of HHV-8 in selected study participants. This 
region was chosen because of its hypervariable nature and because ORF K1A/1 
sequence data was already available for each individual. Using this technique, up to 
40 clones could be analysed from one gel. Subsequent sequencing of selected 
clones was necessary to determine both the sequence of the majority of clones 
isolated from a single individual and to investigate the level of intra-individual diversity 
present.
During sequencing, Taq polymerase error can be minimised by either sequencing 
directly from a PCR product to obtain the consensus sequence of all amplicons or by 
taking the majority sequence from a number of cloned PCR products. In studies 
where viral diversity is to be investigated by examining the sequence of individual 
cloned amplicons, the effect of Taq polymerase error can be magnified and maybe 
falsely interpreted as true viral diversity, especially that sporadic mutations often 
occur at a rate equivalent to Taq polymerase error (Smith et a/., 1997a). Therefore, it 
was necessary to evaluate the impact that Taq polymerase error may have on the 
apparent presence of variant HHV-8 genomes in an individual compared to EXPAND.
Clones amplified from the BCBL-1 cell lines were analysed using both the EXPAND 
system, designed to introduce fewer polymerase induced errors, and Taq polymerase
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by DGGE. The results from this experiment suggested that when using the EXPAND 
system, only 1 of 11 (9%) BCBL-1 clones had a sequence differing from the majority, 
while Taq polymerase produced a significantly greater number of variant clones (6 of 
11; 54.5%), potentially overestimating the extent of viral diversity. Moreover, 5 out of 
11 (45.5%) clones generated using Taq polymerase to amplify ORF K1A/1 PCR 
products followed by the use of EXPAND during colony PCR had a sequence 
differing from the majority. All of these clones were verified by sequence analysis and 
were found to differ by 1 to 3 bp from the majority.
The use of high-fidelity polymerases in this study was crucial to enquiring if multiple 
HHV-8 infection had occurred in patients with renal disease. Intra person genotype 
and subgenotype K1A/1 sequence differences were found among samples of 7 
patients. Because direct PCR sequencing may not identify minor populations of the 
virus, it was necessary to study a large number of cloned PCR products to investigate 
the level of intrasample diversity present. Using DGGE, multiple ORF K1A/1 clones 
from two CRF patients, from whom non-identical ORF K1A/1 sequences were 
recovered and K1A/1 amplification using EXPAND was possible, were screened 
simultaneously. The high-fidelity (EXPAND) PCR was applied to the sample extracts. 
However, high-fidelity PCR was relatively inefficient in generating amplicons from 
other CRF patients of interest, explaining why, of extracts from CRF patients from 
whom intersample K1A/1 sequence differences could be evaluated by direct 
sequencing, K1A/1 amplicons could be generated from sample extracts from only 2 
people.
DGGE and nucleotide sequencing of clones permitted intrasample K1A/1 variability to 
be further characterized from individual samples. Analyses revealed genotypic 
differences and confirmed findings from direct K1A/1 PCR sequencing that CRF 24 
carried >1 genotype. For the BE sample, direct sequencing of K1A/1 generated
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sequences assignable as genotype C2, but clonal analysis revealed carriage of 
minority sequences belonging to A1 genotype. This A1 sequence was also detected, 
by direct sequencing, in his CD 19+ and CD31+ blood cells. Why this minority 
sequence was detected in the buccal sample but not the palatal, CD45+ cells or 
WMS® is unclear. On the other hand, DGGE and nucleotide sequencing analyses of 
CRF 57 CD45+ cells and WMS® clones detected only one genotype (C2), similar to 
that detected by direct K1 A/1 PCR sequencing of these two samples.
The findings from this study are supported by other reports (Gao et al., 1999; Beyari 
at a!., 2003) but contrast with some studies in individuals with (Meng at a!., 2001; 
Stebbing at a/., 2001; Zong at a/., 2002) and without (Mbulaiteye at a/., 2006) KS, 
which have not revealed evidence for intra-person variation in HHV-8 sub-genomic 
sequences. The paucity in the number of reports of mixed HHV-8 infection may be 
due to a combination of factors. First, homosexual men, involved in most KS studies, 
are exposed to HHV-8 later in life, rather than early in childhood, and favour HHV-8 
strains transmitted via sexual routes, rather than those transmitted nonsexually within 
the household, renal units or community. Second, in previous studies examining for 
HHV-8 genomic polymorphisms, the PCR products were directly amplified from the 
samples (Poole at a/., 1999; Gao at a!., 1999; Codish at a!., 2000; Meng at a!., 2001; 
Stebbing at a/., 2001; Zong at a/., 2002); in doing so, the existence of minor virus 
populations would have been revealed only if they constituted a relatively large 
fraction (>20%) of the entire population (Ngui and Teo, 1997). When consensus 
sequencing protocols are applied, the sequence information obtained will not 
differentiate minority sequences from the sequence of the dominant variant. Third, 
previous studies have been largely confined to patients with KS or patients who are 
at risk of developing KS. When sequence polymorphism of subgenomic HHV-8 DNA 
in the blood is sought from such people, the tendency is for none to be found, 
particularly when consensus sequencing is applied, because the high HHV-8 genome
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load (Tedeschi et al., 2001) favours the generation of sequences reflecting the 
dominant variants.
The design of the current study, owing to its cross-sectional nature, precludes 
resolution of whether concurrent HHV-8 infections in the patients resulted from co- 
infection or super-infection and was confined to examination of HHV-8 carried in the 
blood and the mouth. Sampling of other body sites may reveal more evidence of 
multiple HHV-8 carriage in patients with renal disease.
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4.1 Introduction
The previous chapter describes an investigation into the extent of serologic as well as 
genomic prevalences of HHV-8 infection in the Saudi Arabian general population, 
patients with end-stage renal disease, and renal allograft recipients without KS. 
Shedding of HHV-8 via different anatomical compartments, and polymorphisms in 
HHV-8 subgenomic sequences were characterised. It was revealed that a higher 
HHV-8 seroprevalence existed in Saudi Arabian patients with renal disease without a 
history of KS, when compared to the general population. On the other hand, no 
statistically significant difference was found with regard to HHV-8 DNA prevalence 
rates in CD45+ cell samples. While HHV-8 DNA was significantly more detectable in 
the oral samples of CRF patients than in their blood, a similar difference could not be 
detected in renal allograft recipients. With regard to HHV-8 polymorphisms in patients 
with renal disease, evidence was provided of inter- and intra-compartmental multiple 
HHV-8 infection.
KS is the most common malignancy in renal allograft recipients in Saudi Arabia, 
comprising 87.5% of 16 neoplasms in one report (Qunibi et al., 1988) and 70% of 37 
neoplasms in another (Qunibi at a!., 1993), both studies having been conducted in 
the King Faisal Specialist Hospital and Research Centre in Riyadh. The single report 
from the Riyadh Armed Forces Hospital found KS constituting 76% of 46 post­
transplant neoplasms (aI Sulaiman and al Khader, 1994). KS was found to affect 
3.4% of 350 (aI Suleiman at a/., 1987), 5.3% of 263 (Qunibi at al., 1988) and 4.7% of 
730 (al Sulaiman and al Khader, 1994) Saudi Arabian renal allograft recipients.
This chapter reports on studies into the extent of blood and oral HHV-8 shedding in a 
group of Saudi Arabian KS-experienced renal allograft recipients. The presence of 
multiple HHV-8 infection was also determined by comparing the genomic diversity of 
HHV-8 found in the mouth with that in other body compartments.
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4.2 Patients, materials, and methods
4.2.1 Study population
The study group was 5 male Saudi Arabian renal allograft recipients with 
histologically confirmed KS (the RAR-KS group) seen at the Armed Forces Hospital 
in Riyadh, Saudi Arabia. The patients came from five different areas of the Kingdom 
of Saudi Arabia (Albaha, Aseer, Jizan, Qaseem and Hail). The recipients were 
diagnosed with KS between 1999 and 2004. All had received live renal allografts 
between 1982 and 2001. The kidney donors were of 4 different nationalities (Table
4.1). The mean age of recipients was 56 yr and mean time between transplant and 
diagnosis of KS was 9.7 yr. KS affected the skin of the lower limbs in 4 renal allograft 
recipients and the eyelid in 1 patient. For 1 patient (patient 5), KS lesions were 
clinically evident at the time of study, while for the other patients the clinically evident 
lesions had cleared. All patients had been on a dual immunosuppressive regimen 
(ciciosporin and prednisolone) at the time of KS diagnosis. Two patients (patients 1 
and 4) were treated by surgical removal of the KS. In another 2 patients (patients 2 
and 3), KS regression followed the discontinuation of ciciosporin. The fifth patient 
(patient 5) underwent chemotherapy (a combination of dexamethasone, doxorubicin, 
bleomycin, vinblastine and dacarbazine) for KS in addition to having the ciciosporin 
dosage reduced; he was still undergoing treatment at the time of sample collection. 
Renal graft function was adequate in 3 patients while the remaining 2 were returned 
to dialysis (Table 4.1).
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Patient
Age*
(yr)
Nationality 
of donor
Date of 
transplant
Interval between 
transplant and KS 
diagnosis 
(months)
Site of 
skin
iesion(s)
Therapy for 
KS Outcome
1 43 Indian 1993 84 Right upper 
eye lid
Surgically
removed
Graft loss; on 
haemodialysis
2 65 Indian 1992 89 Right lower 
limb
Discontinuation 
of ciciosporin
Graft loss; on 
peritoneal dialysis
3 54 Saudi 1982 226 Right lower 
limb
Discontinuation 
of ciciosporin
Graft function 
maintained
4 59 Pakistani 2001 6 Right lower 
limb
Surgically
removed
Graft function 
maintained
5 57 Jordanian 1990 174 Right lower 
limb
Reduction of 
ciciosporin + 
chemotherapy
Treatment still in 
progress
At time of sample collection I
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4.2.2 Sample collection
After a standardized interview and oral examination, as detailed in Table 2.1 and 
Appendix 1, matched oral, blood and biopsy samples were obtained as described in 
Sections 2.2.1, 2.2.2, 2.2.3 and 2.2.4. The oral samples were collected immediately 
after the blood samples were obtained. The mean time between start of KS treatment 
and sample collection for the 5 patients was 3.5 yr (range: 0.5 -  5.2 yr).
4.2.3 Sample processing
After separation of plasma from the blood, the CD45+, CD31+ and GDI9+ cell 
subsets were immunomagnetically fractionated (Kumar et al., 2007) as described in 
Sections 2.2.1.1 & 2.2.1.2. The cellular and supernate fractions of WMS (WIVIS^  and 
WMS^, respectively) were separated by low-speed centrifugation. BE and PE were 
similarly pelleted. Following aspiration of the supernate, WIVIF^ , BE and PE were 
resuspended in 1 ml of PBS, and stored at -20°C until required. DMA was extracted 
from plasma, blood cell subsets and oral samples as described in Section 2.3.2. 
Paraffin-embedded tissue from KS biopsy samples was sectioned (Section 2.2.4) and 
DNA extracted (Section 2.3.2). The presence of DNA in each extract was verified by 
amplifying a fragment of the )9-globin gene as described in Section 2.3.3.
4.2.4 Sequencing analysis of DNA amplified from KS330 and K1
The 211-bp KS330 was amplified from sample extracts by use of nested PGR 
(Section 2.3.4). The 247-bp K1A/1 was amplified from sample extracts by nested 
PGR (Section 2.3.5.1). In addition, all HHV-8 K1A/1 or KS330 DMA-positive samples 
were amplified for long K1 by nested PGR (Section 2.3.5.2). Extracts were tested at 
least twice for KS330, K1A/1 and long K1 DNA, and considered positive when PGR 
repeatedly yielded products. PGR products were sequenced, raw DNA sequence 
data were analyzed and phylogenetic analyses were performed as detailed in Sections 
2.3.10 & 2.3.11.
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4.2.5 Intra-person K1A/1 sequence differences as revealed by DGGE 
Saliva and biopsy samples were subjected again to nested PCR by use of the 
EXPAND High Fidelity PCR System as described in Section 2.6.1. The PCR products 
were then purified directly from the second-round PCR product (Section 2.3.8). 
Clones were generated from both saliva and biopsy K1A/1 purified DNA (Section 
2.3.9). From 15 colonies from each amplificate, another round of PCR was done 
using a clamping primer as described in Section 2.6.2. The PCR products were 
subjected to DGGE (Beyari et al., 2003) as detailed in Sections 2.6.3, 2.6.4 and 
2.6.5, followed by nucleotide sequencing (Section 2.3.10). Raw DNA sequence data 
were analyzed and phylogenetic analyses were performed as detailed in Section 2.3.11.
4.2.6 Screening for and characterising inter- and intra-sample long K1 
sequence differences
Long K1 PCR products from all saliva and biopsy samples were isolated and purified
from agarose gels as described in Section 2.3.8. Purified DNA fragments were
visually verified by gel examination before cloning. The long K1 gene fragment was
cloned into vectors as described in Section 2.3.9. Colonies were screened by PCR
using long K1 second-round primers. At least 10 clones from each amplificate were
sequenced after plasmid DNA purification. Clones were sequenced using forward
and reverse M l3 primers and the inner primers (Kib-f & Kib-r). Sequencing was
performed using the Beckman-Coulter CEQ2000 automated capillary array
sequencer (Section 2.3.10). Raw DNA sequence data were analyzed using Seqman
software (DNAstar) (Section 2.3.11). For the purpose of this study, subgenotypic
differences were considered to be significant if the divergence between long K1
sequences was >5%. This accommodates base incorporation errors due to Taq
polymerase error-prone activity and suggests that the differences are due to
sequences that originated from distinct virus strains.
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PCR products were also subjected to DGGE, with the GC-clamp K1A/1 PCR reaction 
(using EXPAND) incorporating purified DNA generated from cloning long K1 
amplicons into vectors. This allowed the resulting KW1 PCR amplicons to be 
representative of the VR1 of the long K1 colonies.
4.2.7 Quantitative PCR
WMS® extracts from 3 patients, showing concordantly positive results for K1A/1 and 
ORF 26 DNA, were referred to the National Centre for Infectious Diseases, Centres 
for Disease Control and Prevention, Atlanta, GA, where a quantitative, fluorescence- 
based, real-time PCR was applied (Section 2.4).
4.2.8 Anti HHV-8 IgG detection
The Advanced Biotechnologies ELISA was applied to plasma samples (Section 2.5).
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4.3 Results
4.3.1 HHV-8 DNA detection and intra-person sequence diversity
4.3.1.1 Detection rates
Patient 2 was the person with the most samples positive for HHV-8 DNA, and patient 
5 was the one without HHV-8 DNA detected in any oral samples (Table 4.2; Figure
4.1). KS330 DNA could be amplified from all tested biopsy samples and a varying 
number of oral samples. However, none of the patients showed positive results for 
KS330 DNA in their tested blood samples. For KS330 DNA in oral samples, the 
detection rates were as follows: 60% (3/5) for WMS®, 40% (2/5) for WMS®, 20% (1/5) 
for BE and PE, 0% (0/5) for PS.
K1/V1 DNA could be amplified from all plasma and biopsy samples, variably from the 
oral samples, and not from the blood cell subsets. For K1/V1 DNA in oral samples, 
the detection rates were as follows: 80% (4/5) for WMS®, 40% (2/5) for WMS®, and 
20% (1/5) for PS, BE and PE. Seven oral samples (29%) were concordantly positive 
for KS330 and K1/V1 DNA (Table 4.2; Figure 4.1).
All biopsy and majority of oral samples, positive for K1/V1, were concordantly positive 
for long K1 DNA. However, none of the patients showed positive results for long K1 
DNA in their blood samples.
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Table 4.2 Summary of HHV-8 DNA and anti-HHV-8 IgG results, viral loads and oral indices
HHV-8 DNA
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Figure 4.1 Representative agarose gel electrophoresis images of the PCR amplification products
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4.3.1.2 KS330 nucleotide sequence diversity
A dendrogram displaying the diversity of consensus KS330 sequences, and their 
genotypic assignments is shown in Figure 4.2. Identical KS330 sequences were 
observed between the WMS® and WMS® samples for patients 1 and 2, and between 
the WMS® and biopsy sample of patient 4. Intra-person sequence diversities, 
however, reached up to 2.5% between patient 1 biopsy and oral samples, and patient 
2’s buccal and palatal exfoliates. The genotype assignments for patient 1 oral and 
biopsy samples were different; genotype B for the saliva sequences and genotype 
B/C for the biopsy sample, while the genotype assignments for patient 2 buccal and 
palatal exfoliates were similar (B/C) (Figure 4.2; Table 4.3). The extent of intra-person 
sequence diversities relative to the KS biopsy sequence of all patients is summarised 
in Table 4.4.
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Figure 4.2 Predicted phylogenetic distribution of RAR-KS consensus KS330 
sequences. Bootstrapping for 1000 replicates is noted as a percentage at major 
branch points.
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4.3.1.3 K1A/1 nucleotide sequence diversity
A dendrogram displaying the diversity of consensus K1A/1 sequences, and their 
genotypic assignments is shown in Fig 4.3A. Between the WMS® and WMS® samples 
of patient 1, and among the oral samples of patient 2, intra-person sequence 
diversities were narrow (<0.5%). The oral and plasma samples of these 2 patients 
were subtypically distinct, the oral samples belonging to A3 and the plasma ones to 
A1. In patient 3, the PS and WMS® sequences were widely divergent (19%), 
segregating to A1 and C2, respectively: the WMS® sequence was identical to that in 
plasma. For patient 4 but not the other patients, there was sequence identity between 
biopsy and a non biopsy sample. The divergences between plasma and biopsy 
sequences for patients 1,2,4 and 5 were wide (9%, 9%, 16% and 7%, respectively), 
the sequences being assignable to separate subtypes (Fig 4.3A & Table 4.3). The 
extent of intra-person sequence diversities relative to the KS biopsy sequence of all 
patients is summarised in Table 4.4. K1A/1 sequences have been deposited in EMBL 
Nucleotide Sequence Database (accession numbers AM422987 to AM423005).
4.3.1.4 Long K1 nucleotide sequence diversity
A dendrogram displaying the diversity of consensus long K1 sequences, and their 
genotypic assignments is shown in Fig 4.3B. An alignment of the long K1 amino acid 
sequences is shown in Fig 4.4. For patient 2, the divergences among his oral and 
lesional KS sequences were narrow (<0.3%), and both could be assignable to 
genotype C5, contrasting with A3 assigned following K1A/1 sequencing. A 15-bp 
deletion was observed in the C5 sequences (Fig 4.4). For patient 4, the WMS® and 
biopsy sequences were identical. Table 4.4 summarises the extent of intra-person 
sequence diversities relative to the KS biopsy sequence of each patient. Long K1 
sequences have been deposited in EMBL Nucleotide Sequence Database (accession 
numbers AM423127 to AM423139).
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Figure 4.3 Diversity of RAR-KS consensus K1A/1 sequences (A) and consensus 
long K1 sequences (B). Bootstrapping for 1000 replicates is noted as a percentage at 
major branch points.
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Figure 4.4 RAR-KS intra- and inter-person long K1 amino acid sequence diversity. 
Dots indicate residues occupying positions aligned to those of Patient Ts WMS® 
sequence at top. Slashes denote absence of residues due to nucleotide deletions
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Table 4.3 Linkage analysis of KS330, K1 A/1 and longKI genotypes
Patient Patient KS330 K1A/1 long K1sample genotype genotype genotype
WMS® B A3 A3
WMS® B A3 _
1
Plasma - A l -
Biopsy B/C A3 A3&C5
WMS® B/C A3 C5
WMS® B/C A3 C5
BE B/C A3
2
PE B/C A3 C5
Plasma - A l -
Biopsy B/C A3 C5
WMS® - C2 C5&A3
PS A l
3
Plasma - C2 -
Biopsy B/C C2 C2
WMS® F C2 C2
4 Plasma - A l -
Biopsy F C2 C2
Plasma A5
5
Biopsy F A3 C5
WMS®, whole mouth saliva supemate fraction; WMS®, whole mouth saliva cellular fraction; PS, 
parotid saliva; BE, buccal exfoliate; PE, palatal exfoliate; - ,  not detected
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Table 4.4 The extent of intra-person sequence diversities relative to the KS biopsy
sequence
Patient Region
% nucleotide sequence diversity from KS biopsy 
sequence
Plasma WMS" WMS  ^ PS BE PE
KS330 - 2.5 2.5 -  —
1 K1A/1 9 7.4 6.9 -
long K1 - 5.0*, O .f - -
KS330 - 0.6 0.6 1.8 1.8
2 K1A/1 9 0.5 0.5 0.9 0.5
long K1 - 0.3 0.1 0.3
KS330 - - - -
3 K1A/1 13.3 13.3 17.4 -
long K1 - 7.9\ 7.2^ - -
KS330 - 0 - -
4 K1A/1 16.3 0 - -
long K1 - 0 - -
KS330 - - - -
5 K1A/1 7.4 - “ -
long K1 - - - -
WMS®, whole mouth saliva supernate fraction; WMS^, whole mouth saliva cellular fraction; PS, parotid 
saliva; BE, buccal exfoliate; PE, palatal exfoliate; - ,  not detected
* as compared with the minority clade of Patient 1 ’s biopsy 
as compared with the majority clade of Patient 1 ’s biopsy
 ^as compared with the majority clade of Patient 3’s WMS®
* as compared with the minority clade of Patient 3’s WMS®
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4.3.2 Intra-person K1A/1 nucleotide sequence differences demonstrated by 
DGGE
Patient 3’s WMS^ and biopsy samples, which showed the greatest saliva-biopsy 
K1/V1 sequences divergence (Table 4.4), also exhibited, by cloning and DGGE 
(Figure 4.5), a significant sequence diversity of up to 15% between clones from the 
two samples, while intra-sample divergence was found to be <0.9%. A dendogram 
generated after sequencing the below DGGE samples is displayed in Figure 4.6.
Figure 4.5 DGGE photograph accommodating K1A/1 DNA amplified from 15 clones 
generated from supernate fraction of whole mouth saliva (WMS®) and biopsy samples 
of patient 3. Arabic numerals represent assigned clone numbers, coinciding with lane 
positions in the gel.
1 2  3 4 9 10 11 12 13 14 15 1 2 3 4 5 6 7
WMS^
9 10 11 12 13 14 15
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Figure 4.6 Dendrogram showing phylogenetic distribution of K1A/1 consensus 
derived from clones of patient 3’s WMS® and biopsy. Bootstrapping for 1000 
replicates is noted as a percentage at major branch points.
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4.3.3 Clonal analysis of inter- and intra-sample long K1 sequence differences 
by direct sequencing
The sequences of the long K1 clones originating from the saliva and biopsy samples
of the 5 individuals belonged to 3 genotypes (A3, 02 & 05). All five patients had
confirmed clonal viral sequence variation at the nucleotide and amino acid levels from
both the saliva and biopsy samples. Table 4.5 summarizes the range of intra-sample
nucleotide divergence between clones for each patient and the genotype
designations. For patient 1, cloning studies revealed that sequences of 8 of 10 clones
sampled from his biopsy sample belonged to subtype A3 and 2 of them to 05 (Figure
4.7A); the consensus sequence of the A3 clade was 0.1% divergent from the A3
sequence of WMS^(Fig 4.3B & Fig 4.4). For patient 3, the WMS® sequences could, by
cloning, be resolved into 2 separate clades, 3 of 10 clones belonging to A3, and 7 to
05 (Figure 4.7B); these subtypes were distinct from 02 to which the sequence of his
biopsy sample belonged (Fig 4.3B & Fig 4.4). The subgenotypic differences between
the intra-sample clades for these two patients were considered to be significant as
the divergence between long K1 sequences was > 5%.
High-fidelity K1A/1 PCR of the previously generated clones from patients 1 and 3 
yielded K1A/1 DNA to show the different extents of intra-sample diversity in the VR1 
region of long K1 colonies (Figure 4.8).
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Figure 4.7 Dendrogram showing phylogenetic distribution of long K1 consensus 
derived from clones of patient 1’s biopsy (A) and clones of patient 3’s WMS® (B). 
Bootstrapping for 1000 replicates is noted as a percentage at major branch points.
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Table 4.5 Range of intra-sample long K1 nucleotide divergence between clones and genotype designation
Patient
No. Of clones sequenced Range of IntwsmApie ‘ nucleotide divergence (%) ^
No. of clones with minority 
genotype (genotype)/no. 
of clones sequen<^
assignment
Saliva Biopsy Saliva saliva Biopsy Biopsy
1 10 10 Otol 0.1 to 5.8 - 2(C5)/10 A3 A3+ 05
2 10 10 0 to 0.6 0.1 to 0.9 - - 05 05
3 10 11 Oto 6.8 0 to 0.6 3( A3)/10 - 05 +A3 02
4 11 11 0 to 0.8 0 to 0.8 - - 02 02
5 - 10 - Oto 1.2 - - - 05
I
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Figure 4.8 Composite of 2 DGGE gel photographs. (A) K1A/1 DNA amplified from 
10 clones generated per sample from patients 1 and 3. (B) K1 A/1 DNA amplified from 
10 clones generated per sample from patient 3. Arabic numerals represent assigned 
clone numbers, coinciding with lane positions in the gel.
A)
1 2 3 4 5 6 7 8 9
Patient 1 Biopsy
10 1 2 3  4 5 6 7  8 9  10
Patient 3 WMS®
B)
9 10 11 1 2 3  4 5 6 7
Patient 3 WMSPatient 3 Biopsy
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4.3.4 Whole saliva supernate viral load
For 3 patients, viral load estimation in WMS® was possible (Table 4.2). The load in 
patient 2 was particularly high. No association was observed between salivary viral 
load and oral inflammation (as indicated by the plaque, gingival and bleeding oral 
indices) or between salivary viral load and the dosage of immunosuppressives 
administered (Table 4.6). However, due to the small sample number, statistical 
analysis was not possible.
4.3.5 Serological detection of HHV-8
All the plasma samples were reactive for anti-HHV-8 IgG.
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Table 4.6 Patients daily dosage of administered immunosuppressives in relation to 
HHV-8 WMS® viral loads
Patient WMS  ^viral load copies/mi
Ciciosporin dose 
(mg)
Prednisolone 
dose (mg)
1 1238 0 0
2 2198250 0 0
4 3778 150 5
WMS®, whole mouth saliva supernate fraction
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4.4 Discussion
The mean time between kidney transplant and diagnosis of KS in this sample group 
was 9.7 yr, which is greater than that previously reported in Saudi Arabian renal 
allograft recipients (aI Suleiman et al., 1987; Qunibi et al., 1988; Qunibi et al., 1993). 
KS affected only the skin in all the 5 patients studied. This is not unusual as the skin is 
the most common organ involved with KS, followed by the gastrointestinal tract and 
the lungs, among renal transplant recipients in Saudi Arabia (Qunibi et al., 1993; al 
Sulaiman and al Khader, 1994). In the present study, the lower limbs were affected in 
the majority of patients (80%), coinciding with previous reports of skin KS mostly 
affecting the lower extremities (Moosa, 2005). No oral KS, specifically palatal KS, was 
reported in this group of patients. This may be due to low replicative activity of HHV-8 
in the palatal mucosa (Beyari et al., 2003) or because it had gone undetected during 
the course of active KS.
The study described in this chapter contributes to the growing body of evidence 
implicating the oral cavity as a major site of HHV-8 replication and shedding. Earlier 
studies have found evidence of HHV-8 in oral samples taken from people with or 
without active KS and those who were or were not co-infected with human 
immunodeficiency virus (Koelle et al., 1997; Blackboum et al., 1998; Lampinen et al., 
2000; Pauk et al., 2000; Cook et al., 2002b; Beyari et al., 2003; Taylor et al., 2004; 
Duus et al., 2004; Triantos et al., 2004; Mbulaiteye et al., 2004; Widmer et al., 2006; 
Casper et al., 2007). HHV-8 DNA was previously found in buccal and palatal 
exfoliates of Malawian KS patients and their relatives (Cook et al., 2002a; Cook et al., 
2002b; Beyari et al., 2003). The present findings show that also for KS-experienced 
renal allograft recipients the buccal mucosa and palate support HHV-8 persistence. 
That HHV-8 replicates at these sites is suggested by data from patient 2, whose 
HHV-8 load in WMS exceeded 2 million genome copies/ml and in whom viral DNA 
could be detected in both BE and PE samples. The inability to detect HHV-8 DNA in
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the BE and PE of some patients does not rule out the possibility that the virus may 
still replicate in areas of the palatal or buccal mucosa further away from the selected 
sampling site.
For most of the patients studied, WMS yielded higher PCR amplification rates than 
other oral samples, likely reflecting HHV-8 shed from other sites, such as tonsils 
(Koelle et a/., 1997; Chagas et al., 2006b) and tongue (Triantos et a/., 2004; Widmer 
et a/., 2006). The limited HHV-8 DNA detection rate in saliva collected from the 
parotid duct supports previous findings indicating that major salivary glands are not 
important contributors to HHV-8 shedding (Pauk et a/., 2000). Gingival crevicular fluid 
is unlikely to contribute significantly, given that HHV-8 plasma viraemia in the studied 
patients was not extensive, as suggested by the discordant KS330, K1A/1 and long 
K1 detection rates in plasma. Semi-quantitative dilution studies showed that the limits 
of HHV-8 DNA PCR detection for long K1 was 10  ^times less than the limit for K1 A/1.
The failure to detect HHV-8 in the saliva of patient 5, who was still undergoing 
treatment for KS, could be attributed to the fact that HHV-8 shedding in saliva may be 
episodic in some patients and missed when only single specimens are analyzed 
(Koelle et a/., 1997; Pauk et a/., 2000; Laney et a/., 2004; Casper et a/., 2007). 
Patients 1 and 4 each had a relatively low saliva HHV-8 load (<50,000 copies/ml). 
However, HHV-8 viral loads have been reported to be variable and fluctuate over 
time (Tedeschi et al., 2001).
Previous studies among HIV-infected patients with KS showed that the prevalence of 
salivary HHV-8 DNA were similar between patients with and without oral KS lesions 
and that HHV-8 could be detected in saliva from patients with resolved KS (Koelle et 
a/., 1997), an observation consistent with the study patients here who had cutaneous 
and not oral KS.
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HHV-8 DNA was not detected in any blood cellular sample, possibly reflecting the 
absence of active KS at the time of sampling and the tapering of immunosuppressive 
drug dosages. Previous reports of the presence of HHV-8 genome in peripheral blood 
cells reported its detection mainly in people with active KS or at high risk of KS 
(Purvis et al., 1997; Metaxa-Mariatou et al., 2004), and to a lesser extent in those 
with regressing iatrogenic KS and in none upon complete remission (Aluigi et al., 
1996).
Although previous work found HHV-8 plasma viraemia to be positively associated 
with active disease (Harrington et al., 1996; Tedeschi et al., 2001; Campbell et al., 
2003; Duus et al., 2004), HHV-8 plasma viraemia was found in all the study patients 
here despite the absence of clinically evident KS in 4 of the 5 patients. These various 
outcomes in detection rates likely result from different sensitivities of the PCR 
protocols applied.
The results of previous serologic studies support the view that infection with HHV-8 is 
nearly universal in patients with non-iatrogenic KS (Lennette et al., 1996; Sitas et al., 
1999a; Hbid et al., 2005; Mwakigonja et al., 2007). Studies involving renal allograft 
recipients with post-transplantation KS found 93% of Saudi (Qunibi et al., 1998) and 
100% of Portuguese (Weigert et al., 2004) renal allograft recipients to be seropositive 
for HHV-8. The finding here, that all 5 renal allograft recipients were seropositive, 
shows again high concordance between HHV-8 seropositivity and KS.
After thorough intra-oral examination and data analysis we were unable to find an 
association between inflammation in the oral cavity and HHV-8 shedding, contrary to 
what was reported elsewhere (Casper et al., 2004). However, due to the small 
sample size, this interpretation should be treated with caution.
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The extreme polymorphism of ORF K1 was exploited to investigate the genomic 
diversity of HHV-8 more comprehensively (Hayward and Zong, 2007). The genotypes 
of HHV-8 (A, B, C and D) differ in this ORF by sequence divergences that vary 
between 5% and 30% at the amino acid level, with A and 0 being the most related. 
Genotyping and subtyping are based on the extent of amino acid sequence 
differences and the presence of specific deletions or duplications. In the study 
reported in this chapter, K1A/1 and long K1 segments from ORF K1 were amplified. 
The K1A/1 fragment, being shorter, confers higher sensitivity to PCR detection of the 
HHV-8 genome, but limits the information on the extent of HHV-8 genomic sequence 
polymorphism. The long K1 segment, by contrast, lends lesser sensitivity to PCR 
detection but the amplicons, being >3 times longer than K1A/1, potentially allow HHV- 
8 strains to be better differentiated. Particularly as it encompasses the VR2 region, 
long K1 enables sharper discrimination between A and C genotypes. Thus, long K1 
sequencing led to the assignment of sequences originating from patient 5’s biopsy as 
well as patient 2’s biopsy, WMS and PE to C5 (Figure 4.38) on account of the 15-bp 
deletion in the VR2 region (Figure 4.4), whereas K1A/1 sequencing assigned these 
samples to an A genotype (Figure 4.3A). However, not all samples assigned an A 
genotype by K1A/1 sequencing, were assigned to C5 following long K1 sequencing 
(Table 4.3). Therefore, when for such samples, K1A/1 sequence is available alone, 
the genotype should preferably be referred to as A3/C5, especially since the C5 
variant is thought to be a hybrid between A and C genotypes (Zong et al., 1999). 
Noteworthy is that the C5 variant has been previously identified by Zong et ai. (1999) 
in KS samples from Saudi Arabian renal transplant recipients.
Direct sequencing studies, however, have an important limitation in that they are 
unable to produce consensus sequence data that will allow sequences of minority 
variants to be identified. Whereas, the high HHV-8 genome load (Tedeschi et a!., 
2001) favours the generation of sequences reflecting the dominant variants.
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Accordingly, the combined DGGE screening-nucieotide sequencing protocol was 
applied to K1A/1 amplicons generated from clonal inserts. To reduce the degree to 
which PCR induces nucleotide misincorporation, which may lead to false 
representations of natural inter- or intra- sample sequence polymorphism, high-fidelity 
PCR was applied to sample extracts. By applying this combined DGGE-sequencing 
protocol, it could be shown that patient 3’s saliva and biopsy samples exhibited a 
significant sequence diversity of up to 15% between the saliva and biopsy clones. 
This is slightly higher than the 13.3% detected by direct sequencing of K1A/1 PCR 
products.
When clones of long K1 sequences were characterised, 2 populations of HHV-8 
variants in the KS biopsy sample of patient 1 and in the WMS® of patient 3 could be 
identified. The populations of HHV-8 variants in the biopsy sample of patient 1 implies 
concurrent HHV-8 infection at the lesional level and does not support the view that 
KS is monoclonal (Rabkin et al., 1997; Judde et al., 2000). In each of the samples, 
the clade comprising minority sequences was genotypically distinct from the majority 
clade. Further evidence substantiating the phenomenon of multiple HHV-8 infection 
comes from the divergences in K1A/1 sequences observed in the oral samples of 
patient 3. These findings point to intra-compartmental (oral) carriage of multiple HHV- 
8 strains.
Inter-compartmental multiple HHV-8 infection is revealed from the comparison of 
sequences originating from oral, plasma and biopsy samples. Of the long K1 
sequences recovered from 4 saliva-biopsy sample pairs, complete sequence identity 
was observed in one patient only (patient 4). In the other 3 patients, the maximal 
intra-person divergences in sequences between an oral sample and biopsy were 5% 
for patient 1, 0.3% for patient 2 and 7.9% for patient 3 (Table 4.4). While the 
divergences in patient 2 may be insubstantial and attributable to PCR-generated
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mutation, those in patients 1 and 3 were relatively wide, and genotypically disparate. 
Another set of data implicating multiple inter-compartmental HHV-8 carriage arises 
from the wide divergences in K1A/1 amino acid sequences between plasma and 
biopsy sequences of all 5 patients, ranging from 7.4% to 16.3% at the nucleotide (bp) 
level.
The findings from this study are supported by other reports (Gao et al., 1999; Beyari 
et al., 2003) but contrast with some studies in individuals with (Meng et al., 2001; 
Stebbing et al., 2001; Zong et al., 2002) and without (Mbulaiteye et al., 2006) KS, 
which have not revealed evidence for intra-person variation in HHV-8 sub-genomic 
sequences. The paucity in the number of reports of mixed HHV-8 infection may be 
due to a combination of factors, as described in Chapter 3. The design of the current 
study precludes resolution of whether concurrent HHV-8 infections in the patients 
resulted from co-infection or super-infection, of the transplanted kidney as source of 
infection (Parravicini et al., 1997; Regamey et al., 1998), or of the extent to which 
immunosuppression predisposed the recipients to reactivation or future HHV-8 
infection.
Because HHV-8 genomic sequences carried in biopsy, plasma and oral samples from 
these 5 patients with KS could be either genotype, conclusions could not be drawn 
about the selective tropism of HHV-8 strains. Current evidence from other studies 
suggests that HHV-8 exhibits broad tropism (Dupin et al., 1999; Pauk et al., 2000; 
Blackboum et al., 2000).
This study has therefore identified the oral cavity as a major site of HHV-8 shedding 
in KS-experienced renal allograft recipients, and suggests that their saliva has 
greater potential than blood to spread HHV-8. Further, such patients may be infected 
by multiple HHV-8 strains, implying their poor immunity from past infection.
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5.1 Introduction
Post-transplant KS may be caused by two possible mechanisms: HHV-8 reactivation 
in patients who were infected before the graft; and HHV-8 neo-infection either by 
blood products or from allogeneic transplant tissue. Studies from various groups, 
which generate findings based on serology and molecular tracking of infection 
(summarized in Table 5.1) have shown that organ-related transmission of HHV-8 is 
more common than previously thought. Primary infection after transplantation has 
been suggested as posing a greater risk of complications than reactivation of pre­
existing virus (Sarid et al., 2001; Marcelin et al., 2004), and the risk of KS can be 
exceedingly high when the organ donor and recipient are both HHV-8-positive 
(Parravicini et al., 1997; Bergallo et al., 2007). Therefore the distinction between HHV- 
8 reactivation and primary infection may be important for predicting outcome in regard 
to KS development. Accordingly, systematic screening for HHV-8 antibodies in 
recipients and organ donors and screening of grafts for HHV-8 have been advocated 
(Milliancourt et a i, 2001; Marcelin et a i, 2007).
This chapter reports an investigation into the geno- and sero-prevalence of HHV-8 in 
a group of patients awaiting kidney transplantation and in their donors. Furthermore, 
the potential for a HHV-8 transmission via organ transplantation and the correlation 
between HHV-8 infection and the development of KS was also investigated.
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T a b le  5.1 Solid organ transplant recip ients d eve lop in g  KS
a
Reference Type of transplant Country
No. of recipients HHV-8 
positive before 
transplantation and 
developing KS / 
recipients developing 
KS(%)
No. of recipients HHV-8 
sero-converting after 
transplantation and 
developing KS / 
recipients developing 
KS(%)
No. of HHV-8 geno- or 
sero-positive 
corresponding 
donors / donors to 
recipients developing 
KS(%)
Parravicini etal. (1997) Heart and kidney Italy 10/11 (91%) 1/11 (9%) 4*/11 (36.4%)
Regamey ef a/. (1998) Kidney Switzerland 0/2(0%) 2/2(100%) NA
Sachsenberg ef a/. (1999)^ ^ Lung Switzerland 1 /1 (100%) 0 /1 (0%) 01 1 (0%)
Frances et al. (2000) Kidney France 9/9(100%) 0/9(0%) NA
Luppi et al. (2000)+ Kidney Italy 0/2(0%) 2/2(100%) V11 (100%)
Andreoni ef a/. (2001) Kidney and liver Italy 3/4(75%) 1/4(25%) NA
Cattaniefa/. (2001) Kidney Italy 6 / 7 (86%) 1/7(14%) NA
Kapeiushnik et al. (2001 ) + Kidney Israel 0/1(0%) 1 /1 (100%) 1*/1(100%)
Munoz etal. (2002) Kidney, liver and heart Spain NA 3/7(43%) NA
EmorxJ etal. (2002) Heart France 1 /1 (100%) 0 /1 (0%) NA
Collart et al. (2004)+ Heart France 0 /1 (0%) 1 /1 (100%) 1'/1(100%)
Marcelin et al. (2004) Liver France 0 / 2 (0%) 2/2(100%) 2*/2 (100%)
Becuwe etal. (2005)
Kidney, Kid ne y- 
pancreas. Liver and 
Heart
France 16/20 (80%) 2 / 20 (20%) NA
Bergallo et al. (2007) Kidney Itaiy 1 /1 (100%) 0 /1 (0%) 1 /1 (100%)
o
s
I
I3
II
\  including donors to the seroconverting recipients: case report; NA, not available
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5.2 Patients, Material and Methods
5.2.1 Study population
The study sample included 6 CRF patients undergoing kidney transplant (CRF-tr), as 
well as 6 renal allograft donors (RADs) and 3 relatives of renal allograft recipients 
(RRARs). All renal transplant surgeries were conducted at the Armed Forces Hospital 
in Riyadh, Saudi Arabia during the months of March, April and May, 2004. The mean 
age of the renal allograft recipients was 35 yr while the mean age of the allograft 
donors was 28 yr. In both donor and recipient groups, the maleifemale ratio was 5:1, 
while all RRARs were male. Four out of the six CRF-tr patients received renal 
allografts from live related donors, while the remaining two received allografts from 
cadavers. Five out of the six CRF-tr patients were Saudi Arabian (3 from Jizan and 2 
from Riyadh) and one was Jiboutian. The RADs were of four different nationalities 
(Table 5.2). Serum from the CRF-tr patients, RADs and RRARs was tested, prior to 
kidney transplantation, for various infectious agents by the hospital’s haematology 
department (Table 5.3). After 3 months post-transplantation, one patient, CRF-tr 5, 
the only non-Saudi CRF-tr amongst the participants, travelled back to his home 
country (Jibouti), where his medical care was continued.
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Table 5.2 Demoaraphic and clinical characteristics of renal alloqraft recipients and donors at transplantation
CRF-tr/RAD 
pair no.
Date of 
transplant
CRF-tr RAD
Gender
Age*
(years) Nationality Gender
Age*
(years)
Nature of 
allograft
Relation to 
recipient Nationaiity
1 2 9 - 3 - 0 4 M 30 Saudi M 32 live brother Saudi
2 1 7 - 3 - 04 F 36 Saudi M 30 cadaver - Pakistani
3 3 0 - 3 - 0 4 M 38 Saudi M 30 cadaver - Indian
4 3 - 4 - 0 4 M 33 Saudi F 21 live sister Saudi
5 7 - 4 - 0 4 M 37 Jiboutian M 33 live brother Jiboutian
6 8 - 5 - 0 4 M 34 Saudi M 24 live brother Saudi
CRF-tr, patients with chronic renal failure undergoing kidney transplant; RAD, renal allograft donors; *, age at time of transplant
T ab le 5 .3  R esu lts o f pre-transplant antibody testing for various Infectious a g en ts
CRF-tr/RAD / RARR 
Groups HBV HCV HIV HSV vzv EBV CMV
CRF-tr neg neg neg NT NT pos* 1:128
•f RAO neg neg neg 1:32 NT NT 1:32
RARR-1 neg neg neg NT NT NT NT
RARR-2 neg neg neg NT NT NT NT
CRF-tr neg neg neg 1:64 1:8 NT 1:128
2
RAD neg neg neg NT NT NT NT
CRF-tr neg neg neg NT NT NT NT
3
RAD post neg neg NT NT NT neg
CRF-tr neg pos neg NT NT NT neg
4 RAD neg neg neg 1:64 NT NT 1:128
RARR neg neg neg NT NT NT NT
CRF-tr neg neg neg 1:64 NT NT 1:128
5
RAD neg neg neg 1:16 NT NT NT
CRF-tr neg neg neg 1:32 NT NT 1:8
RAD neg neg neg 1:32 NT NT 1:16
NJLnLA CRF-tr, patient with chronic renal failure undeiigoing kidney transplant; RAD, renal allograft donor; RARR, relative of renal allograft recipient; , EBV test result obtained from a different testing centre; Hepatitis B core antibody positive only
1
I
Ï!3
0)
E.
I
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5.2.2 Sample collection
After a standardized interview and oral examination, as detailed in Table 2.1 and 
Appendix 1, blood samples were obtained from the RRARs while matched oral and 
blood samples were obtained from both the CRF-tr and the RAD groups, as 
described in Sections 2.2.1, 2.2.2 and 2.2.3, with the exception of the two cadaver 
donors. The oral samples were collected immediately after the blood samples were 
obtained. Samples from both the live RAD and RRAR groups were obtained pre- 
transplantion only, while samples from CRF-tr patients were obtained both pre- and 
post-transplantion; at weeks 1,2, 4, 6 and 8 from all six CRF-tr patients and at month 
8 from 5 of the 6 CRF-tr patients.
5.2.3 Sample processing
After separation of plasma from the blood, the CD45+ cell subset was 
immunomagnetically fractionated from the blood samples of the CRF-tr, live RAD and 
RRAR groups as described in Sections 2.2.1.1 and 2.2.1.2. In addition, CD31+, 
CD19+, CD 14+ and CD2+ cell subsets were immunomagnetically fractionated from 
the CRF-tr and live RAD blood samples. The cellular and supernate fractions of WMS 
(WMS*^  and WMS®, respectively) were separated by low-speed centrifugation. BE and 
PE were similarly pelleted. Following aspiration of the supernate, WMS*^ , BE and PE 
were resuspended in 1 ml of PBS, and stored at -20°C until required. DNA was 
extracted from blood cell subsets and oral samples as described in Section 2.3.2. 
The presence of DNA in each extract was verified by amplifying a fragment of the yff- 
globin gene as described in Section 2.3.3.
5.2.4 Sequencing analysis of DNA amplified from KS330 and K1
The 211-bp KS330 was amplified from sample extracts by use of nested PCR 
(Section 2.3.4). The 247-bp K1A/1 was amplified from sample extracts by nested 
PCR (Section 2.3.5.1). In addition, all HHV-8 K1A/1- or KS330-DNA-positive samples
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were amplified for long K1 by nested PCR (Section 2.3.5.2). Extracts were tested at 
least twice for KS330, K1A/1 and long K1 DNA, and considered positive when PCR 
repeatedly yielded products. PCR products were sequenced, raw DNA sequence 
data were analyzed and phylogenetic analyses were performed as detailed in Sections
2.3.10 & 2.3.11.
5.2.5 Quantitative PCR
All WMS® and PS extracts, showing positive results for K1A/1 or KS330 DNA, or both, 
were sent to the National Centre for Infectious Diseases, Centres for Disease Control 
and Prevention, Atlanta, GA, where a quantitative, fluorescence-based, real-time 
PCR was applied (Section 2.4).
5.2.6 Anti HHV-8 IgG detection
The Advanced Biotechnologies ELISA was applied to all plasma samples (Section 
2.5).
5.2.7 Clinical progress
The clinical progress and laboratory investigations of all CRF-tr patients, both pre- 
and post-transplantion, were monitored and recorded.
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5.3 Results
5.3.1 HHV-8 DNA detection
5.3.1.1 In blood
HHV-8 DNA was not detected in the peripheral leucocyte fractions of live RADs or 
RRARs. It was detected in the peripheral leucocyte fractions of only one CRF-tr 
patient (CRF-tr 4) pre- and post-transplant (discussed in Chapter 6). Figure 5.1 is a 
gel electrophoresis image showing HHV-8 DNA in CD45+ cells obtained from CRF-tr 
4.
5.3.1.2 In oral samples
HHV-8 DNA was not detected in oral samples of the live RADs. It was detected in the 
WMS® (Figure 5.1 ) and other oral samples (discussed in Chapter 6) of one (CRF-tr 4) 
out of the six CRF-tr patients.
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Figure 5.1 Gel eietcrophoretic images of (A) CD45+ cells and (B) WMS^ of CRF- 
tr/RAD/RRAR 4.
(A) + RRAR RAD - p r«  1 2 4 6 8 38  -  +
K1/V1  ^
247-bp
< CRF-tr # 4 ---------:
CD45
+ RRAR RAD -  p r«  1 2 4 6 8 38
KS330 
211-bp
< CRF-tr # 4 --------->
(B)
K1/V1
247-bp
KS330
211-bp
^ C ixR*tr ijjfc 4 — — — î>
WMSS
<---------- CRF-tr # 4 ---------->
WMS®, whole mouth saliva supernate fraction; RAD, renal allograft donor 4; RRAR, relative of renal 
allograft recipient 4; pre, pre-transplant sample; Numerals above lanes denote weeks post-transplant.
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5.3.2 Whole saliva supernate viral load
WMS^ HHV-8 viral load was determined for CRF-tr 4. Prior to transplantation, his 
whole mouth saliva carried 2,606,250 copies/ml. After one month of post-transplant 
immunosuppression, the HHV-8 WMS® load increased to 4,106,500 copies/ml, 
thereafter dropping significantly (discussed in Chapter 6).
5.3.3 Serological detection of HHV-8
None of the RAD s, RRAR s or CRF-tr's plasma samples were reactive for anti-HHV- 
8 IgG, except for CRF-tr 4’s, who's pre- and post-transplant plasma samples were all 
reactive for anti-HHV-8 IgG.
5.3.4 Clinical progress
All patients received oral valaciclovir post-transplantation at various doses and for 
various periods of time. CRF-tr 1 developed chicken pox at 4 months post-transplant 
and CRF-tr 3 developed herpes zoster at 5 months post-transplant. These infections 
were treated by intravenous aciclovir and famciclovir respectively.
Twenty-six wk following allograft receipt, CRF-tr 4 developed cutaneous KS at the 
upper trunk, arms and legs, which was later confirmed histologically. KS affecting the 
stomach and colon was later diagnosed 14 and 15 months post-transplant, 
respectively (discussed in Chapter 6).
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5.4 Discussion
This chapter describes an investigation into HHV-8 reactivation and organ-related 
transmission in a prospectively studied group of CRF patients undergoing kidney 
transplantation. The work was accomplished through the examination of oral and 
blood samples for HHV-8 geno- and sero- positivity, from both the allograft recipients 
and their corresponding donors.
Pre-transplant prevalence of HHV-8 antibodies among graft recipients was 1/6 
(16.7%), which is identical to the seroprevalence we previously detected in Saudi 
CRF patients (Chapter 3), but less than that detected (29%) by Qunibi et al. (1998) 
and greater than that detected (7%) by Almuneef et al. (2001) in ESRD patients. 
Unlike most studies reporting seroprevalences among donors and recipients which 
found similar rates to those among the general population of the country considered 
(Cattani et al., 2001), an increased HHV-8 seroprevalence in Saudi CRF patients 
undergoing renal allograft transplant when compared with Saudi blood donors (0.6%) 
is observed.
Previous reports from Saudi Arabia have found the incidence of KS among 350 (aI 
Suleiman et al., 1987) 263 (Qunibi et al., 1988) and 730 (al Sulaiman and al Khader, 
1994) renal allograft recipients, who were followed for more than three months, to be 
3.4%, 5.3% and 4.7%, respectively. In addition, Alzahrani et al. found a very high 
HHV-8 sero positivity rate (70%) in an Arab family affected with KS. In the present 
small sample study, the overall incidence of KS after transplantation was 16.7%.
All seronegative recipients with seronegative donors did not seroconvert at any time 
during the follow-period, coinciding with similar findings in Italy (Andreoni et al., 
2001). However, for one patient, the latest sample collected was at 8 wk post­
transplant. Therefore, the possibility of seroconversion occurring at a later date
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cannot be excluded, although it is unlikely.
In the case of the two renal allograft recipients (CRF-tr 1 and CRF-tr 3) who 
developed post-transplant chicken pox and herpes zoster respectively, it cannot be 
known whether these infections were primary or were transmitted via the transplanted 
graft, as VZV screening was not done for both these allograft recipients or their 
corresponding donors.
Routine hepatitis B assessment of organ donors usually includes testing for HBsAg, 
anti-HBs and anti-HBc. Although HBsAg positivity excludes from organ donation, anti- 
FI Bc-positive donors may be used under certain life-threatening circumstances, even 
if their infectivity is established. Nonetheless these grafts were found to be suitable 
either to effectively vaccinated recipients or to those who are given HBIG to prevent 
FIBV recurrence (Roque-Afonso et al., 2002).
There are only a few case-control studies of solid organ transplant recipients with and 
without KS, matched to their respective donors investigating the risk of HHV-8 
transmission from donor grafts (Parravicini at a/., 1997; Marcelin et al., 2004; Bergallo 
et al., 2007). Most other studies have evaluated the seroprevalence of HHV-8 in 
groups awaiting heart (Emond et al., 2002), kidney (Regamey et al., 1998; Frances et 
al., 2000; Cattani et al., 2001; Andreoni et al., 2001) or liver (Andreoni et al., 2001) 
transplants. However, similar studies are lacking in Middle Eastem countries such as 
Saudi Arabia, where precise estimates of HHV-8 seroprevalence in the organ donor 
and recipient populations are needed.
Most post-transplant KS develops as a result of viral reactivation, whereas more than 
75% of transplant recipients developing KS have been reported to be sero-positive 
for HHV-8 before undergoing transplantation. In an Italian retrospective study, 10 of
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11 (91%) organ recipients who developed KS were HHV-8 seropositve before 
transplantation (Parravicini et al., 1997). This finding was later supported by other 
Italian studies, where 6 of 7 (86%) (Cattani et a!., 2001) and 3 of 4 (75%) (Andreoni et 
a!., 2001) organ recipients who developed KS were also found to be seropositive 
before transplantation. In France, a country of low HHV-8 endemicity, no KS was 
observed in renal allograft recipients without anti-HHV-8 antibodies at the time of 
transplantation (Frances et a!., 2000). Additionally, a more recent French study, 
reported 16 of 20 (80%) organ recipients developing KS as being seropositive before 
transplantation (Becuwe etal., 2005).
The first report suggesting de novo infection from transplantation involved a kidney 
transplant patient in Italy who was HHV-8-seronegative before transplantation and 
seroconverted 13 months after transplantation with onset of Castleman disease 
(Parravicini et al., 1997). Cases of HHV-8 séroconversions after kidney 
transplantation resulting in KS development have been identified in Italy (Cattani et 
al., 2001; Andreoni et al., 2001), Israel (Kapeiushnik et al., 2001) and Spain (Munoz 
et al., 2002). In a cohort of 220 transplant recipients in Switzerland, KS developed 
within 26 months in two of 25 patients who had developed a primary HHV-8 infection 
after kidney transplantation (Regamey et al., 1998). Similarly, cases of HHV-8 
seroconversion and KS development after heart (Collart et al., 2004) and liver 
transplantation (Marcelin et al., 2004) have been reported. These studies suggested 
that transmission of HHV-8 can occur by the organ allograft. Moreover, a primary 
HHV-8 infection has been described in two patients after both received kidneys from 
a seropositive cadaver donor. One of the patients developed disseminated KS, and 
the other developed an acute syndrome characterized by fever with plasmacytosis 
followed by bone marrow failure and ultimately died of renal and cardiac failure (Luppi 
et al., 2000b). Sex and genetic markers specific to the donor have been detected in 
neoplastic HHV-8-infected cells in KS lesions isolated from renal transplant
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recipients, suggesting that not only HHV-8 but also KS progenitor cells may be 
seeded after solid organ transplantation, survive in the recipients, and undergo 
neoplastic transformation and progression (Barozzi et al., 2003).
The results reported in this chapter do not suggest HHV-8 transmission via organ 
transplantation, as none of the renal allograft donors were geno- or sero-positive for 
HHV-8. In addition, the only seropositive allograft recipient was both geno- and sero­
positive for HHV-8 prior to transplantation. Therefore, the suggestion that HHV-8 
transmission in regions where the virus is not endemic occurs via the transplanted 
organ (Regamey at a/., 1998; Marcelin et al., 2004) cannot be applied to the sample 
group studied here, in whom other factors could have contributed to KS development. 
However, in the view of the small number of participants, no definitive conclusion 
regarding the most likely cause of KS in the Saudi renal allograft recipients may be 
drawn.
Knowledge of the HHV-8 infection status of the graft donor and recipient can help in 
identifying individuals at high risk for post-transplantation KS, early detection and 
management of KS. This small case control study is the first prospective study 
conducted in Saudi Arabia evaluating the prevalence of HHV-8 in organ donors and 
corresponding recipients; hence it is described in a separate (this) chapter. The 
findings, though not definitive, stress the need to proceed with larger-scale studies of 
this nature, including screening cadaver donors for HHV-8, to determine the risk of 
post-transplantation KS, its relationship to HHV-8 reactivation or organ-related 
transmission, and the morbidity and mortality due to KS.
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Chapter 6_____________________________________ Persistent HHV-8 Oral and Blood Shedding Prior to KS
6.1 Introduction
Previous studies have shown that HHV-8 infection, identified by the presence of 
HHV-8 DNA sequences in PBMCs or of serum antibodies to HHV-8, precedes and is 
predictive of the subsequent onset of KS (Whitby et al., 1995; Gao et al., 1996a; Gao 
et al., 1996b; Moore et al., 1996c; Whitby et al., 1998; Pozo et al., 2000; Garcia- 
Astudillo and Leyva-Cobian, 2006). However, not all pre-transplantation HHV-8 
seropositive patients develop KS even when they are undergoing 
immunosuppression (Parravicini et al., 1997; Frances et al., 2000; Cattani et al., 
2001; Bergallo et al., 2007). In addition, it is not known if HHV-8 shedding from the 
oral cavity, an important site of shedding (Teo, 2006), can precede, and potentially 
predict development of KS in people given immunosuppressive drugs.
This chapter describes an evaluation of the extent of oral and blood HHV-8 shedding 
in a prospectively-studied individual who developed KS 6 months after receiving a 
renal allograft. Included in the study is an evaluation of the cellular distribution of 
HHV-8 DNA detection in PBMC sub-populations, multiple HHV-8 infection and the 
effects of immunosuppressive drugs, antiviral drugs and oral health on salivary HHV- 
8 viral load.
6.2 Patient, Material and Methods
6.2.1 Patient and sample collection
Matched oral and blood samples were obtained from a 33-yr-old Saudi male who was 
undergoing renal allograft transplantation at the Armed Forces Hospital in Riyadh, 
Saudi Arabia in April 2004. Samples were obtained pre-transplant and up to 8 months 
post transplant. This patient is identical to CRF-tr 4 of Chapter 5. At each visit, a 
standardized interview and oral examination, as detailed in Table 2.1 and Appendix 
1, were conducted. This was followed by the collection of body fluid samples as 
described in Sections 2.2.1, 2.2.2 and 2.2.3. The oral samples were collected
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immediately after the blood samples were obtained.
6.2.2 Sample processing
After separation of plasma from the blood, the CD45+, CD31+, CD19+, CD14+ and 
CD2+ cell subsets were immunomagnetically fractionated as described in Sections
2.2.1.1 & 2.2.1.2. The cellular and supernate fractions of WMS (WMS^ and WMS®, 
respectively) were separated by low-speed centrifugation. BE and PE were similarly 
pelleted. Following aspiration of the supernate, WMS®, BE and PE were resuspended 
in 1 ml of PBS, and stored at -20°C until required. DNA was extracted from plasma, 
blood cell subsets and oral samples as described in Section 2.3.2. The presence of 
DNA in each extract was verified by amplifying a fragment of the yff-globin gene as 
described in Section 2.3.3.
6.2.3 Sequencing analysis of DNA amplified from KS330 and K1
The 211-bp KS330 was amplified from sample extracts by use of nested PCR 
(Section 2.3.4). The 247-bp K1A/1 was amplified from sample extracts by nested 
PCR (Section 2.3.5.1). In addition, all HHV-8 KS330 or K1A/1 DNA positive samples 
were amplified for long K1 by nested PCR (Section 2.3.5.2). Extracts were tested at 
least twice for KS330, K1A/1 and long K1 DNA, and considered positive when PCR 
repeatedly yielded products. PCR products were sequenced, raw DNA sequence 
data were analyzed and phylogenetic analyses were performed as detailed in Sections
2.3.10 and 2.3.11.
6.2.4 Combined DGGE screening-nucieotide sequencing to reveal inter- and 
intra-sample K1A/1 sequence differences
Samples which concordantly amplified positively for KS330, K1A/1 and long K1 DNA
and showed a significant divergence in their K1A/1 sequences were subjected again
to nested PCR by use of the EXPAND High Fidelity PCR System, as described in
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Section 2.6.1. The PCR products were then purified directly from the second-round 
PCR product (Section 2.3.8) and clones were generated (Section 2.3.9). From each 
amplificate, 22 colonies were randomly picked, and each colony subjected to another 
round of PCR using a clamping primer as described in Section 2.6.2. The PCR 
products from 14 selected colonies were subjected to DGGE (Beyari et ai, 2003) as 
detailed in Sections 2.6.3, 2.6.4 and 2.6.5, followed by nucleotide sequencing 
(Section 2.3.10). Raw DNA sequence data were analyzed using Seqman software 
(DNAstar) (Section 2.3.11).
6.2.5 Quantitative PCR
All WMS® and PS extracts, showing positive results for K1A/1 or CRF 26 DNA or 
both, were sent to the National Centre for Infectious Diseases, Centres for Disease 
Control and Prevention, Atlanta, GA, where a quantitative, fluorescence-based, real­
time PCR was applied (Section 2.4).
6.2.6 Anti HHV-8 IgG detection
The Advanced Biotechnologies ELISA (Section 2.5) was applied to all plasma 
samples collected pre and post transplantion.
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6.3 Results
6.3.1 HHV-8 DNA detection 
6.3.17 In blood
HHV-8 was detected in the patient’s PBMCs both pre- and post-transplant. However, 
plasma viraemia was not observed until 9 months post-transplant. Seven blood 
samples (7/42; 17%) were concordantly positive for KS330 and K1/V1 (CD 19+ cells: 
1; CD31+ cells: 1; and CD45+ cells: 5), 3 samples (3/42; 7%) were positive for K1/V1 
only (CD2+ cells: 1; CD 19+ cells: 1; and CD31+ cells: 1), and 4 samples (4/42; 9.5%) 
for KS330 alone (CD19+ cells: 2; CD45+ cells: 1; and plasma:1) (Table 6.1). Seven 
blood samples (7/14; 50%) were also positive for long K1 DNA, six of which were 
concordantly positive for KS330 and K1/V1 (Table 6.2).
6.3.1.2 In oral samples
HHV-8 was detected in the patient’s oral samples both pre- and post-transplant. Prior 
to transplantation, HHV-8 was present in the patient’s WMS (WMS® and WMS^) and 
BE. Throughout the 38 wk of post-transplant sample collection, HHV-8 was present in 
all WMS (WMS® and WMS^) samples studied and in the BE for the first 4 wk. 
However, HHV-8 was only detected in the PS and PE at 2 wk and 4 wk post­
transplant, respectively. Sixteen oral samples (16/35; 46%) were concordantly 
positive for KS330 and KW 1 (WMS®: 5; WMS' :^ 6; PS: 1; BE: 3; PE: 1), 2 samples 
(2/35; 6%) were positive for K1/V1 only (WMS®: 1; WMS*^ : 1), and another 2 (2/35; 
6%) for KS330 alone (WMS®: 1; BE: 1) (Table 6.1). Sixteen oral samples (16/20; 
80%) were also positive for long K1 DNA, 14 of which were concordantly positive for 
KS330 and K1A/1 (Table 6.2).
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Table 6.1 HHV-8 DNA PCR findings, ELISA and viral load assessments in oral and blood samples
HHV-8 PCR RESULTS
Blood ORAL
CD2 CD14 CD19 CD31 CD45 Plasma WMS* WMS' PS BE PE
HHV-8 virai
II II I I 11 I I 11 I I 5 § I I I I 11 loadTiming WMS / PS (copies / ml) ELISA
Pre - - - - + * + + - + + + - + + - 2,606,250 / NT +
1 wk 
post - - + - + + - + + + + - + -
2,270,000 / 
NT +
2w k 788,750 /
post 479
4 wk 4,106,500 /
post NT
6 wk 
post - + + + - - -
170/
NT
8 wk - /
post NT
38 wk 1,495/
post NT
WMS®, whole mouth saliva supernate fraction; WMS®, whole mouth saliva cellular fraction; PS, parotid saliva; BE, buccal exfoliate; PE, palatal exfoliate; +, HHV-8 DNA 
amplified; -, HHV-8 DNA not amplified; NT, not tested
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6.3.2 KS330 nucleotide sequence diversity
A dendrogram displaying the diversity of consensus KS330 sequences and their 
genotypic assignments is shown in Fig 6.1. A narrow inter-sample KS330 sequence 
diversity (<1.2% ) was observed. The genotype of HHV-8 in all blood and oral 
samples taken at different intervals was identical (genotype B/C). KS330 sequences 
have been deposited in EMBL Nucleotide Sequence Database (accession numbers 
AM745354 to AM745382).
Figure 6.1 Dendrogram showing diversity of CRF-tr 4’s consensus KS330 
sequences. Bootstrapping for 1000 replicates is noted as a percentage at major 
branch points.
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6.3.3 K1A/1 nucleotide sequence diversity
A dendrogram displaying the diversity of consensus K1A/1 sequences and their 
genotypic assignments is shown in Fig 6.2. Inter-sample sequence diversities ranged 
between 0% and 11.7%. Various blood and oral samples, taken pre-transplant, 2 wk 
and 8 wk post-transplant, segregated into two genotypes (A1 and A5 or A2 and A5), 
while those taken 1 wk, 4 wk, 6 wk and 9 months post-transplant all belonged to the 
A5 genotype (Table 6.2). K1A/1 sequences have been deposited in EMBL Nucleotide 
Sequence Database (accession numbers AM745383 to AM745410).
Figure 6.2 Dendrogram showing diversity of CRF-tr 4’s consensus K1A/1 
sequences. Bootstrapping for 1000 replicates is noted as a percentage at major 
branch points.
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6.3.4 Inter- and intra-sample K1A/1 nucleotide sequence differences studied 
by the combined DGGE screening-nucleotide sequencing protocol
The patient’s pre-transplant WMS®, showing concordantly positive results for KS330, 
K1A/1 & long K1 DNA, showed a 9.5% K1A/1 consensus sequence divergence from 
the pre-transplant BE sample (Figure 6.2). By cloning, DGGE (Figure 6.3 (A)) and 
sequencing 14 colonies from the pre-transplant WMS® and BE K1A/1 amplificates a 
maximum divergence of 0.5% among the WMS® and 9.5% among the BE clonal 
sequences was observed. The majority sequence (V) was identical to the consensus 
ORF K1A/1 sequence from the pre-transplant WMS®. The BE sequences could be 
assigned to belong to 2 genotypes (A1 and A5), while the WMS® sequences all 
belonged to A5. In addition, a sequence diversity of up to 9.5% between the pre­
transplant WMS® clones and the majority of buccal clones was observed. A 
dendrogram displaying the diversity of sequences generated after sequencing a 
selected number of clones, indicated by (*) in Figure 6.3(A), is displayed in Figure 
6.3(B). Sequences derived from the PCR clones indicated by (*) have been deposited 
in EMBL Nucleotide Sequence Database (accession numbers AM745411 to 
AM745428). A comparison of the nucleotide sequences is shown in Figure 6.3(C).
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Figure 6.3 A) DGGE photograph accommodating K1A/1 DNA amplified from 14 
clones generated from CRF-tr 4’s pre-transplant WMS® and BE samples. Arabic 
numerals represent assigned clone numbers, coinciding with lane positions in the gel; 
colony products with unique sequences are assigned different Roman numerals. B) 
Dendrogram showing phylogenetic distribution of K1A/1 consensus derived from (*) 
indicated clones of pre-transplant WMS® and BE samples; Roman numerals in 
parenthesis denote unique sequences found within specimen; Bootstrapping for 1000 
replicates is noted as a percentage at major branch points. C) A comparison of 
nucleotide sequences; Roman numerals denote unique sequences and numbers in 
the parenthesis denote the number of clones with the unique sequences. Dots 
indicate residues occupying positions aligned to those of the majority sequence (V) at 
top.
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0.1
6.3.5 Long K1 nucleotide sequence diversity
The sequences of long K1 consensus all belonged to A5 genotype, with very narrow 
sequence diversities (<0.1%) (Figure 6.4; Table 6.2).
Figure 6.4 Dendrogram showing diversity of CRF-tr 4’s consensus long K1 
sequences. Bootstrapping for 1000 replicates is noted as a percentage at major 
branch points.
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Table 6.2 Linkage analysis of KS330, K1A/1 and long K1 genotypes as determined 
by consensus sequencing
Timing of Patient sample KS330 K1/V1 long K1
sample genotype genotype genotype
1 CD19 A5 _
1 CD45 B/C A5 AS
Pre-transplant I  WMS® B/C A5 AS
WMS'^ B/C A5 AS
1 BE B/C A1 AS
I CD19 B/C _ .
B/C
B/C
A5
A5
AS
AStransplant j B/C A5 AS
1 BE B/C - AS
i CD31 . A5
1 CD45 B/C A5 AS
2 wk post- j  WMS* B/C A5 AS
transplant I WMS*^ B/C A5 AS
1 PS B/C A2 -
i BE B/C A5 -
i CD19 B/C A5
CD45 B/C - AS
4 wk post- i WMS® B/C A5 AS
transplant 1 WMS*^ B/C A5 AS
i BE B/C A5 AS
I PE B/C A5 AS
6 wk post- 1 WMS^ B/C _ .
transplant | WMS*^ B/C A5 AS
1 CD2 _ A1
8 wk post- I CD45 B/C A5 AS
transplant ! WMS® - A1 -
1 WMS'^ B/C A1 AS
I  CD19 B/C
1 CD31 B/C A5 AS
38 wk post- I CD45 B/C A5 AS
transplant I Plasma B/C - -
i WMS" B/C AS AS
WMS" AS AS
WMS®, supemate fraction of wfiole-mouth saliva; WMS' ,^ cellular fraction of whole-mouth saliva; PS, 
parotid saliva; BE, buccal exfoliate; PE, palatal exfoliate; -, not detected
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6.3.6 Whole mouth saliva supemate viral load
Prior to transplantation, the patient’s whole mouth saliva carried 2,606,250 copies/ml. 
After one month of post-transplant immunosuppression, the HHV-8 WMS® load 
increased to 4,106,500 copies/ml, thereafter dropping significantly, coinciding with an 
increase to the dosage of valaciclovir given (Table 6.3; Figure 6.5).
Table 6.3 Daily dosage of administered drugs in relation to HHV-8 WMS® viral loads
Viral load 
copies/ml
Timing WMS"
of sample
Drug dose (mg)
Cidosporin Prednisolone Mycophenolate Valaddovir
mof^l
Pre-
transplant
1 wk 
post-
transplant
2 wk 
post­
transplant
4 wk 
post­
transplant
6 wk 
post­
transplant
2,606,250
2,270,000
788,750
4,106,500
170
750
600
450
450
30
30
30
25
2000
1000
1000
2000
2000
4500
8 wk 
post­
transplant
neg 450 25 1000 4500
38 wk 
post­
transplant
1,495 250 10 1000
WMS®, supemate fraction of whole-mouth saliva; neg, negative
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Figure 6.5 Time charts illustrating change in CRF-tr 4’s HHV-8 WMS® viral loads in 
relation to administered drug daily dosage
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6.3.7 Association between oral inflammation and HHV-8 shedding 
Salivary HHV-8 shedding in the first 8 wk post-transplant, as indicated by the WMS® 
viral load, was shown to be associated with changes in both the gingival and bleeding 
oral indices. At 38 wk post-transplant, the WMS® viral load exceeded that at 6 wk 
post-transplant, although both the gingival and bleeding indices remained relatively 
less than those detected at 6 wk (Table 6.4; Figure 6.6)
Table 6.4 CRF-tr 4’s oral health in relation to HHV-8 WMS® viral loads
Timing of 
sample
WMS* viral load 
copies/ml
Plaque
index
Gingivai
index
Bleeding
index
Pre-transplant 2606250 1.79 1.17 0.33
1 wk post 
transplant 2270000 1.5 1.17 0.33
2 wk post 
transplant 788750 NT NT NT
4 wk post 
transplant 4106500 1.37 1.21 0.42
6 wk post 
transplant 170 1.33 1.17 0.29
8 wk post 
transplant neg 1.33 0.88 0
38 wk post 
transplant 1495 1 1.13 0.13
WMS®, Whole mouth saliva supemate fraction; NT, not tested; neg, negative
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Figure 6.6 Column and line charts illustrating CRF-tr 4’s HHV-8 WMS^ viral loads in 
relation to oral indices
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6.3.8 Clinical progress
The patient’s clinical progress and laboratory investigations were monitored and 
recorded both pre- and post-transplantion, for a period of up to 34 months. Twenty- 
six wk following allograft receipt the patient developed cutaneous KS at the upper 
trunk, arms and legs, which was later confirmed histologically. KS affecting the 
stomach and colon was later diagnosed 14 and 15 months post-transplant, 
respectively (Table 6.6).
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Table 6.5 Summary of CRF-tr 4’s clinical progress and outcomes of laboratory
investigations
Timing (Date) Clinical presentation & investigation
Pre-transplant HCV Antibody and PCR +ve
(2002/2003) Liver biopsy HCV liver cirrhosis; administered Interferon and
Ribavirin
Pre-transplant End stage renal disease on regular haemodialysis 3x week;
(2003) controlled hypertension (5mg Amlor once daily)
(April 2004) Left Renal allograft transplant
8 wk post­ Developed post transplant Diabetes Mellitus (DM) Insulin
transplant (May prescribed
2004)
26 wk post­ Developed multiple nodules over the upper trunk, arms and
transplant (Sept legs
2004)
38 wk post­ Skin punch biopsy taken from upper trunk -> Dx: KS
transplant (Dec
2004)
10 months post­ Gastroscopy & colonoscopy -> multiple extensive polypoid
transplant (Jan lesions in stomach and duodenum resembling KS
2005) Biopsy from stomach and rectum -> Dx: negative for KS
12 months post­ No new skin lesions; upper arm lesions disappeared
transplant (April
2005)
14 months post­ Gastric Biopsy DX: Focal area suspicious for KS + Mild
transplant (June chronic gastritis
2005)
15 months post­ Colon Biopsy -> DX: Focal area of KS and chronic colitis
transplant (July
2005)
16 months post­ All KS skin lesions flat or disappeared; start sirolimus
transplant (Aug (rapamune®) with an overlap period with cidosporin, until
2005) rapamune level achieved.
17 months post­ Cidosporin stopped
transplant (Sept 
2005) Allograft maintained on prednisolone + sirolimusimmunosuppressive regimen
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Table 6.6 Summary of patient’s clinical progress and outcomes of laboratory 
investigations... continued
to llTiSaW D ate) & investigation
19 months post­
transplant (Nov 
2005)
Patient complained of abdominal pain abdominal ultrasound 
and liver biopsy
20 months post­
transplant (Dec 
2005)
Skin KS completely disappeared
Liver biopsy result -> no fibrosis, very mild portal inflammation 
& lobulitis.
Improved liver function with reduction of Rapamune dose
28 months post­
transplant (Aug 
2006)
Liver Ultrasound -> fatty liver infiltrate 
Thyroid Ultrasound bilateral thyroid nodules
31 months post­
transplant (Nov 
2006)
Oedema and thick skin of lower limbs starting 40 mg 
furosemide (Lasix®) once daily.
Bilateral thyroid nodules -> referral to Endocrinologist
Abnormal liver function test referral to Hepatologist
34 months post­
transplant (Feb 
2007)
Transplanted kidney -> stable
Lower limbs -> Oedema, mild pitting and thick skin starting 
25mg Atenolol once daily
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6.4 Discussion
Although KS was diagnosed by histopathological examination of KS tissues on week 
38 post-transplant, analysis showed that HHV-8 DNA was present in a variable 
number of successive pre-KS oral and blood samples. Among the various pre-KS 
tests conducted, saliva HHV-8 PCR and plasma anti-HHV-8 testing proved to be 
consistently positive. WMS yielded higher PCR amplification rates than other oral 
samples, likely reflecting HHV-8 shed from other sites, such as tonsils (Koelle et a/., 
1997; Chagas at a/., 2006b) or tongue (Triantes et al., 2004; Widmer et al., 2006). 
Given that the WMS® HHV-8 viral load was found to be directly related to the gingival 
bleeding index, blood present in the crevicular fluid could have contributed to HHV-8 
in saliva as well. Such association between inflammation in the oral cavity and HHV-8 
salivary viral load was previously reported elsewhere using leukocyte esterase 
chemical indicator strips to assess oral inflammation semi-quantitatively (Casper et 
al., 2004) rather than oral gingival indices. The association observed in this case 
between inflammation in the oral cavity and HHV-8 WMS® viral load, as indicated by 
both the gingival and bleeding oral indices, may be coincidental, however, especially 
as it could not be verified when a larger cohort of Saudi Arabian end-stage renal 
disease patients and allograft recipients was examined (Chapter 3). In addition, while 
HHV-8 has been detected in the periodontal tissues of HIV infected individuals 
without KS, it has not been observed in periodontitis sites of non-HIV-infected 
persons (Mardirossian et al., 2000; Contreras et al., 2001).
Salivary HHV-8 shedding in immunocompromised individals may be very high, even 
before immunosuppression is administered, and increase further when 
immunosuppression is started. The salivary HHV-8 genome viral load, in this case, 
was found to increase by 60% following one month of immunosuppression, thereafter 
dropping significantly, coinciding with an increase to the dosage of valaciclovir given.
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Valaciclovir is an ester of aciclovir (antiviral drug), which is licensed for herpes zoster 
and herpes simplex infections of the skin and mucous membranes. Aciclovir has 
previously been found to have some, although minimal, effects on the inhibition of 
HHV-8 DNA production (Neyts and De Clercq, 1997; Kedes and Ganem, 1997; 
Medveczky et al., 1997). This relatively weak effect may explain why, in this case, 
higher doses of valaciclovir were required to produce a significant reduction in the 
WMS® HHV-8 viral load. Noteworthy is the observation that the HHV-8 load in WMS® 
later increased following the cessation of valaciclovir, substantiating the effect of 
aciclovir. Nevertheless, valaciclovir administered throughout wk 2 to 8 post­
transplant, as a means of prophylaxis against herpes infection, was inefficient in the 
prevention of KS. This outcome is in agreement with previous studies showing 
aciclovir having no affect on the development of KS in AIDS patients (Mocroft et a/., 
1996; Glesby et a/., 1996), although it can be argued that the early cessation of 
valaciclovir could have attributed to the development of KS in this case.
Previous studies have detected HHV-8 DNA in the buccal mucosa and palate of KS 
patients (Cook et a/., 2002a; Cook et a/., 2002b; Beyari et a/., 2003) and in the normal 
oral mucosa of healthy immunocompetant individuals (Duus et a/., 2004). The 
present study supports these findings, but in the context of an iatrogenically 
suppressed individual. HHV-8 DNA was found in both pre- and post-transplant BE 
when WMS® viral loads were >788750 copies/ml and in post-transplant PE when the 
WMS® viral load was at its highest, indicating that HHV-8 in the buccal and palatal 
cells contributed to the increased WMS® HHV-8 viral load or vice versa. The inability 
to detect HHV-8 DNA in the BE or PE at other intervals does not rule out the 
possibility that the virus may still replicate in areas of the palatal or buccal mucosa 
further away from the selected sampling site. The limited HHV-8 DNA detection rate 
in saliva collected from the parotid duct supports previous findings indicating that 
major salivary glands are not important contributors to HHV-8 shedding (Pauk et a!.,
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2000).
To assure broad representation of the blood subpopulations, a variety of which have 
previously been reported to support HHV-8 persistence (Table 1.4), immunomagnetic 
fractioning of CD45+, CD31+, CD19+, CD 14+ and CD2+ cell subsets was conducted 
and all the fractions tested for HHV-8 infection. HHV-8 DNA was detected in the 
PBMGs before the development of clinically evident KS and even before renal 
transplant, contrary to previous reports of HHV-8 genome being present in mainly 
PBMGs of people with active KS (Purvis et a/., 1997; Metaxa-Mariatou at a/., 2004). 
The detection rate of HHV-8 in PBMGs varied according to the cell subsets studied, 
with the GD45+ cells generating the most positive results (6/7), followed (in 
descending order) by: GDI9+ cells (4/7), GD31+ cells (2/7) and GD2+ cells (1/7). The 
GDI4+ cells, previously reported to haiix)ur HHV-8 in patients with KS (Henry at a/., 
1999; Pellet at a/., 2006), were negative for HHV-8 DNA throughout the entire 
sampling period. This result may reflect a specific HHV-8 cellular tropism or may be a 
result of a low copy number-carriage of viral DNA that was below the PGR detection 
limit. Likewise, the failure to detect HHV-8 at 6 wk post-transplant, in any of the blood 
cell subsets, may be due to a low viral load (Decker at a/., 1996; Blackboum at a/., 
1997), possibly due to the increase in dosage of valaciclovir, or intermittent shedding 
of HHV-8 DNA by PBMGs (Laney at a/., 2004).
HHV-8 plasma viraemia was found only upon the development of clinical KS. This 
observation is in agreement with previous work where HHV-8 plasma viraemia was 
found to be positively associated with active disease (Harrington at a/., 1996; 
Tedeschi at a/., 2001 ; Gampbell at a/., 2003; Duus at a/., 2004).
The HHV-8 detection rate in oral and blood samples varied according to the amplified 
HHV-8 genome region, with 23/77 (30%) of samples being concordantly positive for
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KS330 and K1A/1, 6/77 (8%) positive for KS330 alone and 5/77 (7%) positive for 
K1/V1 alone. HHV-8 in WMS was amplified from a single region only when WMS® 
viral load was low (<170 genome-equivalents/ml). Therefore, single region-positivity 
in other samples may also reflect a low viral load.
The extreme polymorphism of ORF K1 was again exploited to investigate the 
genomic diversity of HHV-8 in different anatomical compartments of the patient 
through amplification of K1/V1 and long K1 segments from ORF K1. The K1/V1 
sequencing led to the assignment of sequences originating from the patient’s pre­
transplant BE, 8 wk CD2, WMS® and WMS® samples to the A1 genotype, from the 
patient’s 2 wk PS to the A2 genotype, and the remaining samples to the A5 genotype 
(Fig 6.2). These findings point to inter-compartmental (blood vs. oral) and intra- 
compartmental (oral) carriage of multiple HHV-8 strains. The long K1 segment 
sequencing, on the other hand, led to the assignment of all sequences to the A5 
genotype, including the pre-transplant BE and 8 wk WMS® previously assigned by 
K1/V1 sequencing to A1 genotype.
Long K1 could not be amplified from the remaining K1/V1 genotype A1 samples (8 
wk CD2 and WMS®). This may be explained by the fact that long K1 segment, being 
>3 times longer than K1/V1, confers lesser sensitivity to PCR detection. The absence 
of long K1 amplification could also be due to the presence of a new unidentified 
hybrid HHV-8 strain carrying a K1/V1 A1 genotype, with a primer binding site 
sequence preventing the annealing of the long K1 primers used. It has recently been 
reported that the HHV-8 K1 07 genotype shows a difference in the nucleotide 
sequence at the long K1 inner forward primer binding site (Duprez et al., 2006). 
Additionally, the genotyping of HHV-8 strains have been continuously modified with 
the description of new strains from different geographical areas (Kajumbula et a!., 
2006; Hayward and Zong, 2007); thus other strains may yet be identified (Duprez et
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a/., 2006).
The dominant A5 variant, reported here, has previously been identified in African 
(Zong et al., 2002; Treumicht et al., 2002; Mbulaiteye et al., 2006; Hayward and 
Zong, 2007) and Brazilian (Nascimento et al., 2005) samples, but not in Saudi 
samples. It has been suggested that the A5 variant may be more efficiently 
transmitted as it has been detected more frequently in children than in mothers 
(Mbulaiteye et al., 2006).
Direct sequencing studies have an important limitation in that they are unable to 
produce consensus sequence data that will allow sequences of minority variants to 
be identified. To overcome this limitation, the combined DGGE screening-nucleotide 
sequencing protocol was applied to K1A/1 amplicons generated from clonal inserts. 
To reduce the degree to which PCR generates nucleotide misincorporation, high- 
fidelity PCR was applied to sample extracts. Applying this combined DGGE- 
sequencing protocol showed that the patient's pre-transplant BE clones exhibited a 
significant sequence diversity of up to 9.5%, segregating BE clones into two 
genotypes (A1 and A5), with the minority clade (A5) comprising sequences 
genotypically distinct from the majority clade (A1). The findings from this patient are 
supported by other reports (Gao et al., 1999; Beyari et al., 2003) but contrast with 
some studies in individuals with (Meng et al., 2001; Stebbing et al., 2001; Zong et al.,
2002) and without (Mbulaiteye et al., 2006) KS, which have not revealed evidence for 
intra-person variation in HHV-8 sub-genomic sequences. Unfortunately, KS biopsy 
samples for this patient could not be retrieved, so the origin of the viral strain that led 
to KS in this patient could not be defined.
Because HHV-8 genomic sequences carried in this patient’s blood and oral samples 
could belong to either genotype, conclusions cannot be drawn about the selective
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Gompartmental tropism of HHV-8 strains. Current evidence from other studies also 
suggests that HHV-8 exhibits broad tropism (Dupin et al., 1999; Pauk et al., 2000; 
Blackboum et al., 2000).
Upon continuous thorough oral examination, no oral KS, specifically palatal KS, could 
be detected at any time. The time between kidney transplant and KS presentation ( « 
6 months) or actual diagnosis (« 9  months) for this patient, was less than that 
previously reported in Saudi Arabian renal allograft recipients (Qunibi et al., 1988). 
The first presentation of KS was in the form of multiple nodules affecting the skin of 
the upper trunk, arms and legs. This was followed by the diagnosis of focal areas of 
KS in the stomach and colon at 14 and 15 months post-transplant respectively, 
consistent with previous reports of skin and gastrointestinal tract KS in Saudi Arabian 
renal transplant recipients (aI Sulaiman and al Khader, 1994) and reports of skin KS 
mostly affecting the lower extremities (Moosa, 2005).
Two months after the histopathological diagnosis of abdominal KS, the patient was 
started on a relatively new immunosuppressant (sirolimus). A month later, when the 
sirolimus blood level was achieved, cidosporin was stopped and the allograft 
maintained on a regimen of prednisolone and sirolimus. Conversion from calcineurin 
inhibitors such as cidosporin, to sirolimus has been reported as an option for renal 
transplant patients who develop a tumour (Sanchez-Fructuoso et al., 2006; Lebbe et 
al., 2006; Campistol and Schena, 2007) and can result in the regression of KS 
(Campistol and Schena, 2007; Volkow et al., 2007; Yilmaz et al., 2007; Hassan et al., 
2007) and may prevent its recurrence (Segoloni et al., 2007). Sirolimus exhibits 
antiangiogenic activity related to impaired production of vascular endothelial growth 
factor (VEGF) and limiting proliferative response of endothelial cells to stimulation by 
VEGF, limiting the progression of KS (Guba et al., 2002). The skin KS lesions in this 
case completely disappeared 11 months after their initial clinical appearance and 3
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months after the cessation of cidosporin.
This case study involving a prospectively-studied individual undergoing renal allograft 
transplant again identifies the oral cavity as a major site of HHV-8 shedding, 
suggesting that asymptomatic and persistent oral HHV-8 viraemia, before or after 
renal allograft transplantation may precede the appearance of iatrogenic-KS lesions 
and may also predict the development of KS. Furthermore, such patients may be 
infected by multiple viral strains, implying their poor immunity from past infection. 
Hence, monitoring potential transplant recipients for HHV-8 oral infection may be 
useful for developing therapeutic and prophylactic strategies using antiviral agents, 
known to inhibit HHV-8 production (e.g., ganciclovir, foscamet and cidofovir).
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7.1 Summary and significance of results
Transplantation-associated KS is more prevalent among renal allograft recipients in 
Saudi Arabia than many other geographic regions of the world. The present study 
has been undertaken to evaluate the extent of oral and blood HHV-8 shedding and 
the genomic diversity of the virus involving samples collected from eight study groups 
representing Saudi Arabian populations with different risks of HHV-8 infection. This 
study further explores the factors that may influence the shedding of the virus in the 
groups in which the prevalence of HHV-8 infection is particularly high. The study was 
primarily cross sectional in design, with a prospective component involving chronic 
renal failure patients undergoing kidney transplant.
The findings reported in this thesis substantiate the hypothesis that a disparity in 
HHV-8 prevalence rates exists between the Saudi Arabian general population and 
patients with kidney disease. A higher HHV-8 seroprevalence was observed in Saudi 
Arabian patients with renal disease than in the general population. Plasma HHV-8 IgG 
was detected in all renal allograft recipients with a history of KS (the RAR-KS group) 
and in all pre-KS samples from a CRF patient undergoing renal transplant (CRF-tr 4), 
thus showing high degree of concordance between HHV-8 seropositivity and KS.
When evaluating the sub-cellular distribution of HHV-8 DNA detection, HHV-8 DNA 
was detected in CD2+, CD19+, CD31+ and CD45+ cells with some variation in the 
rate of detection, suggesting that HHV-8 is pleotropic for a wide variety of cells 
circulating in the blood. In the case of CRF-tr 4, who later developed KS, the 
amplification rate of HHV-8 sub-genomic DNA by nested PCR in CD45+ cells 
compared to the rates in other cell populations was consistently higher. This finding 
suggests that the principal cell types in peripheral blood carrying HHV-8 are not B 
cells, T cells, monocytes or endothelial cells.
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HHV-8 DNA was found to be more frequently detectable in the oral samples of CRF 
patients than in blood, reflecting the high load of shedding into the oral cavity and 
possible lower replicative activity of the virus systemically. Among the various pre-KS 
PCR tests conducted on CRF-tr 4, saliva HHV-8 PCR testing consistently proved to 
yield positive results. Additionally, the viral load in the cell-free fraction of whole- 
mouth saliva, throughout this study, ranged between approximately 1.7 x 10  ^and 1.2 
X 10® genome-copies/ml. Thus, in the patients studied, salivary shedding of HHV-8 
was frequent and could be extensive. Moreover, the number of renal disease patients 
with detectable HHV-8 DNA in their whole saliva samples exceeded those with 
detectable HHV-8 DNA in their buccal or palatal exfoliates. This lower HHV-8 DNA 
detection rate in buccal and palatal exfoliates compared to whole saliva probably 
reflects active HHV-8 replication in the oral epithelium other than the buccal mucosa 
or hard palate or in areas of the palate or buccal mucosa further away from the 
selected sampling sites. Thus, patients with both buccal and palatal exfoliates that 
were concordantly positive for K1A/1 and KS330 HHV-8 DNA showed the highest 
WMS® viral load DNA when compared to others in the group with a detectable WMS® 
viral load (patient CRF 24: 119,562,500 genome-copies/ml; RAR-KS 2: 2,198,250 
genome-copies/ml; and CRF-tr 4: 4,106,500 genome-copies/ml at week 4 post­
transplant). These findings indicate that HHV-8 in their buccal and palatal cells 
contributed to the increased WMS® HHV-8 viral load.
Results from the present study suggest that HHV-8 carriage in saliva is independent 
of its carriage in blood. Further, the virus in saliva may not be due to transfer from 
blood to the mouth, since HHV-8 was not always present simultaneously in both 
blood and saliva and no association between inflammation in the oral cavity and 
HHV-8 shedding was observed in all but one patient (CRF-tr 4).
The current study is the first to report the identification of A2, A3, A5 and B HHV-8 K1
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genotypes in the Saudi Arabian population. When a 840-bp fragment of HHV-8 ORF 
K1 (long K1), which encompasses both HHV-8 ORF K1 VR1 and VR2, was amplified, 
sharper discrimination between A and C genotypes was possible. However, long K1 
could not be amplified from some K1A/1 genotype A1 samples. This may be 
explained by the fact that long K1, being >3 times longer than K1A/1, confers lesser 
sensitivity to PCR detection. The absence of long K1 amplification may also be due to 
the presence of a new unidentified hybrid HHV-8 strain. Because overall HHV-8 
genomic sequences carried in blood and oral samples could belong to either 
genotype, conclusions could not be drawn about the selective tropism of HHV-8 
strains.
Whether intrahost HHV-8 subgenomic sequence polymorphism exists among and 
within oral and blood samples of renal disease patients was also investigated. 
Sequence variation was sought in DNA segments derived from HHV-8 ORFs 26 and 
K1 using both direct sequencing and PCR combined with DGGE analysis of K1A/1 
clones. Intraperson genotype and subgenotype K1A/1 sequence differences were 
found among samples from chronic renal failure patients and renal allograft 
recipients. Such multiple HHV-8 carriage may reflect simultaneous coinfection by 
more than 1 HHV-8 strain, reactivation of latent strains, or superinfection. If it reflects 
superinfection, then such transmissions may not be prevented by vaccination. 
Nonetheless, although the immune system might not prevent superinfecting virus 
from initiating replication in the host, it might, after vaccination, prevent the further 
spread of the initial infecting strain (following reactivation) and of subsequent 
superinfecting strains.
As an extension of the study of polymorphism in HHV-8 subgenomic sequences 
ampilified from blood and oral samples, KS biopsy specimens of five patients with a 
history of KS were retrieved and tested. The extent of HHV-8 biopsy sequences
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variation derived particulariy from K1 was examined and compared with sequences 
derived from oral samples of the same individual. Amongst the five patients, 
genotypically distinct viral strains were evident; intra-lesionally in 1 patient; intra-orally 
in 1 patient; between an oral sample and biopsy in 2 patients; and in 4 patients, 
between an oral sample and plasma, and between plasma and biopsy. While the 
findings in these patients again substantiate multiple HHV-8 infection, the cross- 
sectional sampling prevented the identification of which body compartment harboured 
HHV-8 strains that became associated with KS development.
In the present study, there was a marked disparity in HHV-8 DNA detection rates 
according to the criteria used to consider HHV-8 DNA as being detectable: PCR 
positivity for KS330 alone, for K1A/1 alone, or for both KS330 and K1A/1. Great care 
was taken to rule out possible cross contamination as contributing to solitary K1A/1 or 
KS330 reactivities. Samples found with identical K1 sequences and those with single 
K1 or KS330 positivities underwent another round of DNA extraction and 
amplification. Furthermore, nucleotide sequencing of the positive control (HHV-8 
infected BCBL-1 cell line) was carried out for comparison, and its KS330 and K1A/1 
sequences were determined to be different from the KS330 or K1A/1 sequences of 
patient samples. Previous studies into HHV-8 genome detection rates in KS patients 
from Malawi (Beyari et al., 2003) and blood donors from the UK (Kumar et a/., 2007) 
using identical PCR conditions for the amplification of both K1A/1 and KS330 
detected similar discordance between K1 and KS330 in a small number of their 
samples, especially from people who were anti-HIV seronegative (Beyari et a/.,
2003). This discordant result may be due to a low copy number-carriage in them of 
HHV-8 DNA. In the present study, HHV-8 in WMS® was amplified from a single region 
only when WMS® viral load was low (<170 genome-equivalents/ml).
The present study is limited by several factors. The first is the cross-sectional nature
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(in most part), which precludes resolution of whether concurrent HHV-8 infections in 
the patients resulted from co-infection or super-infection and identification of episodic 
HHV-8 shedding. Second, buccal and palatal sample collection from renal disease 
patients was restricted to a single sample for each investigated area from each 
patient, which may not be representative of the entire anatomical area. Third, saliva 
and oral cells samples were not collected from the healthy control groups to allow 
comparison with renal disease patients with regard to HHV-8 oral shedding. 
Additionally, only CD45+ cell subsets were isolated from the control group’s whole 
blood samples, preventing a comprehensive comparison between blood HHV-8 
genoprevalence amongst the study groups.
7.2 Conclusion
Several explanations can be given for the approximately 10-fold increased incidence 
of KS in Saudi Arabian renal transplant recipients by comparison to such patients in 
other areas. One is that the background prevalence of HHV-8 infection is unusually 
high in the Saudi Arabian population. Findings from the present study and previous 
studies (Qunibi et al., 1998; Almuneef et a!., 2001; Alzahrani et a/., 2005) suggest 
that this is not the case. A second possibility is that HHV-8 infection in Saudi Arabia 
occurs more frequently via allografts from infected donors. This hypothesis was 
tested directly in the present study which revealed that HHV-8 transmission via organ 
transplantation is unlikely. A third possibility is that immunosuppressive regimens 
used in the post-transplant management are substantially different from those used in 
other countries, but the present study found no indication that this was so, and, 
further, no association was observed in the present study between type, dose or 
duration of immunosuppressives and HHV-8 infection. The last possibility, and the 
one favoured here, is that HHV-8 transmission occurred iatrogenically in patients with 
chronic renal disease in the course of their receiving health care, particularly during 
haemodialysis when the patients are accommodated in proximity to each other, and
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there is close contact with or transfer of saliva of infected individuals. Upon renal 
allograft receipt, these patients are further subjected to immunosuppressives 
(ciclosporin, prednisolone, mycophenolate mofetil, etc.), some of which have been 
known to have a cancer-promoting effect, which further predispose already infected 
transplant recipients to develop KS.
The results of this study support the recommendation to adopt strict measures to 
control nosocomial, salivary spread of HHV- 8  to pre- and post-transplantation 
patients, particularly in health-care facilities that accommodate them at close quarters 
without regard to their susceptibility, immunity and infectivity status. Guidelines for 
infection control in such facilities would need to stipulate that immunocompromised 
patients minimise contact with human saliva. For control and prevention of post 
transplantation KS specifically, these measures would complement others that are 
being evaluated to reduce its incidence, e.g., antibody screening of organ donors and 
recipients, and those to effect its regression after disease has developed, e.g., 
conversion to the use of sirolimus as immunosuppressant. Moreover, monitoring 
potential transplant recipients for HHV- 8  oral infection could be useful for developing 
therapeutic and prophylactic strategies against post-transplantation KS.
7.3 Suggestions for further studies
- Further work to clarify the oral HHV- 8  genoprevalence in Saudi Arabian healthy 
individuals should be conducted. As HHV- 8  shedding in saliva may be episodic in 
some patients and missed when only single specimens are analyzed (Koelle et al., 
1997; Pauk et al., 2000), it would be necessary to serially sample from the oral cavity.
Further larger-scale studies comparing groups on different immunosuppressive 
regimens and including other factors, such as the length of exposure to a specific 
immunosuppressive drug, may be required to study possible associations between
298
Chapter 7____________________________________________________Summary. Conclusion and Suggestions
immunosuppressive drugs and HHV- 8  infection, viral load and KS.
- In order to accurately assess the differences in CRF patients HHV- 8  sero- or geno­
prevalence rates according to the different areas of the country, it is proposed that a 
multi-centre study be conducted involving haemodialysis units from a wider sample of 
Saudi Arabian administrative areas. Moreover, evaluating the prevalence of HHV- 8  
infection in renal dialysis unit health care workers may be beneficial.
- Prospective studies evaluating the prevalence of HHV- 8  in ESRD patients upon 
initiation and at different stages of haemodialysis are needed to determine the risk of 
acquiring HHV- 8  infection in the dialysis unit.
- There is a need to proceed with larger-scale prospective studies evaluating the 
prevalence of HHV- 8  in organ recipients and corresponding donors, including 
cadaver donors, to determine the risk of post-transplantation KS, its relationship to 
HHV- 8  reactivation and organ-related transmission, and the morbidity and mortality 
due to KS.
- The design of the current study was confined to examination of HHV- 8  carried in 
the blood, mouth and KS biopsy samples. Sampling of other body sites might reveal 
yet more evidence of multiple HHV- 8  carriage. It may be useful to examine tissue 
specimens from various organs, e.g. lung, brain, spleen, liver, or possibly non-oral 
mucosal surfaces obtained from renal allograft recipients who died from KS, in order 
to confirm the presence of HHV- 8  sequences in these tissues.
Further studies should be undertaken involving the selection of HHV-8 -infected 
individuals and the use of larger blood volumes to undertake immunomagnetic cell 
separation for a wider array of cell sub-types to further characterise which cell type
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carries HHV-8 .
- Although all possible measures were undertaken to reduce the contamination of 
BE and PE with saliva, there remains the possibility that contamination contributes to 
the positive detection rates. In order to overcome this, future studies using in situ 
hybridisation for HHV- 8  mRNA or DMA in these exfoliates may be advantageous.
- Further attempts to amplify long K1 through altering PCR conditions and usage of 
different sets of primers may be necessary to explore the possibility of the presence 
of yet unidentified HHV- 8  strains.
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Appendices
Appendix 1. Template for intra-oral findings
Missing teeth #;
X #16 #12 #24 #36 #32 #44 Mean
Q)
■o buccal
c mesial
0)
3 lingual
TO distalQ. Mean PI
CD “
buccal
mesial
lingual
distal
Mean Gl
i  g
CO
buccal
mesial
lingual
distal
Mean Bl
Criteria for scoring:
• The plaque index system (Silness J and Loe H, 1964)
0 = No plaque in the gingival area.
1 = A film of plaque adhering to the free gingival margin and adjacent area of the tooth. The plaque 
may only be recognized by running a probe across the tooth surface.
2 = Moderate accumulation of soft deposits within the gingival pocket, on the gingival margin and/ or 
adjacent tooth surface, which can be seen by the naked eye.
3 = Abundance of soft matter within the gingival pocket and/or on the gingival margin and adjacent 
tooth surface.
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Criteria for the gingival index system (Loe H and Silness J, 1963) *
0 = Normal gingival
1 = Mild inflammation -  slight change in colour, slight oedema. No bleeding on probing.
2 = Moderate inflammation -  redness, oedema and glazing. Bleeding on probing.
3 = Severe inflammation -  marked redness and oedema. Ulceration. Tendency to spontaneous 
bleeding.
Criteria for the bleeding index system (Muhlemann and Son, 1971)
0 = No bleeding on blunt probing
1 = Bleeding on blunt probing up to 30 seconds later
2 = Immediate bleeding on probig
3 = Spontaneous bleeding
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